

Supplementary Material: Additional inserts of methods and results

This supplementary material is hosted by *Eurosurveillance* as supporting information alongside the article ‘Epidemiology of gonorrhoea: systematic review, meta-analyses, and meta-regressions, World Health Organization European Region, 1949 to 2021’, on behalf of the authors, who remain responsible for the accuracy and appropriateness of the content. The same standards for ethics, copyright, attributions, and permissions as for the article apply. Supplements are not edited by *Eurosurveillance* and the journal is not responsible for the maintenance of any links or email addresses provided therein.

Table of Contents

Supplementary Table S1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist [1].	3
Supplementary Box S1. Search strategies used to identify studies reporting <i>Neisseria gonorrhoeae</i> infection prevalence in Europe.	6
Supplementary Box S2. Variables extracted from relevant reports meeting the inclusion criteria.	7
Supplementary Table S2. Range of quality components applicable to prevalence studies [2].	8
Supplementary Box S3. Predictors selected a priori and included in univariable and multivariable meta-regression analyses.	9
Supplementary Box S4. List of articles from which <i>Neisseria gonorrhoeae</i> prevalence measures in Europe were extracted.	10
Supplementary Table S3. Number of <i>Neisseria gonorrhoeae</i> prevalence measures by European subregion and country/territory.	33
Supplementary Table S4. Summary of precision assessment and risk of bias (ROB) assessment for studies reporting <i>Neisseria gonorrhoeae</i> prevalence in Europe.	34
Supplementary Figure S1. Forest plots presenting outcomes of the pooled urogenital <i>Neisseria gonorrhoeae</i> prevalence among the different populations in Europe.	35
Supplementary Table S5. Univariable and multivariable meta-regression analyses for <i>Neisseria gonorrhoeae</i> prevalence in urogenital specimens in Europe using the year of publication instead of the year of data collection as the time variable.	46
Supplementary Table S6. Univariable and multivariable meta-regression analyses for <i>Neisseria gonorrhoeae</i> prevalence in anorectal specimens in Europe using the year of publication instead of the year of data collection as the time variable.	48
Supplementary Table S7. Univariable and multivariable meta-regression analyses for <i>Neisseria gonorrhoeae</i> prevalence in oropharyngeal specimens in Europe using the year of publication instead of the year of data collection as the time variable.	50
Supplementary Figure S2. Forest plots displaying the results of cumulative meta-analyses, utilizing the year of publication as the ordering variable, to confirm the trend in <i>Neisseria gonorrhoeae</i> prevalence identified by the meta-regression analyses.	52
References	62

Supplementary Table S1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist [1].

Section and topic	Item #	Checklist item	Location where item is reported
Title			
Title	1	Identify the report as a systematic review.	Title
Abstract			
Abstract	2	See the PRISMA 2020 for Abstracts checklist (table 2).	Abstract section
Introduction			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Introduction section
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Introduction section
Methods			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Methods: Study selection eligibility criteria and section
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Methods: Data sources and search strategy section; Study selection and eligibility criteria section
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Methods: Data sources and search strategy section; Supplementary Box S1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Methods: Study selection and eligibility criteria section
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Methods: Data extraction and synthesis section
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Methods: Study selection and eligibility criteria section; Data extraction and synthesis section; Supplementary Box S2
	10b	List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Methods: Study selection and eligibility criteria section; Data extraction and synthesis section; Box 2; Supplementary Box S2
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Methods: Precision and risk of bias assessments section
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Methods: Meta-analyses section; Meta-regressions section; Supplementary Box S3
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Methods: Meta-analyses section; Meta-regressions section; Supplementary Box S3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Methods: Meta-analyses section; Meta-regressions section
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Methods: Meta-analyses section; Meta-regressions section
	13d	Describe any methods used to synthesise results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Methods: Meta-analyses section
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, metaregression).	Methods: Meta-regressions section; Supplementary Box S3

	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesised results.	Methods: Meta-analyses section; Meta-regressions section
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	N/A
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	N/A
Results			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram (see fig 1).	Results: Search results section; Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Results: Search results section; Figure 1
Study characteristics	17	Cite each included study and present its characteristics.	Results: Scope of evidence for the prevalence measures section; Tables 1-3; Supplementary Box S4
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Results: Precision and risk of bias assessments section; Supplementary Table S3
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Tables 1-6; Supplementary Figure S1
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Results: Precision and risk of bias assessments section; Supplementary Table S3
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Results: Pooled estimates for NG prevalence section; Tables 1-3; Supplementary Figure S1
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Results: Associations with NG prevalence section; Tables 4-6
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesised results.	Results: Sensitivity analyses to confirm the findings section; Supplementary Tables S4-S6; Supplementary Figure S2
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	N/A
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	N/A
Discussion			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Discussion section
	23b	Discuss any limitations of the evidence included in the review.	Discussion section
	23c	Discuss any limitations of the review processes used.	Discussion section
	23d	Discuss implications of the results for practice, policy, and future research.	Conclusions section
Other information			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	N/A
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	N/A
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Funding statement
Competing interests	26	Declare any competing interests of review authors.	Conflict of interest statement

Availability of data, code, and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Data availability statement
---	----	--	-----------------------------

Abbreviations: NA: Not applicable, NG: *Neisseria gonorrhoeae*.

Supplementary Box S1. Search strategies used to identify studies reporting *Neisseria gonorrhoeae* infection prevalence in Europe.

PubMed
<p>“Neisseria gonorrhoeae”[Mesh] OR “Gonorrhea”[Mesh] OR “Pelvic Inflammatory Disease”[Mesh] OR “Epididymitis”[Mesh] OR “Orchitis”[Mesh] OR “Seminal vesicles”[Mesh] OR “Neisseria gonorrhoeae”[Text] OR “Gonorrhoeae”[Text] OR “Gonorrhea”[Text] OR “Gonococcus”[Text] OR “Gonococci”[Text] OR “Gonococcal”[Text] OR “Gonococcal infection”[Text] OR “Pelvic inflammatory disease”[Text] OR “Gonococcal epididymitis”[Text] OR “Orchi-epididymitis”[Text] OR “Orchiepididymitis”[Text] OR “seminal vesicle disease”[Text] OR “Seminal vesiculitis”[Text] OR “Infertility”[Mesh] OR “Fertility”[Mesh] OR “Reproductive Techniques, Assisted”[Mesh] OR “Infertility”[Text] OR “Infertile”[Text] OR “Fertility”[Text] OR “Reproductive”[Text] OR “Subfertility”[Text] OR “Subfertile”[Text] OR “Sub-fertility”[Text] OR “Sub-fertile”[Text] AND (“Europe”[MeSH] OR “Israel”[MeSH] OR “Turkey”[MeSH] OR “USSR”[MeSH] OR “Cyprus”[MeSH] OR Albania*[Text] OR Andorra*[Text] OR Armenia*[Text] OR Austria*[Text] OR Azerbaijan*[Text] OR Belarus*[Text] OR Belgi*[Text] OR Bosnia*[Text] OR Bosnia and Herzegovina[Text] OR Bulgaria*[Text] OR Croatia*[Text] OR Cypr*[Text] OR Czech Republic[Text] OR Czech*[Text] OR Denmark*[Text] OR Danish[Text] OR Estonia*[Text] OR Finland*[Text] OR Finnish[Text] OR France*[Text] OR French[Text] OR Georgia*[Text] OR German*[Text] OR Gree*[Text] OR Hungar*[Text] OR Iceland*[Text] OR Ireland*[Text] OR Irish[Text] OR Israel*[Text] OR Ital*[Text] OR Kazakh*[Text] OR Kyrgyz*[Text] OR Latvia*[Text] OR Lithuania*[Text] OR Luxembourg*[Text] OR Malta*[Text] OR Monac*[Text] OR Montenegr*[Text] OR Netherlands*[Text] OR Dutch[Text] OR Norway*[Text] OR Norweg*[Text] OR Poland*[Text] OR Polish[Text] OR Portug*[Text] OR Republic of Moldova*[Text] OR Moldov*[Text] OR Romania*[Text] OR Russia*[Text] OR Russian Federation*[Text] OR San Marino*[Text] OR Serbia*[Text] OR Slovakia*[Text] OR Slovenia*[Text] OR Spain*[Text] OR Spanish[Text] OR Swed*[Text] OR Switzerland*[Text] OR Swiss[Text] OR Tajik*[Text] OR Yugoslav*[Text] OR Republic of Macedonia*[Text] OR Macedonia*[Text] OR Turkey*[Text] OR Turkmen*[Text] OR Ukrain*[Text] OR United Kingdom*[Text] OR Great Britain*[Text] OR UK[Text] OR Uzbek*[Text])</p>
Embase
<p>exp gonorrhea / or exp 6eisseria gonorrhoeae / or exp epididymitis / or exp orchitis / or exp pelvic inflammatory disease/ or gonorrhea.mp. or 6eisseria gonorrhoeae.mp. or gonorrhoeae.mp. or gonococcus.mp. or gonococci.mp. or gonococcal.mp. or gonococcal infection.mp. or pelvic inflammatory disease.mp. or gonococcal epididymitis.mp. or orchi-epididymitis.mp. or orchiepididymitis.mp. or seminal vesicle disease.mp. or seminal disease.mp. or seminal vasculitis.mp. or exp infertility/ or exp fertility/ or exp infertility therapy/ or exp reproductive procedure/ or reproductive.mp. or infertility.mp. or infertile.mp. or fertility.mp. or subfertility.mp. or subfertile.mp. or sub-fertility.mp. or sub-fertile.mp. and (exp Europe/ or exp Cyprus/ or exp Israel/ or exp USSR or exp Turkey republic/) or (Albania* or Andorra* or Armenia* or Austria* or Azerbaijan* or Belarus* or Belgi* or Bosnia* or Bosnia and Herzegovina or Bulgaria* or Croatia* or Cypr* or Czech Republic* or Czech* or Denmark* or Danish* or Estonia* or Finland* or Finnish* or France* or French* or Georgia* or German* or Gree* or Hungar* or Iceland* or Ireland* or Irish* or Israel* or Ital* or Kazakh* or Kyrgyz* or Latvia* or Lithuania* or Luxembourg* or Malta* or Monac* or Montenegr* or Netherlands* or Dutch* or Norway* or Norweg* or Poland* or Polish* or Portug* or Republic of Moldova* or Moldov* or Romania* or Russia* or Russian Federation* or San Marino* or Serbia* or Slovakia* or Slovenia* or Spain* or Spanish* or Swed* or Switzerland* or Swiss* or Tajik* or Yugoslav Republic of Macedonia* or Macedonia* or Turk* or Turkmen* or Ukrain* or United Kingdom* or Great Britain* or UK or Uzbek*).mp.</p>

Abbreviations: NG: Neisseria gonorrhoeae; USSR: Union of Soviet Socialist Republics.

Supplementary Box S2. Variables extracted from relevant reports meeting the inclusion criteria.

- Author(s)
- Year of publication
- Full citation
- Country
- City
- Study design
- Sampling methodology
- Year(s) of data collection
- Study site
- Study population
- Population characteristics (e.g., sex and age)
- Response rate
- Sample size of tested population
- Number of participants positive for *Neisseria gonorrhoeae* infection
- Reported *N. gonorrhoeae* prevalence
- Anatomical site urogenital (urethral, vaginal, endocervical, urine, and semen), anorectal, oropharyngeal, serum, and unclear)
- Type of assay used for gonorrhea infection ascertainment (nucleic acid amplification test/polymerase chain reaction, culture, gram staining, direct fluorescent antibody assay, blood tested for antibodies, unclear)

Supplementary Table S2. Range of quality components applicable to prevalence studies [2].

1. Was the study's target population a close representation of the national population in relation to relevant variables?	Met in the study design. The study investigated prevalence in all population groups. The meta-regression analyses also explored the impact of sampling method on observed prevalence.
2. Was the sampling frame a true or close representation of the target population?	Met in the study design. Included as the probability-based vs. non-probability-based sampling domain. The meta-regression analyses also explored the impact of sampling method on observed prevalence.
3. Was some form of random selection used to select the sample, OR was a census undertaken?	Met in the study design. Included as the probability-based vs. non-probability-based sampling domain. The meta-regression analyses also explored the impact of sampling method on observed prevalence.
4. Was the likelihood of nonresponse bias minimal?	Met in the study design. Included as the response rate domain.
Internal validity	Relevance to our study
5. Were data collected directly from the subjects (as opposed to a proxy)?	Met in the study design. The inclusion criteria specified that only studies based on biomarkers collected directly from individuals are included.
6. Was an acceptable case definition used in the study?	Met in the study design. A standardized and consistent case definition was used, that of <i>Neisseria gonorrhoeae</i> infection.
7. Was the study instrument that measured the parameter of interest shown to have validity and reliability?	Met in the study design. Only studies that used diagnostic assays measuring specific biomarkers were included. The reported assays have acceptable specificity and sensitivity and are commonly used in research and clinical settings. The meta-regression analyses also explored the impact of assay type on observed prevalence.
8. Was the same mode of data collection used for all subjects?	Met in the study design. It is standard for STI studies involving biomarkers, by design, to use a consistent mode of data collection from all subjects recruited for a study, including specimen type and assay type.
9. Was the length of the shortest prevalence period for the parameter of interest appropriate?	Met in the study design. Included studies reported point prevalence measures, that is prevalence based on a cross-section survey at a specific and defined time.
10. Were the numerator(s) and denominator(s) for the parameter of interest appropriate?	Met in the study design. The numerator and denominator were defined with no ambiguity: number of positive <i>N. gonorrhoeae</i> cases over total number of tested subjects.

STI: Sexually transmitted infection.

Supplementary Box S3. Predictors selected a priori and included in univariable and multivariable meta-regression analyses.

- 1- Population type as defined in Box 2
- 2- Sex
- 3- Age groups classified to best fit reported data as:
 - <20 years old
 - 20-29 years old
 - 30-39 years old
 - ≥40 years old
 - Mixed ages
- 4- Europe subregion as defined in Box 1
- 5- National income as classified by the World Bank [3]
- 6- Assay type:
 - NAAT/PCR
 - Culture
 - Gram staining
 - Other^a
- 7- Sample size:
 - <200
 - ≥200
- 8- Sampling method:
 - Probability-based sampling
 - Non-probability-based sampling
- 9- Response rate:
 - ≥80%
 - <80%
 - Unclear
- 10- Year of data collection category
 - <2000
 - 2000-2010
 - >2010
- 11- Year of data collection as a linear term
- 12- Year of publication category
 - <2005
 - 2005-2014
 - ≥2015
- 13- Year of publication as a linear term

^aOther assays include unclear testing technique, enzyme immunoassay, complement fixation, or mixed testing techniques.

Abbreviations: NAAT: Nucleic acid amplification test; PCR: Polymerase chain reaction.

Supplementary Box S4. List of articles from which *Neisseria gonorrhoeae* prevalence measures in Europe were extracted.

1. Achterbergh R, van der Helm JJ, van den Boom W, et al. Is rectal douching and sharing douching equipment associated with anorectal chlamydia and gonorrhoea? A cross-sectional study among men who have sex with men. *Sex Transm Infect* 2017; 93(6): 431-7.
2. Achterbergh RCA, Drückler S, van Rooijen MS, et al. Sex, drugs, and sexually transmitted infections: A latent class analysis among men who have sex with men in Amsterdam and surrounding urban regions, the Netherlands. *Drug Alcohol Depend* 2020; 206: 107526.
3. Acik Y, Gungor L, Asci Toraman Z. Prevalance and clinical importance of some pathogen microorganisms found in the cervix of women who apply for voluntary abortion. [Turkish]. *Erciyes Tip Dergisi* 2004; 26(2): 55-61.
4. Adelantado Lacasa M, Beristain X. Prevalence of Mycoplasma genitalium infection and antibiotic resistance in Navarra (North Spain). *Sex Transm Infect* 2019; 95(7): 549.
5. Adler MW. Trends for gonorrhea and pelvic inflammatory disease in England and Wales and for gonorrhea in a defined population. *Am J Obstet Gynecol* 1980; 138(7 Pt 2): 901-4.
6. Adler MW, Belsey EM, Rogers JS. Sexually transmitted diseases in a defined population of women. *Br Med J (Clin Res Ed)* 1981; 283(6283): 29-32.
7. Agacfidan A, Moncada J, Aydin D, et al. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in Turkey among men With urethritis. *Sex Transm Dis* 2001; 28(11): 630-2.
8. Aguirrebengoa O, Vera Garcia M, Arias Ramirez D, et al. Low use of condom and high STI incidence among men who have sex with men in PrEP programs. *PLoS One* 2021; 16(2): e0245925.
9. Agusti C, Montoliu A, Mascort J, et al. Missed opportunities for HIV testing of patients diagnosed with an indicator condition in primary care in Catalonia, Spain. *Sex Transm Infect* 2016; 92(5): 387-92.
10. Ahmed-Jushuf IH, Arya OP, Hobson D, et al. Ciprofloxacin treatment of chlamydial infections of urogenital tracts of women. *Genitourinary Medicine* 1988; 64(1): 14-7.
11. Akgul A, Kadioglu A, Koksall MO, Ozmez A, Agacfidan A. Sexually transmitted agents and their association with leucocytospermia in infertility clinic patients. *Andrologia* 2018; 50(10): e13127.
12. Akhvlediani T, Mdivani K, Ispireli M, et al. Sexually transmitted infections in military personnel in the country of Georgia. *International Journal of STD and AIDS* 2015; 1): 112.
13. Al-Jilahiawi S, Borg K, Jamieson K, Maguire S, Hodes D. Clinical characteristics of children presenting with a suspicion or allegation of historic sexual abuse. *Archives of Disease in Childhood* 2018; 103(6): 533-9.
14. Albus C, Köhler G. [Is there is seasonal incidence of acute adnexitis?]. *Zentralbl Gynakol* 1988; 110(13): 824-6.
15. Alexandre C. [Study of 534 cases of lowered male fertility]. *Gynecol Obstet (Paris)* 1971; 70(4): 377-400.
16. Almeida N, Melo M, Soares I, Carvalho H. [Screening of Human Immunodeficiency Virus and Other Sexually Transmitted Infections in a Group of Sex Workers in Indoor Settings in the Porto Metropolitan Area]. *Acta Med Port* 2020; 33(3): 166-73.
17. Amirkhanian YA, Kelly JA, Kabakchieva E, et al. High-risk sexual behavior, HIV/STD prevalence, and risk predictors in the social networks of young Roma (Gypsy) men in Bulgaria. *J Immigr Minor Health* 2013; 15(1): 172-81.
18. Andersen BL, Nielsen FH. [Gonorrhoea in young women admitted to a gynaecology department]. *Ugeskr Laeger* 1974; 136(36): 2027-9.
19. Andersson N, Allard A, Lidgren Y, Boman J, Nylander E. Are Urogenital Symptoms Caused by Sexually Transmitted Infections and Colonizing Bacteria? *J Low Genit Tract Dis* 2021b; 25(3): 232-5.
20. Andersson N, Ejnestrand J, Lidgren Y, Allard A, Boman J, Nylander E. Are Swedish swingers a risk group for sexually transmitted infections? *Int J STD AIDS* 2021a; 32(5): 427-34.
21. Anestad G, Bruu AL, Thorvaldsen J, et al. [Urogenital Chlamydia trachomatis infection in a student population]. *Tidsskr Nor Laegeforen* 1984; 104(7): 499-502.
22. Anisimova N, Ivanova T, Guschin A, et al. Undiscovered burden of stis in Russia: Current system shortcomings. *Sexually Transmitted Infections* 2011; 1): A100-A1.
23. Annan NT, Sullivan AK, Nori A, et al. Rectal chlamydia--a reservoir of undiagnosed infection in men who have sex with men. *Sex Transm Infect* 2009; 85(3): 176-9.
24. Ansart S, Hochedez P, Perez L, Bricaire F, Caumes E. Sexually transmitted diseases diagnosed among travelers returning from the tropics. *J Travel Med* 2009; 16(2): 79-83.
25. Apers L, Florence E, Crucitti T, Anwar N. Lymphogranuloma venereum among patients presenting at the HIV/STI clinic in Antwerp, Belgium: A case series. *Acta Gastro-Enterologica Belgica* 2017; 80(3): 385-7.
26. Apers L, Koole O, Bottieau E, et al. Incidence of HCV and sexually transmitted diseases among hiv positive msm in antwerp, belgium, 2001-2011. *Acta Clin Belg* 2013; 68(6): 421-6.
27. Arando M, Fernandez-Naval C, Mota-Foix M, et al. Early syphilis: risk factors and clinical manifestations focusing on HIV-positive patients. *BMC Infect Dis* 2019; 19(1): 727.
28. Arumainayagam JT, de Silva Y, Shahmanesh M. Anaerobic vaginosis: study of male sexual partners. *Int J STD AIDS* 1991; 2(2): 102-4.
29. Arvidson M, Hellberg D, Mårdh PA. Sexually transmitted diseases in Swedish women with experience of casual sex with men of foreign nationalities within Sweden. *Acta Obstet Gynecol Scand* 1995; 74(10): 794-8.
30. Arya OP, Hobson D, Hart CA, Bartzokas C, Pratt BC. Evaluation of ciprofloxacin 500 mg twice daily for one week in treating uncomplicated gonococcal, chlamydial, and non-specific urethritis in men. *Genitourinary Medicine* 1986; 62(3): 170-4.
31. Arya OP, Mallinson H, Goddard AD. Epidemiological and clinical correlates of chlamydial infection of the cervix. *Br J Vener Dis* 1981; 57(2): 118-24.
32. Ascioglu O, Gungorduk K, Ozdemir A, et al. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. *Eur J Obstet Gynecol Reprod Biol* 2013; 171(1): 116-21.
33. Asmaryan A, Grigoryan S, Hovhannisyan E. Unprotected sex with non-commercial partners as the main risk factor to get sti for female sex workers in armenia. *Sexually Transmitted Infections* 2017; 93(Supplement 2): A98-A9.
34. Asmaryan A, Papoyan A, Hakobyan A, et al. Prevalence of STI/HIV and assessment of risky behaviours among sex workers. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
35. Avonts D, Piot P. Genital infections in women undergoing therapeutic abortion. *Eur J Obstet Gynecol Reprod Biol* 1985; 20(1): 53-9.
36. Avonts D, Sercu M, Heyerick P, Vandermeeren I, Piot P. Sexually transmitted diseases and Chlamydia trachomatis in women consulting for contraception. *J R Coll Gen Pract* 1989; 39(327): 418-20.
37. Ayerdi Aguirrebengoa O, Vera Garcia M, Rueda Sanchez M, et al. Risk factors associated with sexually transmitted infections and HIV among adolescents in a reference clinic in Madrid. *PLoS One* 2020; 15(3): e0228998.
38. Bacon PM. Social distribution of sexually transmitted diseases. A survey of female clinic registrations. *Br J Vener Dis* 1979; 55(4): 295-9.
39. Bailey JV, Farquhar C, Owen C, Mangtani P. Sexually transmitted infections in women who have sex with women. *Sex Transm Infect* 2004; 80(3): 244-6.

40. Balbi G, Piscitelli V, Di Grazia F, Martini S, Balbi C, Cardone A. [Acute pelvic inflammatory disease: comparison of therapeutic protocols]. *Minerva Ginecol* 1996; 48(1-2): 19-23.
41. Banani S, Schlaeffer F, Leibenson L, et al. [Prevalence of sexually transmitted diseases (STD) in HIV positive women in southern Israel]. *Harefuah* 2013; 152(4): 204-6, 48.
42. Banerjee P, Thorley N, Radcliffe K. A service evaluation comparing home-based testing to clinic-based testing for Chlamydia and gonorrhoea in Birmingham and Solihull. *Int J STD AIDS* 2018; 29(10): 974-9.
43. Bardov PV, Lebediuk MM, Stepanenko VI. [Complex diagnosis of chronic prostatitis complicated by disorders in sexual and reproductive functions]. *Lik Sprava* 2001; (3): 77-81.
44. Barlow D, Nayyar K, Phillips I, Barrow J. Diagnosis of gonorrhoea in women. *Br J Vener Dis* 1976; 52(5): 326-8.
45. Barthell E, Woelber L, Hellner K, et al. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. *Arch Gynecol Obstet* 2009; 279(6): 803-7.
46. Bartholomew RD, Kerry-Barnard S, Beckley-Hoelscher ND, et al. Alcohol use, cigarette smoking, vaping and number of sexual partners: A cross-sectional study of sexually active, ethnically diverse, inner city adolescents. *Health Expect* 2021; 24(3): 1009-14.
47. Bartunek J, Scholtes G. [Significance of modern gonorrhea diagnostics in the management of inflammatory gynecologic diseases]. *Geburtshilfe Frauenheilkd* 1972; 32(11): 928-31.
48. Bassiri M, Mårdh PA, Domeika M. Multiplex AMPLICOR PCR screening for Chlamydia trachomatis and Neisseria gonorrhoeae in women attending non-sexually transmitted disease clinics. The European Chlamydia Epidemiology Group. *J Clin Microbiol* 1997; 35(10): 2556-60.
49. Bayette J, Jreige R, Marchandin H, et al. [Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections in the emergency department]. *Pathol Biol (Paris)* 2013; 61(6): 245-9.
50. Bebear C, Le Roy C, Le Hen I, et al. Performance of the Bio-Rad Dx CT/NG/MG assay for simultaneous detection of chlamydia trachomatis, Neisseria gonorrhoeae and mycoplasma genitalium in urogenital samples. *Sexually Transmitted Infections* 2011; 1): A74.
51. Beckett H, Nulty K, Barber T. Assessing self-taken vaginal swabs compared to clinician sampling in women presenting with vaginal discharge only in our central London location. *HIV Medicine* 2018; 19(Supplement 2): S128.
52. Bell G, Ward H, Day S, et al. Partner notification for gonorrhoea: a comparative study with a provincial and a metropolitan UK clinic. *Sex Transm Infect* 1998; 74(6): 409-14.
53. Beltrami C, Manfredi R, D'Antuono A, Chiodo F, Varotti C. Sexually-transmitted infections in adolescents and young adults in a large city of Northern Italy: a nine-year prospective survey. *New Microbiol* 2003; 26(3): 233-41.
54. Belzunegui J, Rodríguez-Arondo F, González C, et al. Musculoskeletal infections in intravenous drug addicts: report of 34 cases with analysis of microbiological aspects and pathogenic mechanisms. *Clin Exp Rheumatol* 2000; 18(3): 383-6.
55. Benjamin L, Araujo MA, Martin-Bouyer G. [Asymptomatic cases of gonorrhea and syphilis in 2 family planning clinics in the Paris Region]. *Gynecologie* 1978; 29(3): 303-7.
56. Benn PD, Rooney G, Carder C, et al. Chlamydia trachomatis and Neisseria gonorrhoeae infection and the sexual behaviour of men who have sex with men. *Sex Transm Infect* 2007; 83(2): 106-12.
57. Bennett A, Jeffery K, O'Neill E, Sherrard J. Outbreak or illusion: Consequences of "improved" diagnostics for gonorrhoea. *Sexually Transmitted Infections* 2015; 1): A23-A4.
58. Bercot B, Amarsy R, Goubard A, et al. Assessment of coinfection of sexually transmitted pathogen microbes by use of the anyplex II STI-7 molecular kit. *J Clin Microbiol* 2015; 53(3): 991-3.
59. Bernier A, Rumyantseva T, Reques L, et al. HIV and other sexually transmitted infections among female sex workers in Moscow (Russia): prevalence and associated risk factors. *Sex Transm Infect* 2020; 96(8): 601-7.
60. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL. Clinical, laparoscopic and microbiological findings in acute salpingitis: Report on a United Kingdom cohort. *British Journal of Obstetrics and Gynaecology* 1995; 102(5): 407-14.
61. Bhaduri S, Howells V. Evaluation of the Roche Cobas Amplicor polymerase chain reaction test for gonorrhoea in a low prevalence area. *Int J STD AIDS* 2007; 18(11): 796-7.
62. Bhagey A, Foster K, Ralph S, et al. High prevalence of anti-hepatitis A IgG in a cohort of UK HIV-negative men who have sex with men: implications for local hepatitis A vaccine policy. *Int J STD AIDS* 2018; 29(10): 1007-10.
63. Bhatt K, Goodall L. An audit of gonorrhoea management in a UK sexual health clinic. *Sexually Transmitted Infections* 2015; 1): A54.
64. Bialo-Wojcicka E, Mlynarczyk-Bonikowska B, Winiarska A, et al. Syphilis in patients of the Department of Dermatology and Venereology at Medical University of Warsaw in 2015 - Epidemiological and clinical characteristics, and coexistence of other sexually transmitted diseases. *Przegląd Dermatologiczny* 2017; 104(6): 597-605.
65. Bilagi A, Mahavarkar S. Teenage pregnancy: An experience in a university hospital. *BJOG: An International Journal of Obstetrics and Gynaecology* 2018; 125(Supplement 2): 111.
66. Bird E, Micanovic C, McCrann C, Hegazi A. Keeping on top of BV-an audit of bacterial vaginosis and STI screening in gum clinic attendees requesting a termination of pregnancy. *Sexually Transmitted Infections* 2016; 92(Supplement 1): A97.
67. Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. *BJOG* 2010; 117(3): 361-4.
68. Bjornelius E, Lidbrink P, Jensen JS. Mycoplasma genitalium in non-gonococcal urethritis--a study in Swedish male STD patients. *Int J STD AIDS* 2000; 11(5): 292-6.
69. Blackwell AL, Thomas PD, Wareham K, Emery SJ. Health gains from screening for infection of the lower genital tract in women attending for termination of pregnancy. *Lancet* 1993; 342(8865): 206-10.
70. Body G, Quentin R, Lyon J, Pinon G, Lansac J. [Acute gonococcal salpingitis]. *J Gynecol Obstet Biol Reprod (Paris)* 1985; 14(4): 477-85.
71. Boeke AJ, Dekker JH, Peerbooms PG. A comparison of yield from cervix versus vagina for culturing Candida albicans and Trichomonas vaginalis. *Genitourin Med* 1993; 69(1): 41-3.
72. Boesecke C, Kimhofer T, Tocha C, et al. Are we reaching the at-risk patient populations for hiv and other stis? *Topics in Antiviral Medicine* 2021; 29(1): 267.
73. Boiko I, Golparian D, Krynytska I, Unemo M. High prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and particularly Trichomonas vaginalis diagnosed using US FDA-approved Aptima molecular tests and evaluation of conventional routine diagnostic tests in Ternopil, Ukraine. *Apmis* 2019; 127(9): 627-34.
74. Bolumburu C, Zamora V, Munoz-Algarra M, Portero-Azorin F, Escario JA, Ibanez-Escribano A. Trichomoniasis in a tertiary hospital of Madrid, Spain (2013-2017): prevalence and pregnancy rate, coinfections, metronidazole resistance, and endosymbiosis. *Parasitol Res* 2020; 119(6): 1915-23.
75. Bond E, Lu D, Herweijer E, et al. Sexually transmitted infections after bereavement - a population-based cohort study. *BMC Infect Dis* 2016; 16(1): 419.
76. Borges da Costa J, Azevedo J, Santo I. Sexually transmitted infections and related sociodemographic factors in Lisbon's major Venereology Clinic: a descriptive study of the first 4 months of 2007. *J Eur Acad Dermatol Venereol* 2010; 24(7): 811-4.

77. Borges-Costa J, Matos C, Pereira F. Sexually transmitted infections in pregnant adolescents: prevalence and association with maternal and foetal morbidity. *J Eur Acad Dermatol Venereol* 2012; 26(8): 972-5.
78. Bos JM, Fennema JSA, Postma MJ. Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. *Aids* 2001; 15(15): 2031-6.
79. Boucher A, Meybeck A, Alidjinou K, et al. Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France. *Sex Transm Infect* 2019; 95(1): 75-7.
80. Bourgeois-Nicolaos N, Jauregui F, Pozzi-Gaudin S, et al. Benefits of Rapid Molecular Diagnosis of Chlamydia Trachomatis and Neisseria Gonorrhoeae Infections in Women Attending Family Planning Clinics. *Sex Transm Dis* 2015; 42(11): 652-3.
81. Bovet R, Calanchini E, Sakellarides E, Jéquier N. [Pharyngeal and anorectal gonorrhea. Incidence in Lausanne in 1981]. *Schweiz Med Wochenschr* 1982; 112(43): 1494-7.
82. Bozděch V, Drazdákova M, Kvicera J, Zítková A. [Trichomonal infections in promiscuous women]. *Angew Parasitol* 1982; 23(2): 65-9.
83. Bozicevic I, Lepej SZ, Rode OD, et al. Prevalence of HIV and sexually transmitted infections and patterns of recent HIV testing among men who have sex with men in Zagreb, Croatia. *Sexually Transmitted Infections* 2012; 88(7): 539-44.
84. Bozicevic I, Rode OD, Lepej SZ, et al. Prevalence of sexually transmitted infections among men who have sex with men in Zagreb, Croatia. *AIDS and Behavior* 2009; 13(2): 303-9.
85. Braun DL, Kouyos R, Ghenzi R, Grube C, Weber R, Gunthard H. Increasing rates of STI are linked to reduced condom use in patients with primary HIV-1 infection. *Topics in Antiviral Medicine* 2014; 22(E-1): 540-1.
86. Braun DL, Marzel A, Steffens D, et al. High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection. *Clin Infect Dis* 2018; 66(5): 735-42.
87. Braunholtz-Speight J, Turner E, Wallace H, Schoeman S, Evans A. Working the streets-targetting migrant sexworkers through dedicated outreach. *Sexually Transmitted Infections* 2017; 93(Supplement 1): A94.
88. Bremer V, Haar K, Gassowski M, Hamouda O, Nielsen S. STI tests and proportion of positive tests in female sex workers attending local public health departments in Germany in 2010/11. *BMC Public Health* 2016; 16(1): 1175.
89. Bremer V, Jansen K, Steffen G, et al. Prevalence of genital infections with chlamydia trachomatis (CT), neisseria gonorrhoea (NG) and Trichomonas Vaginalis (TV) in clients of public hiv counselling institutions in north rhine-westphalia, Germany: The STI-HIT Study. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
90. Breustedt W. [The incidence of genital chlamydial infections in patients of a venereologic consultation clinic]. *Dermatol Monatsschr* 1989; 175(7): 443-9.
91. Brihmer C, Kallings I, Nord CE, Brundin J. Salpingitis; aspects of diagnosis and etiology: a 4-year study from a Swedish capital hospital. *Eur J Obstet Gynecol Reprod Biol* 1987; 24(3): 211-20.
92. Bro F. Vaginal microbial flora in women with and without vaginal discharge registered in general practice. *Dan Med Bull* 1989; 36(5): 483-5.
93. Broad CE, Furegato M, Harrison MA, et al. High prevalence of coinfection of azithromycin-resistant Mycoplasma genitalium with other STIs: a prospective observational study of London-based symptomatic and STI-contact clinic attendees. *Sex Transm Infect* 2021; 97(1): 63-8.
94. Brorson JE, Holmberg I, Nygren B, Seeberg S. Vancomycin-sensitive strains of Neisseria gonorrhoeae. A problem for the diagnostic laboratory. *Br J Vener Dis* 1973; 49(5): 452-3.
95. Brosh-Nissimov T, Kedem R, Ophir N, Shental O, Keller N, Amit S. Management of sexually transmissible infections in the era of multiplexed molecular diagnostics: a primary care survey. *Sex Health* 2018; 15(4): 298-303.
96. Brunner A, Nemes-Nikodem E, Mihalik N, Marschalko M, Karpati S, Ostorhazi E. Incidence and antimicrobial susceptibility of Neisseria gonorrhoeae isolates from patients attending the national Neisseria gonorrhoeae reference laboratory of Hungary. *BMC Infect Dis* 2014; 14: 433.
97. Bryman I, Granberg S, Norstrom A. Reduced incidence of postoperative endometritis by the use of Laminaria tents in connection with first trimester abortion. *Acta Obstet Gynecol Scand* 1988; 67(4): 323-5.
98. Buekens P, Hubrechts JM, Romero M, Vekemans M. Chlamydia trachomatis and induced abortion. *European Journal of Sexually Transmitted Diseases* 1984; 1(3-4): 133-6.
99. Burns F, Curran B, Tobin R, Kell P. An urban epidemic--an audit of an inner city young persons' clinic. *Int J STD AIDS* 2002; 13(1): 52-4.
100. Burns FM, Mercer CH, Evans AR, Gerry CJ, Mole R, Hart GJ. Increased attendances of people of eastern European origin at sexual health services in London. *Sex Transm Infect* 2009; 85(1): 75-8.
101. Burton R, Duncan S, Wardle E, Patel C, Clarke E. Unintended consequences: the potential impacts of the British Association for Sexual Health and HIV (BASHH) 2019 gonorrhoea guidelines. *Int J STD AIDS* 2021; 32(4): 344-51.
102. Cabello Ubeda A, Fernandez Roblas R, Garcia Delgado R, et al. Anorectal Lymphogranuloma Venereum in Madrid: A Persistent Emerging Problem in Men Who Have Sex With Men. *Sex Transm Dis* 2016; 43(7): 414-9.
103. Cameron RL, Cuschieri K, Pollock KGJ. Baseline HPV prevalence in rectal swabs from men attending a sexual health clinic in Scotland: assessing the potential impact of a selective HPV vaccination programme for men who have sex with men. *Sex Transm Infect* 2020; 96(1): 55-7.
104. Camporiondo MP, Farchi F, Ciccozzi M, et al. Detection of HPV and co-infecting pathogens in healthy Italian women by multiplex real-time PCR. *Infez Med* 2016; 24(1): 12-7.
105. Carlsson I, Breiding K, Larsson PG. Complications related to induced abortion: a combined retrospective and longitudinal follow-up study. *BMC Womens Health* 2018; 18(1): 158.
106. Carne CA, Gibbs J, Delaney A, et al. Prevalence, clinical features and quantification of genital non-viral infections. *Int J STD AIDS* 2013; 24(4): 273-7.
107. Casin I, Vexiau-Robert D, De La Salmoniere P, Eche A, Grandry B, Janier M. High prevalence of Mycoplasma genitalium in the lower genitourinary tract of women attending a sexually transmitted disease clinic in Paris, France. *Sex Transm Dis* 2002; 29(6): 353-9.
108. Cassidy S, Artykov R, White J. Equivocal Aptima Combo 2 results: What do they mean in clinical practice? *Sexually Transmitted Infections Conference: 4th Joint BASHH ASTDA Meeting Brighton United Kingdom Conference Publication: 2012; 88(SUPPL. 1).*
109. Castriiciano S, Montrucchio G, Moglia R, et al. Comparison of copan uriswab with BD probetec urine preservative transport kit for preservation and detection of CT and NG in the probetec assay. *Sexually Transmitted Infections* 2011; 1): A277-A8.
110. Catarino R, Cherkaoui A, Trelu LT, Yaron M. Who should be screened for Chlamydia trachomatis infection? Three years' experience at a University Hospital in Switzerland. *Journal of Infection in Developing Countries* 2018; 12(3): 208-10.
111. Cavilla S, Churchill D, Dean G, Smith S. Greater focus on incident HIV infections is required to end the HIV epidemic. *HIV Medicine* 2020; 21(S4): 16-74.
112. Ceccarani C, Marangoni A, Severgnini M, et al. Rectal Microbiota Associated With Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Men Having Sex With Other Men. *Front Cell Infect Microbiol* 2019; 9: 358.
113. Cevenini R, Possati G, La Placa M. Chlamydia trachomatis infection in infertile women. *Fernstrom Foundation Series* 1982; Vol. 2: 189-92.
114. Chalker VJ, Jordan K, Ali T, Ison C. Real-time PCR detection of the mg219 gene of unknown function of Mycoplasma genitalium in men with and without non-gonococcal urethritis and their female partners in England. *J Med Microbiol* 2009; 58(Pt 7): 895-9.

115. Champion JK, Ross JDC. Referral patterns between primary care and genitourinary medicine. *International Journal of STD and AIDS* 1999; 10(2): 121-3.
116. Chan SY, Hegazi A, Beardall A, Hay P. An audit on the management of pelvic inflammatory disease (PID). *Sexually Transmitted Infections Conference: 4th Joint BASHH ASTDA Meeting Brighton United Kingdom Conference Publication*: 2012; 88(SUPPL. 1).
117. Cherkaoui A, Renzi G, Mombelli M, et al. Comparison of analytical performances of the Roche Cobas 6800 CT/NG assay with the Abbott m2000 Real Time CT/NG assay for detecting *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *J Med Microbiol* 2019; 68(2): 197-200.
118. Childs T, Simms I, Alexander S, Eastick K, Hughes G, Field N. Rapid increase in lymphogranuloma venereum in men who have sex with men, United Kingdom, 2003 to September 2015. *Euro Surveill* 2015; 20(48): 30076.
119. Chima-Okereke C, Burton A, Blackwell A. A comparison of demographic details, source of referral, and spectrum of infection in patients under 16 years attending Singleton Hospital Genitourinary Medicine Department in 1997 and 2000. *Int J STD AIDS* 2002; 13(12): 859-60.
120. Chiodo E, Latino MA, Chiodo F, Gordini G. Genital infections in adult men observed at Ospedale S. Anna department of pathologic anatomy, Turin, from July 1, 1986 to June 30, 1990. *Giornale di Malattie Infettive e Parassitarie* 1991; 43(2): 160-1.
121. Christiansen MAD, Lowhagen GB. Sexually transmitted diseases and sexual behaviour in men attending an outpatients' clinic for gay men in Gotheburg, Sweden. *Acta Dermato-Venereologica* 2000; 80(2): 136-9.
122. Christophersen J, Menne T, Friis-Møller A, Nielsen JO, Hansted B, Ohlenschloeger J. Sexually transmitted diseases in hetero-, homo- and bisexual males in Copenhagen. *Dan Med Bull* 1988; 35(3): 285-8.
123. Chung E, Waters L, Mercey D, Edwards S. High rates of recreational drug use (RDU) in HIV+ men who have sex with men (MSM) with sexually transmitted infections (STI). *HIV Medicine* 2014; 3: 50.
124. Cicinelli E, De Ziegler D, Nicoletti R, et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. *Fertil Steril* 2008; 89(3): 677-84.
125. Cielniak I, Siwak E, Pazdan I, Szymanska-Kotwica B, Parczewski M. Clinical outcomes of pre-exposure prophylaxis from clinical center in Warsaw, Poland. *HIV Medicine* 2019; 20(S9): 317-37.
126. Claesys P, Ismailov R, Rathe S, et al. Sexually transmitted infections and reproductive health in Azerbaijan. *Sex Transm Dis* 2001; 28(7): 372-8.
127. Clarivet B, Picot E, Marchandin H, et al. Prevalence of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Mycoplasma genitalium* in asymptomatic patients under 30 years of age screened in a French sexually transmitted infections clinic. *Eur J Dermatol* 2014; 24(5): 611-6.
128. Coffey AJ, Dwyer J. An insight into STIs commonly encountered in a university health department - Prevalence and predictive factors. *Irish Journal of Medical Science* 2018; 187(3 Supplement 1): S27-S8.
129. Cohen L. The "pill", promiscuity, and venereal disease. *Br J Vener Dis* 1970; 46(2): 108-10.
130. Colon RL, Vives N, Vall M, et al. Sexually transmitted infections surveillance through a primary care sentinel network, Catalonia, 2011-2014. *International Journal of STD & AIDS* 2015; 26(11 suppl): 1-121.
131. Conway RJ, Cook S, Malone C, Bone S, Hassan-Ibrahim MO, Soni S. Resistance-guided treatment of *Mycoplasma genitalium* infection at a UK sexual health centre. *Int J STD AIDS* 2021; 32(8): 758-65.
132. Coorevits L, Traen A, Bingé L, et al. Identifying a consensus sample type to test for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium*, *Trichomonas vaginalis* and human papillomavirus. *Clin Microbiol Infect* 2018; 24(12): 1328-32.
133. Corbeto EL, Lugo R, Martró E, et al. [Prevalence and determining factors of acquiring *C. trachomatis* infection among adolescents and young adults in Catalonia]. *Enferm Infecc Microbiol Clin* 2011; 29(2): 96-101.
134. Cordtz T. A three months survey of gonorrhea in the VD-clinic of Nuuk, Greenland. *Arctic Med Res* 1988; 47 Suppl 1: 683-5.
135. Cornier N, Petrova E, Cavailler P, et al. Optimising the management of vaginal discharge syndrome in Bulgaria: cost effectiveness of four clinical algorithms with risk assessment. *Sex Transm Infect* 2010; 86(4): 303-9.
136. Cousins D, Cutforth R, Ghanem M, Riddell L. Limited clinical benefits of endocervical microscopy when the use of nucleic acid testing for *N. gonorrhoea* is standard practice in symptomatic women. *International Journal of STD and AIDS* 2015; 1: 101.
137. Cox C, Watt AP, McKenna JP, Coyle PV. *Gardnerella vaginalis* and *Mollicute* detection in rectal swabs from men who have sex with men. *Int J STD AIDS* 2017; 28(7): 708-14.
138. Creighton S, Edwards S, Welch J, Miller R. News from the frontline: sexually transmitted infections in teenagers attending a genitourinary clinic in south east London. *Sex Transm Infect* 2002; 78(5): 349-51.
139. Cresswell F, Ross S, Booth T, et al. An outbreak of *shigella flexneri* infection amongst MSM in Brighton: A descriptive study. *HIV Medicine* 2014; 3: 136.
140. Criado MD, Garrido CF, San Martín EM, et al. Is vertical transmission of *chlamydia trachomatis* a health problem in Spain? *European Journal of Pediatrics* 2019; 178(11): 1621-2.
141. Cribrier B, Asch PH, Tardieu JC. Declining rates of gonorrhoea and syphilis in Strasbourg, France: a 20-year study. *Genitourin Med* 1994; 70(4): 273-7.
142. Currie S, Nicol E, Thompson T, Tomassi S, McQuillan O. It's what's inside that counts: Review of sexual health care provision in a large high-security men's prison. *HIV Medicine* 2018; 19(Supplement 2): S136.
143. Cuyper WJ, Niekamp AM, Keesmokers R, et al. High prevalence of HIV, other sexually transmitted infections and risk profile in male commercial sex workers who have sex with men in the Netherlands. *Sexually Transmitted Infections* 2011; 1: A127.
144. Cwikel JG, Lazer T, Press F, Lazer S. Sexually transmissible infections among illegal female sex workers in Israel. *Sexual Health* 2006; 3(4): 301-3.
145. D'Antuono A, Andalo F, Carla EM, De Tommaso S. Prevalence of STDs and HIV infection among immigrant sex workers attending an STD centre in Bologna, Italy. *Sex Transm Infect* 2001; 77(3): 220.
146. D'Antuono A, De Tommaso S, Calderoni O, Negosanti M. Sexually transmitted diseases among foreigners in Bologna. [Italian]. *Giornale Italiano di Dermatologia e Venereologia* 1999; 134(1): 11-5.
147. Dahl E. [Venereal diseases among seamen. Venereal diseases among Norwegian and foreign staff on a Norwegian cruise ship in the Caribbean during 2 and one-half years of sailing]. *Tidsskr Nor Laegeforen* 1974; 94(34-36): 2372-4.
148. Dakshina S, Cowdy C, Dave J, Sampson M, Sarner L, Tong W. Confirmatory tests for oropharyngeal gonorrhoea in GUM clinics. *HIV Medicine* 2014; 3: 104-5.
149. Dale AW, Wilson JD, Forster GE, Daniels D, Brook MG. Management of epididymo-orchitis in Genitourinary Medicine clinics in the United Kingdom's North Thames region 2000. *Int J STD AIDS* 2001; 12(5): 342-5.
150. Dan M, Kaneti N, Levin D, Poch F, Samra Z. Vaginitis in a gynecologic practice in Israel: causes and risk factors. *Isr Med Assoc J* 2003; 5(9): 629-32.
151. Dao TL, Canard N, Hoang VT, et al. Risk factors for symptoms of infection and microbial carriage among French medical students abroad. *Int J Infect Dis* 2020; 100: 104-11.
152. Dautigny M, Ebel A, Merlin S, Souchet A, Ronsin C. Prevalence of *Trichomonas Vaginalis* in France and comparison with *chlamydia trachomatis* and *Neisseria Gonorrhoeae* as determined by the APTIMA *Trichomonas Vaginalis* nucleic acid amplification assay. *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013*; 89(SUPPL. 1).

153. Dave S, Kerry SR, Oakeshott P, McGregor F, Cannon E, Stephenson JM. Women's health study of Mycoplasma genitalium: A feasibility study. Sexually Transmitted Infections Conference: 4th Joint BASHH ASTDA Meeting Brighton United Kingdom Conference Publication: 2012; 88(SUPPL. 1).
154. David N. Sexually transmitted infections in elderly people. Sexually Transmitted Infections 2000; 76(3): 222-.
155. David Parker R, Regier MD, Widmeyer J, Honaker J, Ruutel K. Reported contraceptive use, risk behaviours and STIs among military conscripts in Estonian defence forces. Int J STD AIDS 2015; 26(11): 815-20.
156. Davies B, Daley S, Brown J, Talbot A, Fifer H, Wilson J. An outbreak of high level azithromycin resistant gonorrhoea in a UK City-actions taken by the clinical team and lessons learnt. Sexually Transmitted Infections 2016; 92(Supplement 1): A13.
157. Davies O, Costelloe S, Cross G, et al. Impact of rectal gonorrhoea and chlamydia on HIV viral load in the rectum: potential significance for onward transmission. Int J STD AIDS 2017; 28(10): 1034-7.
158. Day S, Smith J, Perera S, Jones S, Kinsella R. Beyond the binary: sexual health outcomes of transgender and non-binary service users of an online sexual health service. Int J STD AIDS 2021; 32(10): 896-902.
159. De Baetselier I, Apers L, Platteau T, et al. The impact of physical restriction measures imposed during the two waves of COVID-19 on chlamydia and gonorrhea diagnoses in Belgium. Results of an sexually transmitted infection clinic. Int J STD AIDS 2021a; 32(11): 998-1003.
160. De Baetselier I, Osbak KK, Smet H, Kenyon CR, Crucitti T. Take three, test one: a cross-sectional study to evaluate the molecular detection of Chlamydia trachomatis and Neisseria gonorrhoeae in pooled pharyngeal, anorectal and urine samples versus single-site testing among men who have sex with men in Belgium. Acta Clin Belg 2020; 75(2): 91-5.
161. De Baetselier I, Reyniers T, Platteau T, et al. Recurrent Sexually Transmitted Infections Among a Cohort of Men Who Have Sex With Men Using Preexposure Prophylaxis in Belgium Are Highly Associated With Sexualized Drug Use. Sex Transm Dis 2021b; 48(10): 726-32.
162. De Baetselier I, Smet H, Abdellati S, et al. Evaluation of the 'Colli-Pee', a first-void urine collection device for self-sampling at home for the detection of sexually transmitted infections, versus a routine clinic-based urine collection in a one-to-one comparison study design: efficacy and acceptability among MSM in Belgium. BMJ Open 2019; 9(4): e028145.
163. De Francesco D, Verboeket SO, Underwood J, et al. Patterns of co-occurring comorbidities in people living with HIV. Open Forum Infectious Diseases 2018; 5(11).
164. de Jong AS, Rahamat-Langendoen JC, van Alphen P, et al. Large two-centre study into the prevalence of Mycoplasma genitalium and Trichomonas vaginalis in the Netherlands. Int J STD AIDS 2016; 27(10): 856-60.
165. de Salazar A, Espadafor B, Fuentes-Lopez A, et al. Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections. PLoS One 2019; 14(9): e0222439.
166. de Sanjose S, Munoz N, Bosch FX, et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994; 56(3): 358-63.
167. De Silva D, Peters J, Cole K, et al. Whole-genome sequencing to determine transmission of Neisseria gonorrhoeae: an observational study. Lancet Infect Dis 2016; 16(11): 1295-303.
168. de Vries HJ, van der Helm JJ, Schim van der Loeff MF, van Dam AP. Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. Euro Surveill 2009; 14(37).
169. De Vrieze NHN, Van Rooijen M, Van Der Loeff MFS, De Vries HJC. Anorectal and inguinal lymphogranuloma venereum among men who have sex with men in Amsterdam, the Netherlands: Trends over time, symptomatology and concurrent infections. Sexually Transmitted Infections 2013; 89(7): 548-52.
170. De Vrieze NHN, Van Rooijen MS, Van De Loeff MS, De Vries HJC. Additional gonorrhea and chlamydia infections found with rapid follow-up screening in men who have sex with men with an indication for hiv postexposure prophylaxis. Sexually Transmitted Diseases 2014; 41(8): 515-7.
171. de Wit JB, van den Hoek JA, Sandfort TG, van Griensven GJ. Increase in unprotected anogenital intercourse among homosexual men. Am J Public Health 1993; 83(10): 1451-3.
172. Defraye A, Van Beekhoven D, Sasse A. Surveillance of sexually transmitted infections among persons living with HIV. Int J Public Health 2011; 56(2): 169-74.
173. Del Prete R, Ronga L, Lestingi M, et al. Simultaneous detection and identification of STI pathogens by multiplex Real-Time PCR in genital tract specimens in a selected area of Apulia, a region of Southern Italy. Infection 2017; 45(4): 469-77.
174. den Heijer CDJ, Hoebe C, van Liere G, et al. A comprehensive overview of urogenital, anorectal and oropharyngeal Neisseria gonorrhoeae testing and diagnoses among different STI care providers: a cross-sectional study. BMC Infect Dis 2017; 17(1): 290.
175. Desclaux A, Touati A, Neau D, et al. Extra-rectal lymphogranuloma venereum in France: A clinical and molecular study. Sexually Transmitted Infections 2018; 94(1): 3-8.
176. Detels R, Green AM, Klausner JD, et al. The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries. Sex Transm Dis 2011; 38(6): 503-9.
177. Devadass V, Leverett K, Macauley S, Singh S. Evaluation of chlamydia trachomatis (CT) and neisseria gonorrhoeae (GC) infections in female sex workers (FSW) attending a dedicated sex worker clinic. Sexually Transmitted Infections 2016; 92(Supplement 1): A86-A7.
178. Dewilde A, Torpier A, Dewulf J, Wattré P. Evaluation of procedures for laboratory diagnosis of genital infections by Chlamydia Trachomatis in 2310 patients. [French]. Medecine et Maladies Infectieuses 1986; 16(1): 6-12.
179. Dhairyawan R, Creighton S, Sivyour L, Anderson J. Testing the fathers: carrying out HIV and STI tests on partners of pregnant women. Sex Transm Infect 2012; 88(3): 184-6.
180. Diquelou JY, Pia P, Tesquier L, Henry-Suchet J, Gicquel JM, Boyer S. [The role of Chlamydia trachomatis in the infectious etiology of extra-uterine pregnancy]. J Gynecol Obstet Biol Reprod (Paris) 1988; 17(3): 325-32.
181. Dixon J, Chauhan M, Sankar N. Comparative study of STI prevalence as an indicator of increasing risk-taking sexual behaviour in new HIV diagnoses in MSM over a 10-year period. HIV Medicine 2014; 3): 85.
182. Dolapci I, Tekeli A, Ozsan M, Yaman O, Ergin S, Elhan A. Detecting of Mycoplasma genitalium in male patients with urethritis symptoms in Turkey by polymerase chain reaction. Saudi Med J 2005; 26(1): 64-8.
183. Dolenec N. [Bacteriological findings in the cervical mucus of sterile women]. Jugosl Ginekolo Opstet 1980; 20(3-4): 203-7.
184. Dolling D, Desai M, Saunders J, et al. Who accesses prep? An analysis of baseline data in the PROUD pilot. HIV Medicine 2014; 3): 15.
185. Domeika M, Savicheva A, Shipitsyna E, et al. International validation of amplisens naat systems manufactured in Russia for diagnosis of Neisseria Gonorrhoeae, chlamydia trachomatis, mycoplasma genitalium and trichomonas vaginalis. Sexually Transmitted Infections 2011; 1): A353-A4.
186. Dona V, Smid JH, Kasraian S, et al. Mismatch Amplification Mutation Assay-Based Real-Time PCR for Rapid Detection of Neisseria gonorrhoeae and Antimicrobial Resistance Determinants in Clinical Specimens. J Clin Microbiol 2018; 56(9): e00365.
187. Donati M, Di Francesco A, D'Antuono A, et al. Chlamydia trachomatis serovar distribution and other concurrent sexually transmitted infections in heterosexual men with urethritis in Italy. Eur J Clin Microbiol Infect Dis 2009; 28(5): 523-6.
188. Downing J, Cook PA, Madden HC, Phillips-Howard PA, Higgins SP, Bellis MA. Management of cases testing positive for gonococcal infection in a community-based chlamydia screening programme. Sex Transm Infect 2010; 86(6): 474-7.
189. Drasnar J, Uher J, Klanica J. [Results of microbiological diagnosis in complicated female gonorrhea with tubal sterility using laparoscopy (proceedings)]. Cesk Gynkol 1978; 43(7): 538-9.

190. Drew RJ, Cormican M, Machale E, Fleming C. Low rate of co-infection in patients presenting with Chlamydia trachomatis to a sexually transmitted infection clinic in Galway, Ireland. *Int J STD AIDS* 2007; 18(11): 796.
191. Druckler S, Daans C, Hoorenborg E, et al. HIV and STI positivity rates among transgender people attending two large STI clinics in the Netherlands. *Sex Transm Infect* 2021.
192. Druckler S, van Rooijen MS, de Vries HJC. Chemsex Among Men Who Have Sex With Men: a Sexualized Drug Use Survey Among Clients of the Sexually Transmitted Infection Outpatient Clinic and Users of a Gay Dating App in Amsterdam, the Netherlands. *Sex Transm Dis* 2018; 45(5): 325-31.
193. Druckler S, van Rooijen MS, de Vries HJC. Substance Use and Sexual Risk Behavior Among Male and Transgender Women Sex Workers at the Prostitution Outreach Center in Amsterdam, the Netherlands. *Sex Transm Dis* 2020; 47(2): 114-21.
194. Dudareva-Vizule S, Haar K, Sailer A, Wisplinghoff H, Wisplinghoff F, Marcus U. Prevalence of pharyngeal and rectal Chlamydia trachomatis and Neisseria gonorrhoeae infections among men who have sex with men in Germany. *Sex Transm Infect* 2014; 90(1): 46-51.
195. Dukers NHTM, Spaargaren J, Geskus RB, Beijnen J, Coutinho RA, Fennema HSA. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: Using a novel approach for detecting recent infections. *Aids* 2002; 16(10): F19-F24.
196. Dukers-Muijters N, Leenen J, Hoebe C. Implementing home-sampling strategies to engage young heterosexuals in chlamydia trachomatis re-testing and peer-testing. *Sexually Transmitted Infections* 2019; 95(Supplement 1): A89.
197. Dukers-Muijters NH, Niekamp AM, Brouwers EE, Hoebe CJ. Older and swinging; need to identify hidden and emerging risk groups at STI clinics. *Sex Transm Infect* 2010; 86(4): 315-7.
198. Durglishvili G, Galdava G. Influence of epididymitis on reproductive function. *Georgian Med News* 2013; (215): 32-5.
199. Duron S, Panjo H, Bohet A, et al. Prevalence and risk factors of sexually transmitted infections among French service members. *PLoS One* 2018; 13(4): e0195158.
200. Duthie SJ, Hobson D, Tait IA, et al. Morbidity after termination of pregnancy in first trimester. *Genitourin Med* 1987; 63(3): 182-7.
201. Ebel A, Venard C, Brunengo D, Merlin S. Prevalence of Mycoplasma genitalium in France and comparison with Chlamydia trachomatis and Neisseria gonorrhoeae using transcription-mediated amplification assays. *International Journal of STD and AIDS* 2015; 1): 68.
202. Eccleston K, Richards M. Sexual health in men who have sex with men in a rural setting: Is this a population at high risk of acquiring human immunodeficiency virus? *HIV Medicine* 2014; 3): 98-9.
203. Edouard S, Tamalet C, Tissot-Dupont H, et al. Evaluation of self-collected rectal swabs for the detection of bacteria responsible for sexually transmitted infections in a cohort of HIV-1-infected patients. *Journal of Medical Microbiology* 2017; 66(6): 693-7.
204. Edouard S, Tissot-Dupont H, Dubourg G, et al. Mycoplasma genitalium, an agent of reemerging sexually transmitted infections. *Apmis* 2017b; 125(10): 916-20.
205. Eggert J, Sundquist K, van Vuuren C, Fianu-Jonasson A. The clinical diagnosis of pelvic inflammatory disease - Reuse of electronic medical record data from 189 patients visiting a Swedish university hospital emergency department. *BMC Women's Health* 2006; 6 (no pagination).
206. Eggert-Kruse W, Batschulat K, Demirakca T, Strowitzki T. Male immunity to the chlamydial 60 kDa heat shock protein (HSP 60) - associated with semen quality? *Andrologia* 2015; 47(1): 66-76.
207. Eggert-Kruse W, Gerhard I, Hofmann H, Runnebaum B, Petzoldt D. Influence of microbial colonization on sperm-mucus interaction in vivo and in vitro. *Hum Reprod* 1987; 2(4): 301-8.
208. Eggert-Kruse W, Hofmann H, Gerhard I, Bilke A, Runnebaum B, Petzoldt D. Effects of antimicrobial therapy on sperm-mucus interaction. *Hum Reprod* 1988; 3(7): 861-9.
209. Eggert-Kruse W, Reimann-Andersen J, Rohr G, Pohl S, Tilgen W, Runnebaum B. Clinical relevance of sperm morphology assessment using strict criteria and relationship with sperm-mucus interaction in vivo and in vitro. *Fertil Steril* 1995; 63(3): 612-24.
210. Eksi F, Dikensoy E, Gayyurhan ED, et al. The prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in the endocervical swab specimens of symptomatic, asymptomatic and infertile women in Turkey. *Arch Gynecol Obstet* 2011; 283(6): 1349-55.
211. Eldivan O, Evliyaoglu O, Ersoy E, Aksu G, Dilbaz S, Goktolga U. Does screening for vaginal infection have an impact on pregnancy rates in intracytoplasmic sperm injection cycles? *Turkish Journal of Obstetrics and Gynecology* 2016; 13(1): 11-5.
212. Elsner P, Hartmann AA. Gardnerella vaginalis in a female West German STD clinic population. *European Journal of Sexually Transmitted Diseases* 1985; 3(1): 43-6.
213. Elsner P, Hartmann AA, Wecker I. Sexually transmittable organisms in the urethra of males with and without urethritis. *Zentralbl Bakteriell Mikrobiol Hyg A* 1987; 265(1-2): 268-75.
214. Eriksson G, Wanger L. Frequency of N. gonorrhoeae, T. vaginalis, and C. albicans in female venereological patients. A one-year study. *Br J Vener Dis* 1975; 51(3): 192-7.
215. Esser S, Krotzek J, Dirks H, Scherbaum N, Schadendorf D. Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV-positive men who have sex with men (MSM) - approaches for medical prevention. *J Dtsch Dermatol Ges* 2017; 15(4): 421-8.
216. Evaldson GR, Fianu S, Jonasson A. Does the hygroscopic property of the laminaria tent imply a risk for ascending infection in legal abortions? *Acta Obstetrica et Gynecologica Scandinavica* 1986; 65(3): 257-61.
217. Evans BA, Bond RA, MacRae KD. Heterosexual behaviour, risk factors and sexually transmitted infections among self-classified homosexual and bisexual men. *International Journal of STD and AIDS* 1998; 9(3): 129-33.
218. Evans BA, Bond RA, MacRae KD. Racial origin, sexual behaviour, and genital infection among heterosexual men attending a genitourinary medicine clinic in London (1993-4). *Sex Transm Infect* 1998a; 74(1): 40-4.
219. Evans BA, Kell PD, Bond RA, MacRae KD. Heterosexual relationships and condom-use in the spread of sexually transmitted diseases to women. *Genitourin Med* 1995; 71(5): 291-4.
220. Evans DT, Jaleel H, Kinsella MT, Aggarwal V. A retrospective audit of the management and complications of pelvic inflammatory disease. *Int J STD AIDS* 2008; 19(2): 123-4.
221. Evjen OC, Haram K, Ulstein M. [Gonorrhea, candidiasis and vaginal trichomoniasis in patients requesting legal abortion]. *Tidsskr Nor Laegeforen* 1979; 99(9-10): 470-1.
222. Fadrhoncova A. Study on gonorrhea. V. Screening of persons endangered by gonococcal infection. [Czech]. *Ceskoslovenska dermatologie* 1975; 50(4): 268-79.
223. Falk ES, Vandbakk O. Declining trends in some sexually transmitted diseases in Norway between 1975 and 1991 with special reference to a Lapp population. *Acta Derm Venereol Suppl (Stockh)* 1993; 182: 15-20.
224. Falk L, Fredlund H, Jensen JS. Symptomatic urethritis is more prevalent in men infected with Mycoplasma genitalium than with Chlamydia trachomatis. *Sex Transm Infect* 2004; 80(4): 289-93.
225. Fanta D, Gebhart W, Gross W, Kokoschka EM, Soltz-Szots J, Thurner J. Results of routine screening for sexually transmitted diseases in Austria over a six-year period. *Br J Vener Dis* 1979; 55(2): 147-8.
226. Farfour E, Dimi S, Chassany O, et al. Trends in asymptomatic STI among HIV-positive MSM and lessons for systematic screening. *PLoS One* 2021; 16(6): e0250557.
227. Fata LL, Cotte L, Godinot M, et al. High Rate of Asymptomatic Bacterial Sexually Transmitted Infections (STIs) in Men who Have Sex with Men on Pre Exposure Prophylaxis (PrEP). *Open Forum Infectious Diseases* 2017; 4(suppl 1): S669-S.

228. Feeney JG, Badri AE. Screening for gonococcal salpingitis. *Lancet* 1976; 2(7998): 1309.
229. Fennema JS, van Ameijden EJ, Coutinho RA, Van den Hoek A. Clinical sexually transmitted diseases among human immunodeficiency virus-infected and noninfected drug-using prostitutes. Associated factors and interpretation of trends, 1986 to 1994. *Sex Transm Dis* 1997; 24(6): 363-71.
230. Fenoll A, Berron S, Vazquez JA. Analysis of penicillinase-producing *Neisseria gonorrhoeae* isolates in Madrid (Spain) from 1983-85. *Epidemiol Infect* 1987; 99(2): 455-62.
231. Fernandez-Huerta M, Zarzuela F, Barbera MJ, et al. Sexual Transmission of Intestinal Parasites and Other Enteric Pathogens among Men Who Have Sex with Men Presenting Gastrointestinal Symptoms in an STI Unit in Barcelona, Spain: A Cross-Sectional Study. *Am J Trop Med Hyg* 2019; 101(6): 1388-91.
232. Ferrero DV, Biglino A. Successful use of non-invasive self obtained glans/meatal dry floqswabs (COPAN) for CT/NG detection with the BD probetec ET assay in Northern Italy. *Sexually Transmitted Infections* 2011; 1: A277.
233. Fitzgerald MR, Thirlby D, Bedford CA. The outcome of contact tracing for gonorrhoea in the United Kingdom. *Int J STD AIDS* 1998; 9(11): 657-60.
234. Folch C, Casabona J, Brugal MT, et al. Sexually transmitted infections and sexual practices among injecting drug users in harm reduction centers in Catalonia. *Eur Addict Res* 2011; 17(5): 271-8.
235. Folch C, Esteve A, Sanclemente C, et al. Prevalence of human immunodeficiency virus, Chlamydia trachomatis, and *Neisseria gonorrhoeae* and risk factors for sexually transmitted infections among immigrant female sex workers in Catalonia, Spain. *Sex Transm Dis* 2008; 35(2): 178-83.
236. Folch C, Sanclemente C, Esteve A, Martró E, Molinos S, Casabona J. [Social characteristics, risk behaviours and differences in the prevalence of HIV/sexually transmitted infections between Spanish and immigrant female sex workers in Catalonia, Spain]. *Med Clin (Barc)* 2009; 132(10): 385-8.
237. Forbes K, Byrne R, Gupta D. What women want: Opportunities to integrate screening for sexual infections alongside fitting of an intrauterine device. *HIV Medicine* 2014; 15: 17-159.
238. Foronda-Garcia-Hidalgo C, Liebana-Martos C, Gutierrez-Soto B, Exposito-Ruiz M, Navarro-Mari JM, Gutierrez-Fernandez J. [Prevalence among males from the general population of agents responsible of not ulcerative genital tract infections, assisted in specialized care]. *Rev Esp Quimioter* 2019; 32(6): 545-50.
239. Forslin L, Falk V, Danielsson D. Changes in the incidence of acute gonococcal and nongonococcal salpingitis. A five-year study from an urban area of central Sweden. *Br J Vener Dis* 1978; 54(4): 247-50.
240. Forster GE, Pritchard J, Munday PE, Goldmeier D. Incidence of sexually transmitted diseases in rape victims during 1984. *Genitourin Med* 1986; 62(4): 267-9.
241. Foschi C, Banzola N, Gaspari V, D'Antuono A, Cevenini R, Marangoni A. Evaluation of the aptima assays for the detection of bacterial sexually transmitted infections in a selected population of women. *Sexually Transmitted Infections* 2017; 93(Supplement 2): A49.
242. Foschi C, Gaspari V, Sgubbi P, Salvo M, D'Antuono A, Marangoni A. Sexually transmitted rectal infections in a cohort of 'men having sex with men'. *J Med Microbiol* 2018; 67(8): 1050-7.
243. Foschi C, Nardini P, Banzola N, et al. Chlamydia trachomatis infection prevalence and serovar distribution in a high-density urban area in the north of Italy. *J Med Microbiol* 2016; 65(6): 510-20.
244. Foschi C, Zagarrigo M, Belletti M, Marangoni A, Re MC, Gaspari V. Genital and extra-genital Chlamydia trachomatis and *Neisseria gonorrhoeae* infections in young women attending a Sexually Transmitted Infections (STI) clinic. *New Microbiol* 2020; 43(3): 115-20.
245. Fougas J, Hiquet J, Christin E, et al. Sexually transmitted infections among victims attending a French sexual offence centre. *Sex Transm Infect* 2017; 93(6): 451.
246. Fournet N, Koedijk FD, van Leeuwen AP, van Rooijen MS, van der Sande MA, van Veen MG. Young male sex workers are at high risk for sexually transmitted infections, a cross-sectional study from Dutch STI clinics, the Netherlands, 2006-2012. *BMC Infect Dis* 2016; 16: 63.
247. Fowler T, Edeghere O, Inglis N, Bradshaw S. Estimating the positive predictive value of opportunistic population testing for gonorrhoea as part of the English Chlamydia Screening Programme. *Int J STD AIDS* 2013; 24(3): 185-91.
248. Fox H. Non-specific genital infection in a general practice. *Br J Vener Dis* 1974; 50(2): 125-31.
249. Fragozo J, Guerra D, Cipriano A, et al. Sexually transmitted diseases clinic in a Portuguese Infectious Diseases unit. *HIV Medicine* 2019; 20(S9): 317-37.
250. Franceschi S, Smith JS, van den Brule A, et al. Cervical infection with Chlamydia trachomatis and *Neisseria gonorrhoeae* in women from ten areas in four continents. A cross-sectional study. *Sex Transm Dis* 2007; 34(8): 563-9.
251. Fraser G, McAdams R, Heng J, Macpherson A. Psychosocial and sexual healthcare needs in men selling sex in Glasgow: a retrospective case note review. *Sex Transm Infect* 2014; 90(6): 504.
252. Frati ER, Fasoli E, Martinelli M, et al. Sexually Transmitted Infections: A Novel Screening Strategy for Improving Women's Health in Vulnerable Populations. *Int J Mol Sci* 2017; 18(6).
253. Frolova NI, Belokrinskaya TE, Shipunova EA, Spesivtcev AS, Yakimova YV. Preconception risk factors in young healthy women: cross-sectional study. *BJOG: An International Journal of Obstetrics & Gynaecology* 2013; 120: 191-225.
254. Fuchs W, Kreuter A, Hellmich M, et al. Asymptomatic anal sexually transmitted infections in HIV-positive men attending anal cancer screening. *Br J Dermatol* 2016; 174(4): 831-8.
255. Furegato M, Broad C, Phillips L, et al. Importation of ciprofloxacin resistant *Neisseria gonorrhoeae* into the UK: A public health challenge. *Sexually Transmitted Infections* 2019; 95(Supplement 1): A298.
256. García-Lechuz JM, Rivera M, Catalán P, Sánchez-Carrillo C, Rodríguez-Créixems M, Bouza E. Differences in curable STDs between HIV and non-HIV populations in Spain. *AIDS Patient Care STDS* 1999; 13(3): 175-7.
257. Gardner D, French P. An audit of the management and aetiology of proctitis in men who have sex with men (MSM). *Sexually Transmitted Infections* 2016; 92(Supplement 1): A47.
258. Garner A, Gibbons N, Williams N, Olufunso O, Gupta N, Dewsnap C. Sexual health outreach clinic in a deprived GP setting : A service evaluation. *HIV Medicine* 2014; 3: 43.
259. Garner AL, Schembri G, Cullen T, Lee V. Should we screen heterosexuals for extra-genital chlamydial and gonococcal infections? *Int J STD AIDS* 2015; 26(7): 462-6.
260. Gasbarrini N, Dubravic D, Combs L, et al. Increasing integrated testing in community settings through interventions for change, including the Spring European Testing Week. *BMC Infect Dis* 2021; 21(Suppl 2): 874.
261. Geelen TH, Rossen JW, Beerens AM, et al. Performance of cobas 4800 and m2000 real-timeTM assays for detection of Chlamydia trachomatis and *Neisseria gonorrhoeae* in rectal and self-collected vaginal specimen. *Diagnostic Microbiology and Infectious Disease* 2013; 77(2): 101-5.
262. Gellan MC, Ison CA. Declining incidence of gonorrhoea in London: a response to fear of AIDS? *Lancet* 1986; 2(8512): 920.
263. Genc M, Agacfidan A, Yegenoglu Y, Turan O, Kuru U, Mardh PA. Screening for Chlamydia trachomatis and *Neisseria gonorrhoeae* in pregnant Turkish women. *Eur J Clin Microbiol Infect Dis* 1993; 12(5): 395-6.
264. Georgala S, Schulpis K, Georgala C, Karikas G. Gonorrhoea control programme in Athens, 1974-98. *Sex Transm Infect* 2001; 77(6): 458-9.
265. Gesink DC, Mulvad G, Montgomery-Andersen R, et al. Mycoplasma genitalium presence, resistance and epidemiology in Greenland. *Int J Circumpolar Health* 2012; 71: 1-8.

266. Geuenich HH, Muller HE. Comparative clinical, microbiologic and serologic studies of the incidence of genital and para-genital infections in prostitutes and women with mainly monogamous relations. *Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany))* 1993; 55(11): 567-76.
267. Ghanem M, Radcliffe K, Allan P. The role of urethral samples in the diagnosis of gonorrhoea in women. *Int J STD AIDS* 2004; 15(1): 45-7.
268. Ghani AC, Ison CA, Ward H, et al. Sexual partner networks in the transmission of sexually transmitted diseases. An analysis of gonorrhea cases in Sheffield, UK. *Sex Transm Dis* 1996; 23(6): 498-503.
269. Ghinsberg RC, Nitzan Y. Chlamydia trachomatis direct isolation, antibody prevalence and clinical symptoms in women attending outpatient clinics. *New Microbiol* 1994; 17(3): 231-42.
270. Giertz G, Kallings I, Nordenvall M, Fuchs T. A prospective study of Chlamydia trachomatis infection following legal abortion. *Acta Obstet Gynecol Scand* 1987; 66(2): 107-9.
271. Gilbert VL, Simms I, Gobin M, Jenkins C, Oliver I, Hughes G. High-risk drug practises associated with shigella flexneri serotype 3A infections amongst men who have sex with men (MSM) in England. *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013*; 89(SUPPL. 1).
272. Gill H, Portman M, Schoeman S. 2013 RITA data in a UK city centre GUM clinic – a valuable tool in guiding local services. *HIV Medicine* 2014; 15(SUPPL. 3): 17-159.
273. Gillespie T, McKay I. Survey of the use of selective culture for *Neisseria gonorrhoeae* in specimens from the female genital tract sent by general practitioners to a microbiology laboratory. *Br J Gen Pract* 2000; 50(451): 129-30.
274. Giomi B, Silvestri C, Bravi S, et al. Epidemiological and clinical characteristics of patients attending STI clinics in Tuscany, Italy: a multicenter report on new infections in 2011. *G Ital Dermatol Venereol* 2015; 150(2): 135-41.
275. Gnarpe H, Hillstrom L, Pettersson L. [Culture problems in the diagnosis of gonorrhea--study of a gonorrhea epidemic in Gavleborg county]. *Lakartidningen* 1976; 73(48): 4209-10.
276. Gomez-Ayerbe C, Palacios R, Perez C, et al. Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients. *HIV Medicine* 2019; 20(S9): 317-37.
277. Gonzalez V, Alvarez-Dardet C, Rodriguez Pichardo A, Camacho F, Perea EJ. [Gonococcal infection in the male]. *Med Clin (Barc)* 1983; 81(20): 883-6.
278. Gottesman T, Yossepowitch O, Samra Z, Rosenberg S, Dan M. Prevalence of *Mycoplasma genitalium* in men with urethritis and in high risk asymptomatic males in Tel Aviv: a prospective study. *Int J STD AIDS* 2017; 28(2): 127-32.
279. Gotz HM, Luijendijk A, Nuradini B, Van Westreenen M. Women friendly gonorrhoea culture by self taken vaginal swabs for the purpose of surveillance of gonorrhoea resistance. *Sexually Transmitted Infections* 2011; 1): A282.
280. Götz HM, van Oeffelen LA, Hoebe C, van Benthem BH. Regional differences in chlamydia and gonorrhoeae positivity rate among heterosexual STI clinic visitors in the Netherlands: contribution of client and regional characteristics as assessed by cross-sectional surveillance data. *BMJ Open* 2019; 9(1): e022793.
281. Gotz HM, Veldhuijzen IK, Ossewaarde JM, de Zwart O, Richardus JH. Chlamydia trachomatis infections in multi-ethnic urban youth: a pilot combining STI health education and outreach testing in Rotterdam, Netherlands. *Sex Transm Infect* 2006; 82(2): 148-52; discussion 52-3.
282. Grad AI, Vica ML, Ungureanu L, Siserman CV, Tataru AD, Matei HV. Assessment of STI screening in Romania using a multiplex PCR technique. *J Infect Dev Ctries* 2020; 14(4): 341-8.
283. Granitzka S, Nickel C, Schramm K, Kremer P. [Symptomatology and changes in frequency of gonorrhea in gynecologic-obstetrical patients (10-years-study 1968-1977)]. *Arch Gynecol* 1979; 228(1-4): 614-5.
284. Graspeuntner S, Bohlmann MK, Gillmann K, et al. Microbiota-based analysis reveals specific bacterial traits and a novel strategy for the diagnosis of infectious infertility. *PLoS ONE* 2018; 13(1) (no pagination).
285. Grech P, Marchant R, Samuel M. Health care needs of women aged 40 and over attending an inner city integrated sexual health clinic. *Sexually Transmitted Infections* 2016; 92(Supplement 1): A34-A5.
286. Gregersen E. [Incidence of gonorrhea among women admitted to hospitals]. *Ugeskr Laeger* 1972; 134(43): 2268-70.
287. Gronhoj C, Jakobsen KK, Wingstrand VL, et al. Association between head and neck cancer and sexually transmitted diseases: a Danish nationwide, case-control study. *Acta Otolaryngol* 2020; 140(7): 615-9.
288. Groom TM, Nandwani R. Characteristics of men who pay for sex: a UK sexual health clinic survey. *Sex Transm Infect* 2006; 82(5): 364-7.
289. Guillet-Rosso F, Fari A, Taylor S, et al. Systematic semen culture and its influence on IVF management. *Br J Obstet Gynaecol* 1987; 94(6): 543-7.
290. Guralp O, Bostanci A, Basaran EO, Schild-Suhren M, Kaya B. Evaluation of the prevalence of sexually transmitted bacterial pathogens in northern cyprus by nucleic acid amplification tests, and investigation of the relationship between these pathogens and cervicitis. *Turkish Journal of Obstetrics and Gynecology* 2019; 16(4): 242-8.
291. Guschin A, Ryzhikh P, Rumyantseva T, Gomberg M, Unemo M. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of *Mycoplasma genitalium* during treatment of male urethritis with josamycin. *BMC Infect Dis* 2015; 15(1): 40.
292. Gyarmathy VA, Neagius A, Ujhelyi E. Vulnerability to drug-related infections and co-infections among injecting drug users in Budapest, Hungary. *Eur J Public Health* 2009; 19(3): 260-5.
293. Hagemann CT, Nordbo SA, Myhre AK, Ormstad K, Schei B. Sexually transmitted infections among women attending a Norwegian Sexual Assault Centre. *Sex Transm Infect* 2014; 90(4): 283-9.
294. Haidari G, Perry MEO, White JA. P3.121 Are We Seeing a True Rise in *Neisseria Gonorrhoeae* and *Chlamydia Trachomatis* in England in Men Who Have Sex with Men?: Abstract P3.121 Table 1. *Sexually Transmitted Infections* 2013; 89(Suppl 1): A185.2-A.
295. Hakama M, Lehtinen M, Knekt P, et al. Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. *Am J Epidemiol* 1993; 137(2): 166-70.
296. Halvorsen LE, Skjeldstad FE, Nordbo SA, Loge I. Which women should be tested for Chlamydia trachomatis in general practice? *Tidsskrift for den Norske laegeforening* 1992; 112(16): 2080-1.
297. Handy P, Pattman RS, Richards J. 'I'm OK?' Evaluation of a new walk-in quick-check clinic. *Int J STD AIDS* 2006; 17(10): 677-80.
298. Hanna NF, Taylor-Robinson D, Csonka GW, Harris JR, Al-Sowaygh IA. One-step staining of *Neisseria gonorrhoeae* in urethral discharge by methyl green-pyronin. *Br J Vener Dis* 1980; 56(4): 227-9.
299. Hansen JG, Schmidt H, Bitsch N. [Occurrence of Chlamydia trachomatis in vaginal discharges. A study from general practice]. *Ugeskr Laeger* 1983; 145(50): 3896-9.
300. Hansen MK, Lange K. [Incidence of gonorrhoea in women referred to a gynecological department. Routine study with reference to asymptomatic cases]. *Ugeskr Laeger* 1973; 135(20): 914-6.
301. Harb AK, Mohammed H, Furegato M, Wayal S, Mercer CH, Hughes G. The association between region of birth and sexually transmitted infections among people of black Caribbean ethnicity attending sexual health services in England, 2015. *PLoS ONE* 2020; 15(2) (no pagination).
302. Harding-Esch EM, Fuller SS, Chow SLC, et al. Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluation. *Clinical Microbiology and Infection* 2019; 25(3): 380.e1-e7.
303. Harding-Esch EM, Nori AV, Hegazi A, et al. Impact of deploying multiple point-of-care tests with a 'sample first' approach on a sexual health clinical care pathway. A service evaluation. *Sex Transm Infect* 2017; 93(6): 424-9.

304. Harindra V, Tobin JM, Underhill G. Opportunistic chlamydia screening; should positive patients be screened for co-infections? *Int J STD AIDS* 2002; 13(12): 821-5.
305. Hassan SJ, Dunphy E, Navin E, et al. Screening for Chlamydia is acceptable and feasible during Cervical Screening in General Practice. *Ir Med J* 2016; 109(1): 326-7.
306. Hatton S, Snell W, Sacks R, Nugent D. Performance of microscopy to diagnose rectal gonorrhoea. *HIV Medicine* 2021; 22(S2): 24-119.
307. Hay PE, Kerry SR, Normansell R, et al. Which sexually active young female students are most at risk of pelvic inflammatory disease? A prospective study. *Sex Transm Infect* 2016; 92(1): 63-6.
308. Heijman RLJ, Stolte IG, Thiesbrummel HFJ, et al. Opting out increases HIV testing in a large sexually transmitted infections outpatient clinic. *Sexually Transmitted Infections* 2009; 85(4): 249-55.
309. Heijman TL, Van der Bij AK, De Vries HJ, Van Leent EJ, Thiesbrummel HF, Fennema HS. Effectiveness of a risk-based visitor-prioritizing system at a sexually transmitted infection outpatient clinic. *Sex Transm Dis* 2007; 34(7): 508-12.
310. Heijne JCM, van den Broek IVF, Bruisten SM, van Bergen JEA, de Graaf H, van Benthem BHB. National prevalence estimates of chlamydia and gonorrhoea in the Netherlands. *Sex Transm Infect* 2019; 95(1): 53-9.
311. Heiligenberg M, Rijnders B, Schim van der Loeff MF, et al. High prevalence of sexually transmitted infections in HIV-infected men during routine outpatient visits in the Netherlands. *Sex Transm Dis* 2012; 39(1): 8-15.
312. Heiligenberg M, Wermeling P, van Rooijen M, et al. P1-S5.13 Recreational drug use during sex is associated with STI among clients of a large STI outpatient clinic in Amsterdam, The Netherlands. *Sexually Transmitted Infections* 2011; 87(Suppl 1): A179-A.
313. Heinonen PK, Leinonen M. Fecundity and morbidity following acute pelvic inflammatory disease treated with doxycycline and metronidazole. *Arch Gynecol Obstet* 2003; 268(4): 284-8.
314. Hellberg D, Mogilevkina I, Mardh PA. Sexually transmitted diseases and gynecologic symptoms and signs in women with a history of induced abortion. *Sex Transm Dis* 1999; 26(4): 197-200.
315. Hellgren L, Johannisson G, Lofmarck PW. A comparison of diagnostic reliability between smear and culture tests for female gonorrhoea. *Microbios Letters* 1982; 20(79-80): 125-8.
316. Henriques CU, Wilken-Jensen C, Thorsen P, Moller BR. A randomised controlled trial of prophylaxis of post-abortion infection: ceftriaxone versus placebo. *Br J Obstet Gynaecol* 1994; 101(7): 610-4.
317. Henry-Suchet J, Catalan F, Loffredo V, et al. Microbiology of specimens obtained by laparoscopy from controls and from patients with pelvic inflammatory disease or infertility with tubal obstruction: Chlamydia trachomatis and Ureaplasma urealyticum. *Am J Obstet Gynecol* 1980; 138(7 Pt 2): 1022-5.
318. Henry-Suchet J, Solal P, Loffredo V, Pez JP. [Subclinical perihepatitis (Fitz-Hugh-Curtis syndrome) in salpingitis or tubal sterility. Cultures positive for Chlamydia trachomatis in perihepatic adhesions]. *Presse Med* 1983; 12(27): 1725.
319. Heras E, Llibre JM, Martro E, Casabona J, Martin-Iguacel R, Sirera G. [Lymphogranuloma venereum proctocolitis in men with HIV-1 infection]. *Enferm Infecc Microbiol Clin* 2011; 29(2): 124-6.
320. Hermabessiere J, Sirot J, Boucher D, Cluzel R. [Clinical and bacteriological criteria of genital tract infections in male sterility (author's transl)]. *Rev Fr Gynecol Obstet* 1977; 72(10): 653-6, 7-8.
321. Herman A, Roash Z, Samra Z. Prevalence of low genital tract infectious agents in young Israeli women. *Israel Journal of Medical Sciences* 1985; 21(4): 346-50.
322. Hetem DJ, Kuizenga Wessel S, Bruisten SM, et al. High prevalence and resistance rates of Mycoplasma genitalium among patients visiting two sexually transmitted infection clinics in the Netherlands. *Int J STD AIDS* 2021; 32(9): 837-44.
323. Heymans R, A AM, Bruisten SM, et al. Distinct Neisseria gonorrhoeae transmission networks among men who have sex with men in Amsterdam, The Netherlands. *J Infect Dis* 2012; 206(4): 596-605.
324. Higgins SP, Klapper PE, Struthers JK, et al. Detection of male genital infection with Chlamydia trachomatis and Neisseria gonorrhoeae using an automated multiplex PCR system (Cobas Amplicor™). *International Journal of STD & AIDS* 2016; 9(1): 21-4.
325. Hill-Tout N, Harding-Esch EM, Pacho A, Furegato M, Fuller SS, Sadiq ST. Health-related quality of life and psychosocial impacts of a diagnosis of non-specific genital infection in symptomatic heterosexual men attending UK sexual health clinics: a feasibility study. *BMJ Open* 2018; 8(6): e018213.
326. Hilmarsdottir I, Arnardottir EM, Johannesdottir ER, Golparian D, Unemo M. Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis. *Acta Derm Venereol* 2021; 101(2): adv00393.
327. Hilton AL, Richmond SJ, Milne JD, Hindley F, Clarke SK. Chlamydia A in the female genital tract. *Br J Vener Dis* 1974; 50(1): 1-10.
328. Hiltunen-Back E, Kautiainen H. Increasing sexually transmitted infection rates among men who have sex with men in Finland 2004-2014. *International Journal of STD & AIDS* 2015; 26(11 suppl): 1-121.
329. Hiltunen-Back E, Rostila T, Kautiainen H, Paavonen J, Reunala T. Rapid decrease of endemic gonorrhea in Finland. *Sex Transm Dis* 1998; 25(4): 181-6.
330. Hinton RA, Egdel LM, Andrews BE, Clarke SK, Richmond SJ. A double-blind cross-over study of the effect of doxycycline on mycoplasma infection and infertility. *Br J Obstet Gynaecol* 1979; 86(5): 379-83.
331. Hirst G, Richardson D, Soni S. Non-specific urethritis: Can we be a little more specific? *Sexually Transmitted Infections* 2016; 92(Supplement 1): A19.
332. Hjelmvoll SO, Olsen ME, Sollid JU, et al. Appropriate time for test-of-cure when diagnosing gonorrhoea with a nucleic acid amplification test. *Acta Derm Venereol* 2012; 92(3): 316-9.
333. Hodoglougil NN, Aslan D, Bertan M. Intrauterine device use and some issues related to sexually transmitted disease screening and occurrence. *Contraception* 2000; 61(6): 359-64.
334. Hodoglougil NNS, Ozek B, Bertan M. Prevalence of reproductive tract infections in family planning clients in Trabzon, Turkey. *Sexually Transmitted Infections* 1999; 75(5): 360.
335. Hoebe CJ, Rademaker CW, Brouwers EE, ter Waarbeek HL, van Bergen JE. Acceptability of self-taken vaginal swabs and first-catch urine samples for the diagnosis of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae with an amplified DNA assay in young women attending a public health sexually transmitted disease clinic. *Sex Transm Dis* 2006; 33(8): 491-5.
336. Hoenderboom BM, van Benthem BHB, van Bergen J, et al. Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial. *Sex Transm Infect* 2019; 95(4): 300-6.
337. Hofmann H, Petzoldt D. [Detection of the gonococcal antigen with an enzyme immunoassay (Gonozyne). Results of the original and modified test procedure]. *Hautarzt* 1985; 36(12): 675-81.
338. Hofmann H, Petzoldt D, Kunze-Janssenharm F, et al. [Improvement of the diagnosis of gonorrhea in the advisory board of the Public Health Department]. *Offentl Gesundheitswes* 1984; 46(1): 8-10.
339. Homøe AS, Berntsen S, Pedersen ML. Gonorrhoea in Greenland: geographic differences in diagnostic activity and incidence of gonorrhoea in 2015. *Int J Circumpolar Health* 2018; 77(1): 1445938.

340. Hoomenborg E, Coyer L, Achterbergh RCA, et al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. *The Lancet HIV* 2019; 6(7): e447-e55.
341. Hopkins MJ, Smith G, Hart IJ, Alloba F. Screening tests for Chlamydia trachomatis or Neisseria gonorrhoeae using the cobas 4800 PCR system do not require a second test to confirm: an audit of patients issued with equivocal results at a sexual health clinic in the Northwest of England, U.K. *Sex Transm Infect* 2012; 88(7): 495-7.
342. Hovding G, Bjerke JR. [The gonorrhea problem. A 1-year statistics from the Bergen Health Council Ambulatory Clinic for Venereal Diseases]. *Tidsskr Nor Laegeforen* 1977; 97(12): 543-51.
343. Hoverak A, Jagars GA, Casingo PA. [Occurrence of Chlamydia trachomatis and Neisseria gonorrhoeae among asymptomatic soldiers]. *Tidsskr Nor Laegeforen* 1989; 109(13): 1429.
344. Hovhannisyann G, von Schoen-Angerer T, Babayan K, Fenichio O, Gaboulaud V. Antimicrobial susceptibility of Neisseria gonorrhoeae strains in three regions of Armenia. *Sex Transm Dis* 2007; 34(9): 686-8.
345. Hoyos-Mallecot Y, Garcia JN, Sulleiro E, et al. Drassanes Expres: a public and confidential testing service for asymptomatic STIs with same-day result notification. *Sex Transm Infect* 2021.
346. Hughes G, Catchpole M, Rogers PA, et al. Comparison of risk factors for four sexually transmitted infections: results from a study of attenders at three genitourinary medicine clinics in England. *Sex Transm Infect* 2000; 76(4): 262-7.
347. Hunter JM, Neilson M. Sexually transmitted diseases in Edinburgh: patients under 18 years of age. *Health Bull (Edinb)* 1980; 38(1): 23-8.
348. Hunter JM, Smith IW, Peutherer JF, MacAulay A, Tuach S, Young H. Chlamydia trachomatis and Ureaplasma urealyticum in men attending a sexually transmitted diseases clinic. *Br J Vener Dis* 1981; 57(2): 130-3.
349. Hunter JM, Smith IW, Peutherer JF, MacAulay AJ. Chlamydia trachomatis infection of the cervix: the need for a diagnostic service. *Scott Med J* 1982; 27(2): 147-51.
350. Hussey J, Edirisinghe DN, Pattman RS, et al. Does bacterial vaginosis alter the sensitivity of screening tests for Chlamydia trachomatis? An analysis of patient characteristics. *Int J STD AIDS* 2003; 14(7): 448-50.
351. Igoe D, Kelleher M, Cooney F, et al. There has been a true rise in Neisseria gonorrhoeae but not in Chlamydia trachomatis in men who have sex with men in Dublin, Ireland. *Sex Transm Infect* 2014; 90(7): 523.
352. Ivens D, Macdonald K, Bansil L, Nori A. Screening for rectal chlamydia infection in a genitourinary medicine clinic. *Int J STD AIDS* 2007; 18(6): 404-6.
353. Jackson L, Thorley N, Munetsi L, Ross J. Evaluating online and clinic-based STI screening services: A case study of umbrella sexual health services, UK. *Sexually Transmitted Infections* 2019; 95(Supplement 1): A112-A3.
354. Jacob L, Bohler F, Kalder M, Kostev K. Prevalence and treatment of sexually transmitted diseases in gynecological practices in Germany: A retrospective study with more than 1,000,000 patients. *Int J Clin Pharmacol Ther* 2018b; 56(5): 212-6.
355. Jacob L, Duse DA, Kostev K. Prevalence and treatment of sexually transmitted infections in men followed by urologists in Germany - a cross sectional study with 347,090 men. *Ger Med Sci* 2018a; 16: Doc03.
356. Jacobson L, Westrom L. Objectivized diagnosis of acute pelvic inflammatory disease. Diagnostic and prognostic value of routine laparoscopy. *Am J Obstet Gynecol* 1969; 105(7): 1088-98.
357. Jamalova M. Tajikistan: STD survey results. *Entre Nous Cph Den* 1999; (42): 12.
358. Janier M, Lassau F, Casin I, et al. Male urethritis with and without discharge: a clinical and microbiological study. *Sex Transm Dis* 1995; 22(4): 244-52.
359. Janier M, Ramel F, Lajoie C, et al. Asymptomatic urethral carriage of Chlamydia trachomatis in male patients with genital ulcerations in Paris, France [1]. *Sexually Transmitted Diseases* 1990; 17(3): 156-7.
360. Jansen K, Bremer V, Steffen G, et al. Prevalence of genital infections with chlamydia trachomatis (CT), neisseria gonorrhoea (NG) and Trichomonas Vaginalis (TV) in Hard-To-Reach Female Sex Workers in North Rhine-Westphalia, Germany: The STI-Outreach Study. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
361. Jansen K, Steffen G, Potthoff A, et al. STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. *BMC Infect Dis* 2020; 20(1): 110.
362. Jauréguy F, Chariot P, Vessièrès A, Picard B. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections detected by real-time PCR among individuals reporting sexual assaults in the Paris, France area. *Forensic Sci Int* 2016; 266: 130-3.
363. Jaureguay F, Masson C, Lavis F, Larmignat P, Picard B. Interest of the cepheid xpert CT/NG assay to rapid detection and differentiation of chlamydia trachomatis (CT) and Neisseria Gonorrhoeae (NG) uro-genital infections. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
364. Jeffery A, Nielson A. Online innovation to reach men who have sex with men. *HIV Medicine* 2018; 19(Supplement 2): S105-S6.
365. Jenniskens ML, Veerbeek JH, Deurloo KL, van Hannen EJ, Thijsen SF. Routine testing of Mycoplasma genitalium and Trichomonas vaginalis. *Infect Dis (Lond)* 2017; 49(6): 461-5.
366. Jensen NE, Andersen BL. The prevalence of group B streptococci in human urogenital secretions. *Scand J Infect Dis* 1979; 11(3): 199-202.
367. Jeverica S, Unemo M, Mlakar B, et al. Prevalence of Neisseria Gonorrhoeae infection in two distinct men-who-have-sex-with-men (MSM) populations in Slovenia in 2012. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
368. Jiménez E, Pedrazuela MG, Pérez MM, de Mosteyrín SF, Arrieta JJ, Guerrero ML. Prevalence of pharyngeal infection by Neisseria gonorrhoeae among human immunodeficiency virus-positive men who have sex with men in downtown Madrid, 2011. *Int J STD AIDS* 2013; 24(11): 875-8.
369. Joffe H, Bamberger E, Nurkin S, et al. Sexually transmitted diseases among patients with human immunodeficiency virus in northern Israel. *Isr Med Assoc J* 2006; 8(5): 333-6.
370. Johansson E, Forslin L, Moi H, Danielsson D. [Occurrence of gonorrhea, Chlamydia infection and urethritis in permanent partners of women with acute salpingitis]. *Lakartidningen* 1988; 85(37): 2974-6.
371. Joly-Guillou ML, Judlin P, Lefevre JC, et al. [Bacteria isolated in 1994-1995 in female upper genitalia infections and in male urethritis. Distribution and sensitivity to antibiotics]. *Presse Med* 1996; 25(8): 342-8.
372. Joore IK, Twisk DE, Vanrolleghem AM, et al. The need to scale up HIV indicator condition-guided testing for early case-finding: a case-control study in primary care. *BMC Fam Pract* 2016; 17(1): 161.
373. Jungmann E, Johnson AM, Ridgway G, Durrant K, Robinson AJ. How useful are high vaginal swabs in general practice? Results of a multicentre study. *Int J STD AIDS* 2004; 15(4): 238-9.
374. Kabakchieva E, Vassileva S, Kelly JA, et al. HIV risk behavior patterns, predictors, and sexually transmitted disease prevalence in the social networks of young Roma (Gypsy) men in Sofia, Bulgaria. *Sex Transm Dis* 2006; 33(8): 485-90.
375. Kacena KA, Dohnal K, Benesova V, et al. Chlamydia, gonorrhea, and HIV-1 prevalence among five populations of women in the Czech and Slovak Republics. *Sex Transm Dis* 2001; 28(6): 356-62.
376. Kahn JA, Larssen KE, Svarva PL. [Gonorrhea in pregnant women. Hospital case material]. *Tidsskr Nor Laegeforen* 1984; 104(22): 1396-7.

377. Kamarashev J, Riess CE, Mosimann J, Lauchli S. Lymphogranuloma venereum in Zurich, Switzerland: Chlamydia trachomatis serovar L2 proctitis among men who have sex with men. *Swiss Medical Weekly* 2010; 140(13-14): 209-12.
378. Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. *Sex Transm Dis* 1996; 23(5): 384-91.
379. Kamwendo F, Forslin L, Danielsson D. Epidemiology and aetiology of acute non-tuberculous salpingitis. A comparison between the early 1970s and the early 1980s with special reference to gonorrhoea and use of intrauterine contraceptive device. *Genitourin Med* 1990; 66(5): 324-9.
380. Kamwendo F, Johansson E, Moi H, Forslin L, Danielsson D. Gonorrhea, genital chlamydial infection, and nonspecific urethritis in male partners of women hospitalized and treated for acute pelvic inflammatory disease. *Sex Transm Dis* 1993; 20(3): 143-6.
381. Kanbur S. Comparison of screening and treatment protocols of sexually transmitted diseases. [Turkish]. *Zeynep Kamil Tip Bulteni* 2018; 49(1): 15-20.
382. Karp-Damdin M. [Incidence of trichomonal and trichomonal-gonococcal infections in women examined at the Provincial Clinic for Dermatologic and Venereal Diseases in Rzeszow]. *Przegl Dermatol* 1975; 62(2): 215-7.
383. Karp-Damdin M, Wisniewski R. [Extensiveness of infection with *Trichomonas vaginalis*, yeast-like fungi and *Neisseria gonorrhoeae* in women in the city of Rzeszow and its vicinity]. *Wiad Parazytol* 1987; 33(1): 47-51.
384. Kavli G, Saetrom KM, Gundersen T, Volden G. Higher incidence of asymptomatic gonorrhoea in men with initial infection than with reinfection. *Br J Vener Dis* 1984; 60(4): 274.
385. Keaveney S, Sadlier C, O'Dea S, Delamere S, Bergin C. High prevalence of asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: a stimulus to improve screening. *Int J STD AIDS* 2014; 25(10): 758-61.
386. Kelly C, Johnston J, Carey F. Evaluation of a partnership between primary and secondary care providing an accessible Level 1 sexual health service in the community. *Int J STD AIDS* 2014; 25(10): 751-7.
387. Kenyon C, Baetselier I, Wouters K. Screening for STIs in PrEP cohorts results in high levels of antimicrobial consumption. *Int J STD AIDS* 2020; 31(12): 1215-8.
388. Kerry-Barnard S, Beddows S, Reid F, et al. Human papillomavirus (HPV) vaccination and oropharyngeal HPV in ethnically diverse, sexually active adolescents: community-based cross-sectional study. *Sexually transmitted infections* 2020; 03.
389. Khatib N, Bradbury C, Chalker V, et al. Prevalence of *Trichomonas vaginalis*, *Mycoplasma genitalium* and *Ureaplasma urealyticum* in men with urethritis attending an urban sexual health clinic. *Int J STD AIDS* 2015; 26(6): 388-92.
390. Killick P, Goold P. Audit of sexually transmitted infection (STI) screening in HIV-positive pregnant women. *HIV Medicine* 2019; 20(S5): 16-75.
391. Killick V, Kell P, Plumb H, Hurd N, Turner P. Screening for *Neisseria gonorrhoeae* using the BD ProbeTec nucleic acid amplification test in a low prevalence genitourinary medicine clinic. *Int J STD AIDS* 2012; 23(6): e1-3.
392. Kimmitt PT, Tabrizi SN, Crosatti M, et al. Pilot study of the utility and acceptability of tampon sampling for the diagnosis of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infections by duplex realtime polymerase chain reaction in United Kingdom sex workers. *Int J STD AIDS* 2010; 21(4): 279-82.
393. King GP, Evans DT. Behind the camera: Sexual health testing patterns and outcomes amongst UK adult film performers. *Int J STD AIDS* 2020; 31(1): 62-5.
394. Kinghorn GR. Survey of human immunodeficiency virus infection and sexually transmitted diseases in homosexual and bisexual men attending genitourinary medicine clinics in the UK during 1986-88. *Genitourinary Medicine* 1990; 66(5): 387-92.
395. Kinghorn GR. Gonorrhoea in homosexual and bisexual men. *Int J STD AIDS* 1994; 5(5): 379-80.
396. Kinghorn GR, Waugh MA. Oral contraceptive use and prevalence of infection with *Chlamydia trachomatis* in women. *Br J Vener Dis* 1981; 57(3): 187-90.
397. Kjaer SK. Risk factors for cervical neoplasia in Denmark. *APMIS Suppl* 1998; 80(80): 1-41.
398. Kjaergaard N, Kristensen B, Hansen ES, et al. Microbiology of semen specimens from males attending a fertility clinic. *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica* 1997; 105(7): 566-70.
399. Klanica J, Drasnar J, Stejskalova M. [The incidence of chronic gonorrhoea in sterile women (author's transl)]. *Cesk Gynkol* 1978; 43(1): 21-6.
400. Klanica J, Stejskalova M. Direct immunofluorescent test for the detection of gonorrhoea. *Br J Vener Dis* 1976; 52(1): 33-5.
401. Klavs I, Milavec M, Kustec T, et al. Prevalence of chlamydia, Gonorrhoea, M. Genitalium and T. Vaginalis in the general population of Slovenia, 2016-2017. *Sexually Transmitted Infections* 2019; 95(Supplement 1): A187.
402. Klingenberg RE, Mannherz S, Brockmeyer NH, et al. [Local health study : Outreach medical services for female sex workers in Bochum]. *Hautarzt* 2016; 67(12): 989-95.
403. Knapper CM, Temple M, Roderick J, Smith J, Birley HDL. Audit of a network of sexually transmitted infections centred in South Wales. *International Journal of STD and AIDS* 2010; 21(1): 63-5.
404. Knudsen A, Kjaergaard B, Ejlersen T. [Chlamydia trachomatis in at-risk groups in legal abortion in the first trimester]. *Ugeskr Laeger* 1989; 151(47): 3157-9.
405. Knudsen O, Larsen LH, Worm AM. [Simultaneous occurrence of *Trichomonas vaginalis* and gonorrhea in women]. *Ugeskr Laeger* 1985; 147(21): 1691-2.
406. Koch A, Bilina A, Teodorowicz L, Stry A. *Mycoplasma hominis* and *Ureaplasma urealyticum* in patients with sexually transmitted diseases. *Wien Klin Wochenschr* 1997; 109(14-15): 584-9.
407. Koedijk FD, van Benthem BH, Vrolings EM, Zuithof W, van der Sande MA. Increasing sexually transmitted infection rates in young men having sex with men in the Netherlands, 2006-2012. *Emerg Themes Epidemiol* 2014; 11(1): 12.
408. Koedijk FD, van Bergen JE, Dukers-Muijers NH, van Leeuwen AP, Hoebe CJ, van der Sande MA. The value of testing multiple anatomic sites for gonorrhoea and chlamydia in sexually transmitted infection centres in the Netherlands, 2006-2010. *Int J STD AIDS* 2012; 23(9): 626-31.
409. Koedijk FDH, Van Benthem BH, Vrolings EMDC, et al. Increasing STI rates in Young MSM in the Netherlands, 2006-2011. *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013*; 89(SUPPL. 1).
410. Kogoj R, Pervic S, Bernjak SI, Murlik Rau A, Matic M, Kee D. Epidemiology of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and urogenital mycoplasma infections in central Slovenia. *Clinical Chemistry and Laboratory Medicine* 2018; 56(6): eA114.
411. Kolader ME, Dukers NH, van der Bij AK, et al. Molecular epidemiology of *Neisseria gonorrhoeae* in Amsterdam, The Netherlands, shows distinct heterosexual and homosexual networks. *J Clin Microbiol* 2006; 44(8): 2689-97.
412. Kolmogorov K, Seidenschur G, Arab MT. [Second-look laparoscopy--results and pregnancy rate in patients with a state of laparoscopically assessed acute adnexitis]. *Geburtshilfe Frauenheilkd* 1987; 47(10): 724-8.
413. KOSKIMIES AI, PAAVONEN J, MEYER B, KAJANOJA P. Cervicitis and Infertility. *American Journal of Reproductive Immunology* 1981; 1(6): 299-302.
414. Kostyakova E, Korolev S, Andreeva I, et al. DIAGNOSTIC AND TREATMENT PATTERNS FOR ACUTE MALE URETHRITIS IN 4 RUSSIAN CITIES: P269. *Basic & Clinical Pharmacology & Toxicology* 2011; 109(SUPPL. 1): 56-164.
415. Kourbatova EV, Akovbyan VA, Chesson HW, et al. Assessment of the routine, occupation-based gonorrhea and syphilis screening program in Moscow, Russia: an analysis of sexually transmitted infection prevalence and cost-effectiveness. *Sex Transm Dis* 2008; 35(5): 453-60.

416. Krollov K, Frolova J, Tudoran O, et al. Sensitive and rapid detection of *Chlamydia trachomatis* by recombinase polymerase amplification directly from urine samples. *J Mol Diagn* 2014; 16(1): 127-35.
417. Kuklova I, Resl V, Cerna L, et al. International healthcare projects of sexually transmitted infections prevention in prostitutes in the Czech Republic. *Prakticky Lekar* 2005; 85(9): 490-2.
418. Kurova T, Shoubnikova M, Malceva A, Mårdh PA. Prostitution in Riga, Latvia--a socio-medical matter of concern. *Acta Obstet Gynecol Scand* 1998; 77(1): 83-6.
419. Lacey HB. Sexually transmitted diseases and rape: the experience of a sexual assault centre. *Int J STD AIDS* 1990; 1(6): 405-9.
420. Lamb AM. New methods of contact tracing in infectious venereal diseases. *Br J Vener Dis* 1966; 42(4): 276-9.
421. Lampejo T, Abdulcadir M. P093 Audit on the management of epididymo-orchitis in a London-based level 3 sexual health clinic: Abstract P093 Table 1. *Sexually Transmitted Infections* 2016; 92(Suppl 1): A51.1-A.
422. Lampejo T, Turner R, Roberts C, et al. Novel outreach settings to enhance sexually transmitted infection/HIV awareness, diagnosis and treatment in hard-to-reach populations. *Int J STD AIDS* 2018; 29(3): 266-72.
423. Landolt A, Kunz J, Schreiner WE. [Routine gonorrhoeae cultures: a cost--benefit analysis on obstetric--gynaecological patients (author's transl)]. *Geburtshilfe Frauenheilkd* 1978; 38(4): 255-9.
424. Larsson PG, Platz-Christensen JJ, Thejls H, Forsum U, Pahlson C. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. *Am J Obstet Gynecol* 1992; 166(1 Pt 1): 100-3.
425. Latini A, Dona MG, Alei L, et al. Recreational drugs and STI diagnoses among patients attending an STI/HIV reference clinic in Rome, Italy. *Sexually Transmitted Infections* 2019; 95(8): 588-93.
426. Latino MA, Lanza A, Bello L, et al. [Cervico-vaginal infections. Study of a population in the Turin area]. *Minerva Ginecol* 2002; 54(4): 309-16.
427. Lavelle SJ, Jones KE, Mallinson H, Webb AM. Finding, confirming, and managing gonorrhoea in a population screened for chlamydia using the Gen-Probe Aptima Combo2 assay. *Sex Transm Infect* 2006; 82(3): 221-4.
428. Lawrence D, Vera J, Richardson D, Gilbert D, Marchant R, Morgan C. Anal intraepithelial neoplasia (AIN) in a cohort of HIVpositive individuals: A retrospective data analysis. *HIV Medicine* 2017; 18(Supplement 1): 33.
429. Lawton M, Schembri G, Kingston M. Testing for *Trichomonas vaginalis* (TV) by transcription mediated amplification (TMA). An evaluation in a large city clinic. *Sexually Transmitted Infections Conference: 4th Joint BASHH ASTDA Meeting Brighton United Kingdom Conference Publication: 2012; 88(SUPPL. 1)*.
430. Le Faou AE, Bottlaender M, Tardieu JC. Incidence of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infections in Strasbourg over 8 years. *Genitourin Med* 1991; 67(5): 428-30.
431. Le Roy C, Le Hen I, Clerc M, et al. The first performance report for the Bio-Rad Dx CT/NG/MG assay for simultaneous detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Mycoplasma genitalium* in urogenital samples. *J Microbiol Methods* 2012; 89(3): 193-7.
432. Le Roy C, Peuchant O, Le Hen I, Bertrand-Salles I, Bebear C, De Barbeyrac B. *Chlamydia trachomatis/Neisseria Gonorrhoeae* screening in duplex: Should we verify *N. gonorrhoeae* positive results? *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013; 89(SUPPL. 1)*.
433. Lee M, Hegazi A, Barbour A, et al. Chemsex and the city: Sexualised substance use in gay bisexual and other men who have sex with men. *Sexually Transmitted Infections* 2015; 1): A4.
434. Lefèvre JC, Averous S, Bauriaud R, Blanc C, Bertrand MA, Lareng MB. Lower genital tract infections in women: comparison of clinical and epidemiologic findings with microbiology. *Sex Transm Dis* 1988; 15(2): 110-3.
435. Lefevre JC, Lepargneur JP, Bauriaud R, Bertrand MA, Blanc C. Clinical and microbiologic features of urethritis in men in Toulouse, France. *Sex Transm Dis* 1991; 18(2): 76-9.
436. Lelijveld JL, Leentvaar-Kuijpers A, Hekker AC, Polak-Vogelzang AA, de Wit RF. [Sexually transmitted diseases in female clients of an outpatient clinic for venereal diseases in Utrecht]. *Ned Tijdschr Geneesk* 1981; 125(12): 463-6.
437. Leung A, Eastick K, Haddon LE, Horn CK, Ahuja D, Horner PJ. *Mycoplasma genitalium* is associated with symptomatic urethritis. *Int J STD AIDS* 2006; 17(5): 285-8.
438. Leuridan E, Wouters K, Stalpaert M, Van Damme P. Male sex workers in Antwerp, Belgium: A descriptive study. *International Journal of STD and AIDS* 2005; 16(11): 744-8.
439. Levy I, Gefen-Halevi S, Nissan I, et al. Delayed diagnosis of colorectal sexually transmitted diseases due to their resemblance to inflammatory bowel diseases. *Int J Infect Dis* 2018; 75: 34-8.
440. Lewis DA, McDonald A, Thompson G, Bingham JS. The 374 clinic: an outreach sexual health clinic for young men. *Sex Transm Infect* 2004; 80(6): 480-3.
441. Libois A, Hallin M, Crucitti T, Delforge M, De Wit S. Prevalence of *Mycoplasma genitalium* in men with urethritis in a large hospital in Brussels, Belgium. *International Journal of STD and AIDS* 2015; 1): 22.
442. Lind I, Hoffmann S. Recorded gonorrhoea rates in Denmark, 1900-2010: the impact of clinical testing activity and laboratory diagnostic procedures. *BMJ Open* 2015; 5(11): e008013.
443. Linhart Y, Shohat T, Amitai Z, et al. Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence of pharyngeal gonorrhoea. *Int J STD AIDS* 2008; 19(10): 656-9.
444. Lister P, Robinson A. STD in travellers presenting to a GUM clinic. *Int J STD AIDS* 1993; 4(1): 59-60.
445. Lomas DA, Natin D, Stockley RA, Shahmanesh M. Chemotactic activity of urethral secretions in men with urethritis and the effect of treatment. *J Infect Dis* 1993; 167(1): 233-6.
446. Lomholt G, Berg O. Gonorrhoea situation in South Greenland in the summer of 1964. *Br J Vener Dis* 1966; 42(1): 1-7.
447. López-Corbeto E, González V, Lugo R, Rivaya B, Casabona J, Matas L. Pooling of urine samples for molecular detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Mycoplasma genitalium* as a screening strategy among young adults in Catalonia. *Enferm Infecc Microbiol Clin (Engl Ed)* 2020; 38(2): 65-71.
448. Loubinoux J, Reglier-Poupert H, Collobert G, Billoet A, Tavares N, Poyart C. Detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Mycoplasma genitalium* in uro-genital samples by the real-time Dx CT/NG/MGTM PCR assay. *Clinical Microbiology and Infection* 2012; 3): 509.
449. Lourtet Hascoet J, Dahoun M, Cohen M, et al. Clinical diagnostic and therapeutic aspects of 221 consecutive anorectal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* sexually transmitted infections among men who have sex with men. *Int J Infect Dis* 2018; 71: 9-13.
450. Loveday C, Mercey D. The prevalence of human retroviral infections in female patients attending a central London sexually transmitted disease clinic: 1985-1990. *Genitourin Med* 1993; 69(1): 31-4.
451. Low N, Bertisch B, Hauser C, et al. Factors associated with antimicrobial resistant gonorrhoea infections in men who have sex with men: case-control study. *Sexually Transmitted Infections* 2017; 93(Supplement 2): A28.
452. Low N, Connell P, McKevitt C, et al. 'You can't tell by looking': pilot study of a community-based intervention to detect asymptomatic sexually transmitted infections. *Int J STD AIDS* 2003; 14(12): 830-4.
453. Lucisano A, Morandotti G, Marana R, et al. Chlamydial genital infections and laparoscopic findings in infertile women. *Eur J Epidemiol* 1992; 8(5): 645-9.

454. Lycke E, Löwhagen GB, Hallhagen G, Johansson G, Ramstedt K. The risk of transmission of genital Chlamydia trachomatis infection is less than that of genital Neisseria gonorrhoeae infection. *Sex Transm Dis* 1980; 7(1): 6-10.
455. Macauley S, Creighton S. Testing commercial sex workers for chlamydia and gonorrhoea on outreach. *Sex Transm Infect* 2009; 85(3): 231-2.
456. MacDonald R. BASHH Virtual Annual Conference, 19th to 21st October 2020. *International Journal of STD & AIDS* 2020; 31(12_suppl): 1-114.
457. Madjar S, Nativ O, Barbara J, Tal J, Potasman I, Srugo I. [Diagnostic and therapeutic approach to sexually transmitted diseases]. *Harefuah* 1996; 130(12): 811-4, 80, 79.
458. Magnusson SS, Oskarsson T, Geirsson RT. Lower genital tract infection with Chlamydia trachomatis and Neisseria gonorrhoeae in Icelandic women with salpingitis. *American Journal of Obstetrics and Gynecology* 1986; 155(3): 602-7.
459. Mahto M, Evans-Jones J, Mallinson H. Response to 'Trichomonas vaginalis among multiethnic female UK students'. *Sex Transm Infect* 2011; 87(6): 537.
460. Mahto M, Zia S. Measuring the gap: from Home Office to the National Health Service in the provision of a one-stop shop sexual health service in a female prison in the UK. *Int J STD AIDS* 2008; 19(9): 586-9.
461. Mahto M, Zia S, Ritchie D, Mallinson H. Diagnosis, management and prevalence estimation of gonorrhoea: influences of Aptima Combo 2 assay with alternative target confirmation. *Int J STD AIDS* 2009; 20(5): 315-9.
462. Maini M, French P, Prince M, Bingham JS. Urethritis due to Neisseria meningitidis in a London genitourinary medicine clinic population. *International Journal of STD and AIDS* 1992; 3(6): 423-5.
463. Maleckiene L, Nadisauskienė RJ, Barcaite E. Laparoscopy improves the diagnostic accuracy in pelvic inflammatory disease. *Salud(i)Ciencia* 2012; 19(4): 326-9.
464. Malosso P, Badia L, Guardigni V, et al. Absence of hepatitis C infection despite high-risk sexual behavior in a cohort of men who have sex with men screened in the community: preliminary results of SEXCHECK study. *Journal of Hepatology* 2019; 70(1): 500-1.
465. Manavi K, Luo PL, McMillan A. The three-year positivity rate of sexually transmitted infections among a group of HIV-infected men attending the Department of Genitourinary Medicine, Edinburgh, UK. *Int J STD AIDS* 2005; 16(11): 730-2.
466. Manavi K, McMillan A, Young H. The prevalence of rectal chlamydial infection amongst men who have sex with men attending the genitourinary medicine clinic in Edinburgh. *Int J STD AIDS* 2004; 15(3): 162-4.
467. Marangoni A, Ceccarani C, Camboni T, et al. Pharyngeal microbiome alterations during Neisseria gonorrhoeae infection. *PLoS One* 2020; 15(1): e0227985.
468. Marangoni A, Foschi C, Nardini P, et al. Evaluation of Versant CT/GC DNA 1.0 assay for the detection of chlamydia trachomatis and neisseria gonorrhoeae in urine specimens in selected STD patients. *Clinical Microbiology and Infection* 2011; 4): S489.
469. Marangoni A, Foschi C, Tartari F, Gaspari V, Re MC. Lymphogranuloma venereum genovariants in men having sex with men in Italy. *Sex Transm Infect* 2021; 97(6): 441-5.
470. Marchant R, Morgan C, Gilbert D, Vera J, Richardson D, Lawrence D. Anal squamous cell carcinoma (SCC) in a large urban cohort of HIV-positive individuals living in the UK: A retrospective data analysis. *HIV Medicine* 2017; 18(Supplement 1): 33.
471. Marcone V, Recine N, Gallinelli C, et al. Epidemiology of Chlamydia trachomatis endocervical infection in a previously unscreened population in Rome, Italy, 2000 to 2009. *Euro Surveill* 2012; 17(25).
472. Marconi M, Pilatz A, Wagenlehner F, Diemer T, Weidner W. Are antisperm antibodies really associated with proven chronic inflammatory and infectious diseases of the male reproductive tract? *Eur Urol* 2009; 56(4): 708-15.
473. Marcos C, Bergamaschi L, Garcia P, Ubeda A, Fabra G. Prevalence of chlamydia trachomatis, gonorrhea and high-risk human papilloma virus in women older than 50 years old with abnormal cervical cytology. *Maturitas* 2019; 124: 174.
474. Marcus U, Ort J, Grenz M, Eckstein K, Wirtz K, Wille A. Risk factors for HIV and STI diagnosis in a community-based HIV/STI testing and counselling site for men having sex with men (MSM) in a large German city in 2011-2012. *BMC Infect Dis* 2015; 15: 14.
475. Mårdh PA, Lind I, From E, Andersen AL. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections in Greenland. A seroepidemiological study. *Br J Vener Dis* 1980; 56(5): 327-31.
476. Mårdh PA, Lind I, Svensson L, Westrom L, Møller BR. Antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae in sera from patients with acute salpingitis. *Br J Vener Dis* 1981; 57(2): 125-9.
477. Mardh PA, Stormby N, Westrom L. [Gonorrhea in a female out-patient-material]. *Lakartidningen* 1971; 68(38): 4261-2.
478. Mareş M, Socolov D, Doroftei B, Botezatu A, Goia CD. The prevalence of some bacterial markers in female patients undergoing an initial infertility evaluation in north-east Romania. *Roum Arch Microbiol Immunol* 2009; 68(3): 171-4.
479. Markowska-Bernaczyk D, Chodyncka B, Perkowska Z, Budkiewicz-Juchnowicz B, Zdrodowska-Stefanow B. [Relation between alcohol abuse and the prevalence of sexually-transmitted diseases]. *Przegl Dermatol* 1983; 70(2): 185-91.
480. Marschall B. Chlamydia trachomatis infections in a Greenlandic district. *Arctic Med Res* 1992; 51(1): 23-8.
481. Marsh K, Chan S, Wheatley N, Duffell S, Lau R, Hughes G. Missed STI and HIV testing opportunities among male prisoners in England. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
482. Masterton RG, Strike PW. Sexually transmitted diseases in a British military force in peacetime Europe, 1970-83. *Genitourin Med* 1988; 64(1): 54-8.
483. Matinato C, Lunghi G, Orlandi A, et al. Evaluation of a multiplex real-time PCR system (DX CT/ NG/MG assay, Bio-Rad) for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in urogenital specimens. *Clinical Microbiology and Infection* 2012; 18: 114-715.
484. Matser A, Schim van der Loeff M, Geskus R. Determining the Most Likely Source of Infection: An Application to Neisseria Gonorrhoeae Among Men Who Have Sex with Men. *Epidemiology* 2018; 29(3): 421-30.
485. Matteelli A, Capelli M, Sulis G, et al. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. *BMC public health* 2016; 16: 200.
486. Mc Grath-Lone L, Marsh K, Hughes G, Ward H. The sexual health of female sex workers compared with other women in England: analysis of cross-sectional data from genitourinary medicine clinics. *Sex Transm Infect* 2014; 90(4): 344-50.
487. Mc Grath-Lone L, Marsh K, Hughes G, Ward H. The sexual health of male sex workers in England: analysis of cross-sectional data from genitourinary medicine clinics. *Sexually transmitted infections* 2014; 90(1): 38-40.
488. McCarty E, Quinn K, Donnelly C, Quah S, Emerson C. Testing for sexually transmissible infections in patients with HIV infection: What are we missing? *HIV Medicine* 2011; 12(SUPPL. 1): 14-86.
489. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet* 2016; 387(10013): 53-60.
490. McKenna JG, Fallon RJ, Moyes A, Young H. Anogenital non-gonococcal neisseriae: prevalence and clinical significance. *Int J STD AIDS* 1993; 4(1): 8-12.
491. McMillan S, Thompson M, Jones R. Sexual health @ the bush. *HIV Medicine* 2014a; 3): 37.
492. McMillan S, Whitlock G, Day S, et al. Targeted outreach: Does it work? *HIV Medicine* 2014b; 3): 18.
493. Mechie AM, Pritchard JG. Venereal infection in elderly people. *Gerontol Clin (Basel)* 1966; 8(4): 207-14.
494. Mendes-Bastos P, Brasileiro A, Matos-Pires E, et al. De novo HIV infection diagnoses in a Department of Dermatology and Venereology in Lisbon, Portugal. *Int J STD AIDS* 2017; 28(9): 887-92.

495. Mendling W, Krasemann C. Bacteriological findings and therapeutic consequences in adnexitis. *Geburtshilfe und Frauenheilkunde* 1986; 46(7): 462-6.
496. Mensforth S, Radcliffe K. Is it time to reconsider epidemiological treatment for gonorrhoea? *Int J STD AIDS* 2018; 29(10): 1043-4.
497. Mesko M, Lipenský S, Jedinák J. [Gonorrhea in women prior to pregnancy interruption]. *Zentralbl Gynakol* 1972; 94(5): 169-72.
498. Mesko M, Lipenský S, Smotlak A, Jedinák J, Bakos J. [Diagnosis, clinical importance and epidemiology of gonorrhea in pregnancy]. *Cesk Gynkol* 1972; 37(1): 50-1.
499. Mezinova NN. [TREATMENT OF FEMALE STERILITY, CAUSED BY INFLAMMATORY PROCESSES IN THE UTERINE ADNEXA, WITH CORTISONE AND HYALURONIDASE COMBINED WITH ANTIBIOTICS]. *Akush Ginekol (Mosk)* 1963; 39: 92-5.
500. Mierzejewski W, Rogoza A, Zabul J. [Evaluation of the bacteriological examination of the semen of men in childless marriages]. *Ginekol Pol* 1987; 58(12): 811-5.
501. Miettinen A, Heinonen PK, Teisala K, Hakkarainen K, Punnonen R. Serologic evidence for the role of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Mycoplasma hominis* in the etiology of tubal factor infertility and ectopic pregnancy. *Sex Transm Dis* 1990; 17(1): 10-4.
502. Miettinen A, Saikku P, Jansson E, Paavonen J. Epidemiologic and clinical characteristics of pelvic inflammatory disease associated with *Mycoplasma hominis*, *Chlamydia trachomatis*, and *Neisseria gonorrhoeae*. *Sex Transm Dis* 1986; 13(1): 24-8.
503. Mihalik N, Pónyai K, Tóth B, et al. P3.072 STI Co-Infections Without Any Symptoms? - Screening is Necessary. *Sexually Transmitted Infections* 2013; 89(Suppl 1): A170.3-A.
504. Mikl J, Sudar Z, Smith PF, et al. HIV infection and high risk behavior among patients attending an STD referral clinic in Prague, Czech Republic. *Sex Transm Infect* 1998; 74(2): 128-30.
505. Milosovic P, Simkovicova M, Hausmannova Z. In vitro sensitivity of strains of *Neisseria gonorrhoeae* to antibiotics in 1982-1986 in the Regional Hygiene Station Bratislava. *Cesko-Slovenska Dermatologie* 1988; 63(3): 178-84.
506. Miron N, Socolov D, Mares M, et al. Bacteriological agents which play a role in the development of infertility. *Acta Microbiologica et Immunologica Hungarica* 2013; 60(1): 41-53.
507. Modde H, Krech U. [Gonococcal diseases from the clinical and bacteriological viewpoint]. *Schweiz Med Wochenschr* 1969; 99(35): 1242-5.
508. Moi H. Prevalence of bacterial vaginosis and its association with genital infections, inflammation, and contraceptive methods in women attending sexually transmitted disease and primary health clinics. *Int J STD AIDS* 1990; 1(2): 86-94.
509. Moi H, Reinton N, Moghaddam A. *Mycoplasma genitalium* is associated with symptomatic and asymptomatic non-gonococcal urethritis in men. *Sex Transm Infect* 2009; 85(1): 15-8.
510. Möller BR, Ahrons S, Laurin J, Mårdh PA. Pelvic infection after elective abortion associated with *Chlamydia trachomatis*. *Obstet Gynecol* 1982; 59(2): 210-3.
511. Moller BR, Allen J, Toft B. Pelvic inflammatory disease after hysterosalpingography associated with *Chlamydia trachomatis* and *Mycoplasma hominis*. *British Journal of Obstetrics and Gynaecology* 1984; 91(12): 1181-7.
512. Moller BR, From E, Christensen RB, Heilmann B, Jensen KE, Thorsen P. The venereological profile in Godthab District Venereal Clinic, Nuuk, Gronland. A 3-month study in 1991. [Danish]. *Ugeskrift for laeger* 1992; 154(21): 1505-8.
513. Molzhaninov EV, Entin BV, Sliusar ZK. [Results of the anti-inflammatory treatment of women with a history of ascending gonorrhea]. *Akush Ginekol (Mosk)* 1982; (4): 44-5.
514. Mor Z, Shohat T, Goor Y, Dan M. Risk behaviors and sexually transmitted diseases in gay and heterosexual men attending an STD clinic in Tel Aviv, Israel: A cross-sectional study. *Israel Medical Association Journal* 2012; 14(3): 147-51.
515. Moreno-Ribera N, Fuertes-de Vega I, Blanco-Arevalo JL, et al. Sexually Transmitted Infections: Experience in a Multidisciplinary Clinic in a Tertiary Hospital (2010-2013). *Actas Dermosifiliogr* 2016; 107(3): 235-41.
516. Morgat M, Bouiller K, Vuilleminot JB, et al. Number, type and cost of microbiological tests during HIV Pre-Exposure Prophylaxis: The experience of a French hospital. *Infect Dis Now* 2021; 51(4): 357-61.
517. Morris GC, Stewart CM, Schoeman SA, Wilson JD. A cross-sectional study showing differences in the clinical diagnosis of pelvic inflammatory disease according to the experience of clinicians: implications for training and audit. *Sex Transm Infect* 2014; 90(6): 445-51.
518. Mulcahy FM, Lacey CJ. Sexually transmitted infections in adolescent girls. *Genitourin Med* 1987; 63(2): 119-21.
519. Munkvad IM, Klemp P. Co-existence of venereal infection and pediculosis pubis. *Acta Derm Venereol* 1982; 62(4): 366-7.
520. Muñoz-Pérez MA, Rodríguez-Pichardo A, Camacho Martínez F. Sexually transmitted diseases in 1161 HIV-positive patients: a 38-month prospective study in southern Spain. *J Eur Acad Dermatol Venereol* 1998; 11(3): 221-6.
521. Nanov Z, Kholevich Z, Nanova B. [Spermatogenesis disorders in men with a history of gonorrhea]. *Akush Ginekol (Sofia)* 1987; 26(1): 56-9.
522. Napoli Z, Donati S, Caffisi A, et al. Frequency of most important sexually transmitted diseases and methodological implications. *Biochimica Clinica* 2013; 1: S142.
523. Nayyar KC, Cummings M, Weber J. Prevalence of genital pathogens among female prostitutes in New York City and in Rotterdam. *Sexually Transmitted Diseases* 1986; 13(2): 105-7.
524. Netak Y, Vasylyev M, Sluzhynska O, et al. Results of STI/HIV counseling and testing program for commercial sex workers, drug users, men have sex with men and former prisoners during 2012-2013 in Lviv region (Ukraine). *Sexually Transmitted Diseases* 2014; 1: S123.
525. Nicholls JE, Turner KME, North P, et al. Cross-sectional study to evaluate *Trichomonas vaginalis* positivity in women tested for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*, attending genitourinary medicine and primary care clinics in Bristol, South West England. *Sex Transm Infect* 2018; 94(2): 93-9.
526. Nichols K, Sim-Ikere O, Pinto-Sander N, Soni S. Testing for and managing *Mycoplasma genitalium* in women attending a GUM clinic. *HIV Medicine* 2018; 19(Supplement 2): S38.
527. Nicol E, Shaw J, Ward C. A review of sexually acquired proctitis: An array of symptoms, investigations and treatments. *Sexually Transmitted Infections* 2016; 92(Supplement 1): A39.
528. Nielsen FH. [Routine culture for gonococci in a family planning clinic]. *Ugeskr Laeger* 1974; 136(14): 767-8.
529. Nielsen LA, Mikkelsen SJ, Charles AV. [Chlamydia trachomatis and Neisseria gonorrhoeae infections in sexually abused children in Jutland]. *Ugeskr Laeger* 2002; 164(49): 5806-9.
530. Nielsen R, Sondergaard J, Ullman S. Asymptomatic male and female gonorrhoea. *Acta Derm Venereol* 1975; 55(6): 499-501.
531. Nielsen S, Haar K, Sailer A, Hamouda O. STI rates and risk factors among female sex workers attending STI testing sites in Germany, January - December 2010. *Sexually Transmitted Infections* 2011; 1: A125-A6.
532. Nijhuis RHT, Duinsbergen RG, Pol A, Godschalk PCR. Prevalence of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium* and *Trichomonas vaginalis* including relevant resistance-associated mutations in a single center in the Netherlands. *Eur J Clin Microbiol Infect Dis* 2020.
533. Nitschke H, Oliveira F. 10 years of experience: Comprehensive sexual health services for female sex workers (FSW) in Cologne. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
534. Nolskog P, Backhaus E, Nasir S, Enroth H. STI with *Mycoplasma genitalium*-more common than *Chlamydia trachomatis* in patients attending youth clinics in Sweden. *Eur J Clin Microbiol Infect Dis* 2019; 38(1): 81-6.
535. Nouchi A, Caby F, Palich R, Monsel G, Caumes AE. Travel-associated STI amongst HIV and non-HIV infected travellers. *J Travel Med* 2019; 26(8).

536. Nugent D, Stirrup O, Pett S, et al. Performance of human papillomavirus DNA detection in residual specimens taken for Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification testing in men who have sex with men. *Sex Transm Infect* 2021; 97(7): 541-6.
537. O'Brien A, Sherrard-Smith E, Sile B, Watts C, Simms I. Spatial clusters of gonorrhoea in England with particular reference to the outcome of partner notification: 2012 and 2013. *PLoS One* 2018; 13(4): e0195178.
538. Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the "New Chlamydia?" A community-based prospective cohort study. *Clin Infect Dis* 2010; 51(10): 1160-6.
539. Oakeshott P, Kerry-Barnard S, Fleming C, et al. 'Test n Treat' (TnT): a cluster randomized feasibility trial of on-site rapid Chlamydia trachomatis tests and treatment in ethnically diverse, sexually active teenagers attending technical colleges. *Clin Microbiol Infect* 2019; 25(7): 865-71.
540. Oborin DA, Nikolaeva NV, Godovalov AP, Karpunina TI. [Etiology of purulent-inflammatory processes in the genital tract: suspicions of clinicians and problems of laboratory confirmation.]. *Klin Lab Diagn* 2020; 65(5): 328-31.
541. Oganessian MG. [An intracutaneous test with gonococcal allergen in married couples with impaired reproductive function]. *Vestn Dermatol Venerol* 1990; (1): 57-8.
542. Ogaz D, Miltz AR, Desai S, et al. Preparing for prep in England: Prevalence and incidence of HIV and bacterial stis. *Topics in Antiviral Medicine* 2019; 27(SUPPL 1): 20s-1s.
543. Op de Coul ELM, Peek D, van Weert YWM, et al. Chlamydia trachomatis, Neisseria gonorrhoea, and Trichomonas vaginalis infections among pregnant women and male partners in Dutch midwifery practices: prevalence, risk factors, and perinatal outcomes. *Reprod Health* 2021; 18(1): 132.
544. Opaneye AA. Sexually transmitted diseases among women in Coventry. *J R Soc Health* 1997; 117(1): 37-40.
545. Opaneye AA, Willmott C. The role of genito-urinary medicine in adolescent sexuality. *Genitourin Med* 1991; 67(1): 44-6.
546. Orduña Domingo A, Chu JJ, Eiros Bouza JM, et al. [Age and sex distribution of sexually transmitted diseases in Valladolid. A study of 5076 cases]. *Rev Sanid Hig Publica (Madr)* 1991; 65(3): 247-58.
547. Orellana MA, Gómez M, Sánchez MT, Fernández-Chacón T. [Diagnosis of urethritis in men. A 3-year review]. *Rev Esp Quimioter* 2009; 22(2): 83-7.
548. Orellana MA, Gómez-Lus ML. [Which is the best empirical treatment in patients with urethritis?]. *Rev Esp Quimioter* 2011; 24(3): 136-42.
549. Orellana MA, Gomez-Lus ML. Microorganisms isolated in urethral samples in women. *Clinical Microbiology and Infection* 2011; 4): S814-S5.
550. Orellana MA, Gomez-Lus ML. Urethritis epidemiology in men in central Madrid, Spain. *Clinical Microbiology and Infection* 2011; 4): S813-S4.
551. Orsos M, Sziller I, Pulay T, Paulin F, Csomor S, Nasz I. [A microbiology clinic in outpatient gynecologic service]. *Orv Hetil* 1989; 130(24): 1259-62.
552. Ortayli N, Sahip Y, Amca B, Say L, Sahip N, Aydin D. Curable sexually transmitted infections among the clientele of a family planning clinic in Istanbul, Turkey. *Sex Transm Dis* 2001; 28(1): 58-61.
553. Osbak KK, Meehan CJ, S GR, et al. Superimposing incident sexually transmitted infections on HIV phylogram to investigate possible misclassification of men who have sex with men as heterosexuals in a cohort in Antwerp, Belgium. *Int J STD AIDS* 2019; 30(5): 486-95.
554. Oskarsson T, Geirsson RT, Steingrímsson O, Thorarinnsson H. Lower genital tract infection with Neisseria gonorrhoeae and Chlamydia trachomatis in women requesting induced abortion and in their sexual partners. *Acta Obstet Gynecol Scand* 1990; 69(7-8): 635-40.
555. Ostergaard L, Andersen B, Moller JK, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. *Clin Infect Dis* 2000; 31(4): 951-7.
556. Ouzounova-Raykova V, Jordanov D, El-Tibi M, Mitov I. Gonococcal infection in symptomatic and asymptomatic persons seeking medical clinics in Sofia--a 3-year study 2008-2010. *Apmis* 2011; 119(12): 864-7.
557. Ozturk CE, Ozdemir I, Yavuz T, Kaya D, Behcet M. Etiologic agents of cervicovaginitis in Turkish women. *Saudi Medical Journal* 2006; 27(10): 1503-7.
558. Pace CA, Lioznov D, Cheng DM, et al. Sexually transmitted infections among HIV-infected heavy drinkers in St Petersburg, Russia. *Int J STD AIDS* 2012; 23(12): 853-8.
559. Pagani C, Rimoldi SG, Chenal LL, et al. Sexually transmitted infections in women attending the obstetrics and gynaecologic unit of a university hospital in the north of Milan: Prevalence and risk behaviours. *Clinical Microbiology and Infection* 2012; 3): 810.
560. Pagani N, De Bartolo A, Pescatori T, Lusco G, Clerici P. Rapid diagnosis of infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae. *Microbiologia Medica* 1996; 11(3): 246-7.
561. Palous V, Sturma J, Kreckek J, Potuznik V, Hausner O. [Experience with the diagnosis and treatment of gonorrhea in women]. *Cesk Dermatol* 1971; 46(6): 256-61.
562. Papadogeorgaki H, Caroni C, Frangouli E, Flemetakis A, Katsambas A, Hadjivassiliou M. Prevalence of sexually transmitted infections in female sex workers in Athens, Greece - 2005. *Eur J Dermatol* 2006; 16(6): 662-5.
563. Papadogeorgakis H, Pittaras TE, Papaparaskevas J, Pitiriga V, Katsambas A, Tsakris A. Chlamydia trachomatis serovar distribution and Neisseria gonorrhoeae coinfection in male patients with urethritis in Greece. *J Clin Microbiol* 2010; 48(6): 2231-4.
564. Papanagiotou A, Terzi N, Vlachos S, et al. Symptomatic and asymptomatic infections of the lower genital tract in pregnant and non-pregnant women of reproductive age. *Clinical Microbiology and Infection* 2012; 18: 114-715.
565. Parker RD, Rüütel K. Sexually Transmitted Infections - Prevalence, Knowledge and Behaviours among Professional Defence Forces in Estonia: a Pilot Study. *Cent Eur J Public Health* 2017; 25(1): 11-4.
566. Parra-Sanchez M, Garcia-Rey S, Pueyo Rodriguez I, Viciano Fernandez P, Torres Sanchez MJ, Palomares Folia JC. Clinical and epidemiological characterisation of lymphogranuloma venereum in southwest Spain, 2013-2015. *Sexually Transmitted Infections* 2016; 92(8): 629-31.
567. Pasieczny T, Sommerville RG. Outbreak of non-specific urethritis associated with the presence of complement-fixing antibodies to the LB4 strain of TRIC agent. *Br J Vener Dis* 1966; 42(3): 191-4.
568. Pearson RC, Bamber CD, McGhie D, Thammar IV. The relevance of Chlamydia trachomatis in acute epididymitis in young men. *Br J Urol* 1988; 62(1): 72-5.
569. Pec J, Jedinak J, Moravcik P. [Trichomoniasis as a concomitant infection in female gonorrhoea (author's transl)]. *Cesk Dermatol* 1981; 56(2): 119-24.
570. Peeters MF, Bots RS, Merkus JM, Prak FM. [Chlamydia trachomatis, infertility and in vitro fertilization]. *Ned Tijdschr Geneesk* 1988; 132(31): 1438-42.
571. Pena MJ, Campos-Herrero MI, Ruiz MC, Rodriguez H, Lafarga B. Microbiological study of vulvovaginitis in premenarcheal girls. [Spanish]. *Enfermedades Infecciosas y Microbiologia Clinica* 1996; 14(5): 311-3.
572. Penney GC, Thomson M, Norman J, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. *Br J Obstet Gynaecol* 1998; 105(6): 599-604.
573. Perea EJ, Alvarez-Dardet C, Borobio MV, et al. Three years' experience of sexually transmitted diseases in Seville, Spain. *Br J Vener Dis* 1981; 57(3): 174-7.
574. Pereyre S, Laurier Nadalié C, Bébéar C. Mycoplasma genitalium and Trichomonas vaginalis in France: a point prevalence study in people screened for sexually transmitted diseases. *Clin Microbiol Infect* 2017; 23(2): 122.e1-e7.
575. Pérez Bernal AM, Hernández Aguado I, Sánchez-Pedreño Guillén P, Feliu Pérez MM, Camacho Martínez F. [Mucopurulent cervicitis at a clinic for sexually transmitted diseases]. *Med Cutan Ibero Lat Am* 1987; 15(6): 517-22.

576. Perez-Hernandez I, Palacios R, Gonzalez-Domenech C, et al. Should screening for Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-men who have sex with men be recommended? *Journal of the International AIDS Society* 2014; 3): 112-3.
577. Perez-Torralba C, Ruiz-Olivares M, Sanbonmatsu-Gamez S, Exposito-Ruiz M, Navarro-Mari JM, Gutierrez-Fernandez J. [Increased infections by herpes simplex virus type 1 and polymicrobials of the genital tract, in the general population of a Spanish middle city]. *Rev Esp Quimioter* 2021; 34(4): 320-9.
578. Persson K, Persson K, Hansson H, et al. Prevalence of nine different micro-organisms in the female genital tract. A comparison between women from a venereal disease clinic and from a health control department. *Br J Vener Dis* 1979; 55(6): 429-33.
579. Peters RP, Nijsten N, Mutsaers J, Jansen CL, Morré SA, van Leeuwen AP. Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. *Sex Transm Dis* 2011; 38(9): 783-7.
580. Peters RP, Verweij SP, Nijsten N, et al. Evaluation of sexual history-based screening of anatomic sites for chlamydia trachomatis and neisseria gonorrhoeae infection in men having sex with men in routine practice. *BMC Infect Dis* 2011; 11: 203.
581. Petersen CS, Danielsen AG, Renneberg J. Bacterial vaginosis: the leading cause of vaginal discharge in women attending an STD clinic in Copenhagen. *Acta Derm Venereol* 1999; 79(5): 414-5.
582. Peuchant O, de Diego S, Le Roy C, et al. Comparison of three real-time PCR assays for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in young pregnant women. *Diagnostic Microbiology and Infectious Disease* 2015; 83(4): 335-7.
583. Peuchant O, Le Roy C, Desveaux C, et al. Screening for Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium should it be integrated into routine pregnancy care in French young pregnant women? *Diagn Microbiol Infect Dis* 2015; 82(1): 14-9.
584. Peuchant O, Touati A, Laurier-Nadalié C, et al. Prevalence of lymphogranuloma venereum among anorectal Chlamydia trachomatis-positive MSM using pre-exposure prophylaxis for HIV. *Sex Transm Infect* 2020; 96(8): 615-7.
585. Pfortmueller CA, Koetter JN, Zimmermann H, Exadaktylos AK. Sexual activity-related emergency department admissions: eleven years of experience at a Swiss university hospital. *Emerg Med J* 2013; 30(10): 846-50.
586. Phillips MD, Davies A, Hewart R, Acladiou N, Morgan E. An audit of Neisseria gonorrhoeae detection methods in a district general hospital genitourinary medicine service. Sexually Transmitted Infections Conference: 4th Joint BASHH ASTDA Meeting Brighton United Kingdom Conference Publication: 2012; 88(SUPPL. 1).
587. Pilatz A, Hossain H, Kaiser R, et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. *Eur Urol* 2015; 68(3): 428-35.
588. Pittrof R, McLellan J. Test Not Talk screening for asymptomatic men. *Int J STD AIDS* 2007; 18(4): 274-5.
589. Piyadigamage A, Wilson J. Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy. *Sex Transm Infect* 2005; 81(3): 233-5.
590. Plaas K, Eelmets L, Ratnik K, Janes J, Ruutel K, Naaber P. Sexually transmitted infections among men who have sex with men: Prevalence, locations and challenges for molecular assays. *International Journal of STD and AIDS* 2015; 1): 102.
591. Plamenova GM, Raykova V, Pehlivanov G. Reliable methods for detection of sexually transmitted bacterial fastidious microorganisms. *International Journal of STD and AIDS* 2015; 1): 84.
592. Platt L, Grenfell P, Bonell C, et al. Risk of sexually transmitted infections and violence among indoor-working female sex workers in London: the effect of migration from Eastern Europe. *Sex Transm Infect* 2011; 87(5): 377-84.
593. Plecko V, Zele-Starcevic L, Tripkovic V, et al. Unusually low prevalence of Mycoplasma genitalium in urine samples from infertile men and healthy controls: a prevalence study. *BMJ Open* 2014; 4(8): e005372.
594. Pond M, Wagner J, Laing K, et al. Bacterial populations detected within first void urine samples of symptomatic male patients with urethritis. *Sexually Transmitted Infections* 2017; 93(Supplement 2): A58-A9.
595. Pónyai K, Marschalkó M, Schöffler M, et al. [Analysis of syphilis and gonorrhoea cases, based on data from the National STD Centre, Department of Dermatology and Venerology, Semmelweis University (2005-2008)]. *Orv Hetil* 2009; 150(38): 1765-72.
596. Popert AJ, Gill AJ, Laird SM. A Prospective Study of Reiter's Syndrome. An Interim Report on the First 82 Cases. *Br J Vener Dis* 1964; 40(3): 160-5.
597. Prien-Larsen JC, Kjer JJ. [Prevalence of positive gonococcal and chlamydial findings in women applying for termination of pregnancy. A screening evaluation]. *Ugeskr Laeger* 1989; 151(26): 1671-2.
598. Prins M, Hooykaas C, Coutinho RA, van Doornum GJ, van den Hoek AJ. Incidence and risk factors for acquisition of sexually transmitted diseases in heterosexuals with multiple partners. *Sex Transm Dis* 1994; 21(5): 258-67.
599. Pugh E, Pakianathan M, McCormick C, Webb H, Korley K, Patel S. The sexual health behaviour of HIV positive patients in an urban UK cohort. *HIV Medicine* 2012; 1): 17.
600. Pulvirenti MG, McErlean C, McGrath NF, et al. Evaluation of a multiplex array for the simultaneous detection of ten common STI pathogens. *Clinical Chemistry* 2015; 61(10 SUPPL. 1): S139-S40.
601. Punnonen R, Terho P, Nikkanen V, Meurman O. Chlamydial serology in infertile women by immunofluorescence. *Fertil Steril* 1979; 31(6): 656-9.
602. Puolakkainen M, Vesterinen E, Purola E, Saikku P, Paavonen J. Persistence of chlamydial antibodies after pelvic inflammatory disease. *J Clin Microbiol* 1986; 23(5): 924-8.
603. Purola E, Jähkola M, Osterlund K. Gonorrhoea, trichomoniasis and yeast infection in late pregnancy in an unselected series of gravidae. *Ann Chir Gynaecol Fenn* 1967; 56(1): 95-8.
604. Querido L, Haspels AA. The incidence of gonorrhea in an abortion population. *Contraception* 1980; 22(4): 441-4.
605. Qvigstad E, Skaug K, Jerve F, Fylling P, Ulstrup JC. Pelvic inflammatory disease associated with Chlamydia trachomatis infection after therapeutic abortion. A prospective study. *Br J Vener Dis* 1983; 59(3): 189-92.
606. Rahib D, Delagrevierie HM, Bichard I, et al. Expanding testing strategies in Paris: A free postal comprehensive STI test kit. *Topics in Antiviral Medicine* 2019; 27(SUPPL 1): 21s.
607. Raiga J, Canis M, Le Bouedec G, et al. Laparoscopic management of adnexal abscesses: Consequences for fertility. *Fertility and Sterility* 1996; 66(5): 712-7.
608. Rao GG, Bacon L, Evans J, Dejahang Y, Michalczyk P, Donaldson N. Prevalence of Neisseria gonorrhoeae infection in young subjects attending community clinics in South London. *Sex Transm Infect* 2008; 84(2): 117-21.
609. Reimann K, Lind I, Andersen KE. An indirect haemagglutination test for demonstration of gonococcal antibodies using gonococcal pili as antigen. II. Serological investigation of patients attending a dermatovenerological outpatients clinic in Copenhagen. *Acta Pathol Microbiol Scand C* 1980; 88(3): 155-62.
610. Reimann K, Odum L, Larsen SO, Lind I. [The gonococcal antibody test (GAT) as a diagnostic aid. When can GAT be employed?]. *Ugeskr Laeger* 1986; 148(37): 2345-8.
611. Reimann K, Odum L, Larsen SO, Lind I. Indirect haemagglutination test using gonococcal pilus antigen: how useful to diagnose gonorrhoea? *Genitourin Med* 1987; 63(4): 250-5.
612. Reinton N, Moi H, Olsen AO, et al. Anatomic distribution of Neisseria gonorrhoeae, Chlamydia trachomatis and Mycoplasma genitalium infections in men who have sex with men. *Sex Health* 2013; 10(3): 199-203.
613. Renton A, Filatova E, Ison C, et al. A trial of the validity of genital smears and cultures with gonococcal vaccine provocation in diagnosing genital gonorrhoea in women. *Int J STD AIDS* 2009; 20(1): 24-9.

614. Resl V, Resl V, Jr. [Statistical evaluation of the activities of the venereological laboratory and departments of the Dermatological clinic of the University Hospital in Pilsen with regard to gonorrhea. Statistical data from the West Bohemian Region]. *Cesk Dermatol* 1976; 51(2): 117-3.
615. Reynolds M, Wilson J. Is *Trichomonas vaginalis* still a marker for other sexually transmitted infections in women? *Int J STD AIDS* 1996; 7(2): 131-2.
616. Reynolds-Wright J, Verrall F, Hassan-Ibrahim M, Soni S. Implementing a test and treat pathway for mycoplasma genitalium in men with urethritis attending a gum clinic. *Sexually Transmitted Infections* 2016; 92(Supplement 1): A12.
617. Ribeiro S, de Sousa D, Medina D, Castro R, Lopes A, Rocha M. Prevalence of gonorrhea and chlamydia in a community clinic for men who have sex with men in Lisbon, Portugal. *Int J STD AIDS* 2019; 30(10): 951-9.
618. Rich RS, Leventhal A, Sheffer R, Mor Z. Risky sexual behavior and sexually transmitted infections among men who have sex with men and purchase sex attending an Israeli sexually transmitted infection clinic. *Int J STD AIDS* 2020; 31(3): 236-43.
619. Richardson D, Devlin J, Fitzpatrick C, Pinto-Sander N. Sexually transmitted *Shigella flexneri* and *Shigella sonnei* in men who have sex with men. *Sex Transm Infect* 2021; 97(3): 244.
620. Rimoldi SG, Pagani C, Giacomini V, et al. Sexually transmissible infections among young adolescents in Milan areas: A multicentre study. *Clinical Microbiology and Infection* 2012; 3): 235.
621. Riordan T, Macaulay ME, James JM, et al. A prospective study of genital infections in a family-planning clinic. I. Microbiological findings and their association with vaginal symptoms. *Epidemiol Infect* 1990; 104(1): 47-53.
622. Ripa KT, Svensson L, Trehan JD, Westrom L, Mardh PA. Chlamydia trachomatis infection in patients with laparoscopically verified acute salpingitis. Results of isolation and antibody determinations. *Am J Obstet Gynecol* 1980; 138(7 Pt 2): 960-4.
623. Roberts J, Richardson D, Evans D, Hutchinson L, Tweed M, Dean G. Uptake of gonorrhoea and chlamydia self-taken nucleic acid amplification tests by men who have sex with men attending an outreach clinic and sex on premises venues. *International Journal of STD and AIDS* 2013; 1): 34.
624. Robertson DH, George G. Medical and legal problems in the treatment of delinquent girls in Scotland. II. Sexually transmitted disease in girls in custodial institutions. *Br J Vener Dis* 1970; 46(1): 46-53.
625. Robertson JN, Ward ME, Conway D, Caul EO. Chlamydial and gonococcal antibodies in sera of infertile women with tubal obstruction. *J Clin Pathol* 1987; 40(4): 377-83.
626. Robinson DK. Letter: Gonorrhoea of the pharynx. *Br Med J* 1974; 2(5917): 500-1.
627. Rodríguez R, Hernández R, Cabrera L, Fernández A, Alberto J, Prieto P. Análisis del factor cervical de esterilidad. *Clínica e Investigación en Ginecología y Obstetricia* 2003; 30(2): 53-8.
628. Rodríguez R, Hernández R, Fuster F, Torres A, Prieto P, Alberto J. [Genital infection and infertility]. *Enferm Infecc Microbiol Clin* 2001; 19(6): 261-6.
629. Rodríguez-Domínguez M, Puerta T, Menéndez B, et al. Clinical and epidemiological characterization of a lymphogranuloma venereum outbreak in Madrid, Spain: co-circulation of two variants. *Clin Microbiol Infect* 2014; 20(3): 219-25.
630. Rodríguez-Pichardo A, Aznar J, Camacho F, Borobio MV, Perea EJ. Sexually transmitted diseases in homosexual males in Seville, Spain. *Genitourin Med* 1991; 67(4): 335-8.
631. Rolland C, de La Rochebrochard E, Piron P, Shelly M, Segouin C, Troude P. Who fails to return within 30 days after being tested positive for HIV/STI in a free testing centre? *BMC Infect Dis* 2020; 20(1): 795.
632. Rolskov AS, Bjorn-Mortensen K, Mulvad G, Poulsen P, Jensen JS, Pedersen ML. Rapid change in the ciprofloxacin resistance pattern among *Neisseria gonorrhoeae* strains in Nuuk, Greenland: time to reconsider preventive and treatment strategies. *Int J Circumpolar Health* 2015; 74: 26916.
633. Romosan G, Bjartling C, Skoog L, Valentin L. Ultrasound for diagnosing acute salpingitis: a prospective observational diagnostic study. *Hum Reprod* 2013; 28(6): 1569-79.
634. Ronn M, Hughes G, White P, Simms I, Ison C, Ward H. Characteristics of LGV repeaters: analysis of LGV surveillance data. *Sex Transm Infect* 2014; 90(4): 275-8.
635. Rosenvinge MM, Lau R. Screening for asymptomatic chlamydia in women - How often would gonorrhoea be missed? *International Journal of STD and AIDS* 2009; 20(8): 571-2.
636. Ross JD, McMillan A, Young H. Changing trends of gonococcal infection in homosexual men in Edinburgh. *Epidemiol Infect* 1991; 107(3): 585-90.
637. Ross JD, Scott GR, Busuttill A. Rape and sexually transmitted diseases: patterns of referral and incidence in a department of genitourinary medicine. *J R Soc Med* 1991; 84(11): 657-9.
638. Rossignol L, Feuillepain L, Ndeikoundam Ngangro N, et al. Estimate of male urethritis incidences in France between 2007 and 2017 with a specific focus on *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and *Trichomonas vaginalis* infections. *BMC Infect Dis* 2019; 19(1): 561.
639. Rozova M, Beilina O, Koniuchova K, et al. Experiences from working with sexually transmitted infections and related issues among teenagers and Youth in Tver, Russia. *Sexually Transmitted Infections Conference: STI and AIDS World Congress* 2013; 89(SUPPL. 1).
640. Ruijs GJ, Schut IK, Schirm J, Schröder FP. Prevalence, incidence, and risk of acquiring urogenital gonococcal or chlamydial infection in prostitutes working in brothels. *Genitourin Med* 1988; 64(1): 49-51.
641. Ruiz-Olivares M, Foronda-García-Hidalgo C, Sanbonmatsu-Gámez S, Gutiérrez-Fernández J. [Recent prevalence among females from the general population of agents responsible for sexually transmitted infections and other genital infections]. *Aten Primaria* 2020; 52(10): 799-801.
642. Rumyantseva T, Golparian D, Nilsson CS, et al. Evaluation of the new AmpliSens multiplex real-time PCR assay for simultaneous detection of *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Mycoplasma genitalium*, and *Trichomonas vaginalis*. *Apmis* 2015; 123(10): 879-86.
643. Ruozzi Berretta L, Schepisi P. [Etiological factors in masculine sterility: results of 934 cases]. *Patol Clin Ostet Ginecol* 1974; 2(5): 230-9.
644. Rüütel K, Lõhmus L, Jänes J. Internet-based recruitment system for HIV and STI screening for men who have sex with men in Estonia, 2013: analysis of preliminary outcomes. *Eurosurveillance* 2015; 20(15): 21094.
645. Sacks R, Nwokolo N, McOwan A, Whitlock G. Characteristics of those with newly diagnosed HIV at a central London clinic. *HIV Medicine* 2017; 18(Supplement 1): 50.
646. Sakem B, Michel R, Nydegger UE, et al. Diagnostic relevance of simultaneous testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *Infection* 2011; 39(3): 231-7.
647. Salfa MC, Suligoi B. Prevalence of *Chlamydia trachomatis*, *Trichomonas vaginalis* and *Neisseria gonorrhoeae* Based on Data Collected by a Network of Clinical Microbiology Laboratories, in Italy. *Adv Exp Med Biol* 2016; 901: 47-57.
648. Salva AL, Celorio A, Castro A. The clinico-microbiological relationship in pelvic inflammatory disease. *Progresos en Obstetricia y Ginecología* 1986; 29(7): 425-32.
649. Samarasekara K, Fitzpatrick C, Finnerty F, Richardson D. Pilot study of pharyngeal *Chlamydia trachomatis* in HIV-positive and HIV-negative men who have sex with men. *Sex Health* 2021; 18(2): 200-1.
650. Sambri V, Dirani G, Farabegoli P. How to facilitate and improve screening of sexually-transmitted infections in women population. *Sexually Transmitted Infections* 2017; 93(Supplement 2): A64-A5.
651. Samra Z, Dan M, Segev S, et al. Prevalence of sexually transmitted pathogens among women attending a methadone clinic in Israel. *Genitourin Med* 1991; 67(2): 133-6.

652. Santino I, Cauletti M, Del Piano M, Fiamma S, Santi AL. [Bacterial infection from sexual contact in a sampling of a student population]. *Nuovi Ann Ig Microbiol* 1985; 36(2): 105-12.
653. Schabereiter-Gurtner C, Hufnagl P, Sonvilla G, et al. Evaluation of a novel internally controlled real-time PCR assay targeting the 16S rRNA gene for confirmation of *Neisseria gonorrhoeae* infections. *Clinical Microbiology and Infection* 2008; 14(5): 480-6.
654. Schmidt AJ, Rasi M, Esson C, et al. The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of men. *Swiss Med Wkly* 2020; 150: w20392.
655. Schuurs TA, Verweij SP, Weel JFL, Ouburg S, Morre SA. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in an STI population: Performances of the Presto CT-NG assay, the Lightmix Kit 480 HT CT/NG and the COBAS Amplicor with urine specimens and urethral/cervicovaginal samples. *BMJ Open* 2013; 3(12) (no pagination).
656. Sednaoui P, Malkin JE, Alonso JM. *Neisseria gonorrhoeae* RNA/DNA hybridization and culture for screening of gonococcal infections in a low-prevalence population. *Eur J Epidemiol* 1996; 12(6): 651-4.
657. Selvaag E. No differences in the prevalence of venereological disease in Norwegians compared with non-Norwegians. *Sexually Transmitted Infections* 1999; 75(1): 68.
658. Semmola L. [Contribution of observations on the cases of male infertility]. *Minerva Dermatol* 1967; 42(8): 393-7.
659. Sethi G, Holden BM, Gaffney J, Greene L, Ghani AC, Ward H. HIV, sexually transmitted infections, and risk behaviours in male sex workers in London over a 10 year period. *Sex Transm Infect* 2006; 82(5): 359-63.
660. Sethupathi M, Blackwell A, Davies H. Rectal *Chlamydia trachomatis* infection in women. Is it overlooked? *Int J STD AIDS* 2010; 21(2): 93-5.
661. Shafer MA, Pessione F, Scieux C, et al. *Chlamydia trachomatis* in French women: Association with smoking, cervical ectopy and other clinical factors. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction* 1993; 22(2): 163-8.
662. Shahidullah M. Pharyngeal gonorrhoea in homosexuals. *Br J Vener Dis* 1976; 52(3): 168-9.
663. Shakarishvili A, Dubovskaya LK, Zhrabyan LS, et al. Sex work, drug use, HIV infection, and spread of sexually transmitted infections in Moscow, Russian Federation. *Lancet* 2005; 366(9479): 57-60.
664. Shawe J, White A, Ball A, et al. Improving the sexual health of homeless people: Does providing nurse-led care within hostels improve contraceptive use and uptake of sexual health screening? *European Journal of Contraception and Reproductive Health Care* 2014; 1): S140.
665. Shiely F, Hayes K, Horgan M. Comparison of risk factors for prevalent sexually transmitted infections based on attendees at two genitourinary medicine clinics in Ireland. *Int J STD AIDS* 2014; 25(1): 29-39.
666. Shinskii GE, Ignat'eva GF. [Incidence of gonorrhea and characteristics of its course in husbands of women receiving prophylactic anti-gonorrhea treatment in obstetric-gynecologic institutions]. *Vestn Dermatol Venerol* 1975; (6): 78-80.
667. Shipitsyna E, Khusnutdinova T, Budilovskaya O, et al. Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for *Chlamydia trachomatis*, *Mycoplasma genitalium* and *Trichomonas vaginalis* infections in low-risk women, St. Petersburg, Russia. *Eur J Clin Microbiol Infect Dis* 2020; 39(7): 1221-30.
668. Shipitsyna E, Khusnutdinova T, Ryzhkova O, et al. Prevalence of sexually transmitted infections in young people in St. Petersburg, Russia, as Determined using self-collected non-invasive specimens. *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013*; 89(SUPPL. 1).
669. Shipitsyna E, Zolotoverkhaya E, Hjelmvoll S, et al. Evaluation of six nucleic acid amplification tests used for diagnosis of *Neisseria gonorrhoeae* in Russia compared with an international strictly validated real-time porA pseudogene polymerase chain reaction. *Journal of the European Academy of Dermatology and Venereology* 2009; 23(11): 1246-53.
670. Shone J, Winter A, Jones BL, et al. A Scottish multi-centre service evaluation examining the prevalence and diagnosis of *Trichomonas vaginalis* in symptomatic women attending sexual health clinics. *Int J STD AIDS* 2016; 27(12): 1066-70.
671. Silva J, Cerqueira F, Teixeira AL, Campainha R, Amorim J, Medeiros R. Prevalence of *Neisseria gonorrhoeae* and *Trichomonas vaginalis* in Portuguese women of childbearing age. *Journal of Obstetrics and Gynaecology* 2021; 41(2): 254-8.
672. Silva L, Queirós C, Borges-Costa J, Barreto R, Filipe P, Melo-Cristino J. *Chlamydia trachomatis* Infections in a Tertiary Care Portuguese Hospital: An 11-Year Retrospective Study. *Actas Dermosifiliogr* 2021; 112(6): 528-33.
673. Singha HS, Balsdon MJ. Screening for gonorrhoea, trichomoniasis and candidosis in women presenting for termination of pregnancy. *Br J Clin Pract* 1979; 33(6): 163-4.
674. Sivaraj V, Ahamed A, Artykov R, Menon-Johansson A. Epididymitis and its aetiologies in a central London sexual health clinic. *Int J STD AIDS* 2021; 32(1): 96-9.
675. Skaletz-Rorowski A, Potthoff A, Nambiar S, et al. Sexual behaviour, STI knowledge and *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) prevalence in an asymptomatic cohort in Ruhr-area, Germany: PreYoungGo study. *J Eur Acad Dermatol Venereol* 2021; 35(1): 241-6.
676. Skapinyecz J, Smid I, Juhasz A, Jeney C, Rozgonyi F, Kovacs P. Planning of empirical antibiotic therapy for women with pelvic inflammatory diseases: a geographical area-specific study. *Eur J Obstet Gynecol Reprod Biol* 2003; 111(2): 183-8.
677. Skidmore S, Copley S, Cordwell D, Donaldson D, Ritchie D, Spraggon M. Positive nucleic acid amplification tests for *Neisseria gonorrhoeae* in young people tested as part of the National *Chlamydia* Screening Programme. *Int J STD AIDS* 2011; 22(7): 398-9.
678. Skinner CJ, Saulsbury NKG, Goh BT. Sexually transmitted infections in Bangladeshi resident in the UK: A case-control study. *Sexually Transmitted Infections* 2002; 78(2): 120-2.
679. Skinner CJ, Stokes J, Kirlaw Y, Kavanagh J, Forster GE. A case-controlled study of the sexual health needs of lesbians. *Genitourin Med* 1996; 72(4): 277-80.
680. Skjeldestad FE, Dalen A. *Chlamydia trachomatis*: is it possible to reduce the number of infections after abortions? *Scand J Prim Health Care* 1988; 6(2): 125-8.
681. Skjeldestad FE, Jerve F. [*Chlamydia trachomatis* and *Neisseria gonorrhoeae* among women seeking abortion in Norway. Results from a nationwide study]. *Tidsskr Nor Laegeforen* 1992; 112(16): 2082-4.
682. Skjeldestad FE, Johansen OJ, Dalen A. A comparative neonatal study of infants born by mothers with *Chlamydia trachomatis* in cervix uteri. *Acta Paediatr Scand* 1987; 76(2): 359-60.
683. Skok J, Kilczewski W, Bramska S, Lesinski J. [Methods and epidemiologic usefulness of prophylactic testing for gonorrhea in women]. *Przegl Dermatol* 1976; (6 Suppl): 473-6.
684. Skovgaard S, Larsen HK, Sand C, et al. Genital and extra-genital screening for gonorrhoea using the BD Probetec ET system with an in-house PCR method targeting the porA pseudogene as confirmatory test. *Acta Derm Venereol* 2012; 92(1): 45-9.
685. Slater W, Sadler K, Cassell JA, Homer P, Low N. What can be gained from comprehensive disaggregate surveillance? The Avon Surveillance System for Sexually Transmitted Infections. *Sex Transm Infect* 2007; 83(5): 411-5.
686. Slurink IAL, van Benthem BHB, van Rooijen MS, Achterbergh RCA, van Aar F. Latent classes of sexual risk and corresponding STI and HIV positivity among MSM attending centres for sexual health in the Netherlands. *Sex Transm Infect* 2020; 96(1): 33-9.
687. Smith J, Day S, Kinsella R, Perera S. Sexual health beyond the binary: Assessing transgender and non-binary individuals' (TNB) needs and their use of online sexual health services (SHS). *International Journal of STD & AIDS* 2020; 31(12_suppl): 1-114.
688. Smith JR, Murdoch J, Carrington D, et al. Prevalence of *Chlamydia trachomatis* infection in women having cervical smear tests. *Bmj* 1991; 302(6768): 82-4.

689. Snell L, Edwards SG, Benn PD. Potential impact of updated UK guidelines for use of post exposure prophylaxis following sexual exposure in a London sexual health service. Sexually Transmitted Infections Conference: 4th Joint BASHH ASTDA Meeting Brighton United Kingdom Conference Publication: 2012; 88(SUPPL. 1).
690. Solomon F, Sompolinsky D, Caspi E, Alkan WJ. Isolation and identification of Mycoplasma from clinical material in Israel. *Isr J Med Sci* 1970; 6(5): 605-10.
691. Soni S, Alexander S, Verlander N, et al. The prevalence of urethral and rectal Mycoplasma genitalium and its associations in men who have sex with men attending a genitourinary medicine clinic. *Sex Transm Infect* 2010; 86(1): 21-4.
692. Soni S, Bond K, Fox E, Grieve AP, Sethi G. Black and minority ethnic men who have sex with men: a London genitourinary medicine clinic experience. *Int J STD AIDS* 2008; 19(9): 617-9.
693. Soni S, White JA. Self-screening for Neisseria gonorrhoeae and Chlamydia trachomatis in the human immunodeficiency virus clinic--high yields and high acceptability. *Sex Transm Dis* 2011; 38(12): 1107-9.
694. Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). *Lancet* 2013; 382(9907): 1795-806.
695. Sorbye IK, Jerve F, Staff AC. Reduction in hospitalized women with pelvic inflammatory disease in Oslo over the past decade. *Acta Obstet Gynecol Scand* 2005; 84(3): 290-6.
696. Sorensen JL, Thranov I, Hoff G, Dirach J, Damsgaard MT. A double-blind randomized study of the effect of erythromycin in preventing pelvic inflammatory disease after first trimester abortion. *Br J Obstet Gynaecol* 1992; 99(5): 434-8.
697. Sorlózano-Puerto A, Esteban-Sanchís P, Heras-Cañas V, Fernández-Parra J, Navarro-Mari JM, Gutiérrez-Fernández J. Estudio prospectivo de la incidencia de patógenos genitales oportunistas y estrictos que crecen en medios de cultivo artificiales. *Revista del Laboratorio Clínico* 2018; 11(3): 123-30.
698. Southgate LJ, Trehan JD, Forsey T. Chlamydia trachomatis and Neisseria gonorrhoeae infections in women attending inner city general practices. *Br Med J (Clin Res Ed)* 1983; 287(6396): 879-81.
699. Spauwen LW, Niekamp AM, Hoebe CJ, Dukers-Muijters NH. Drug use, sexual risk behaviour and sexually transmitted infections among swingers: a cross-sectional study in The Netherlands. *Sex Transm Infect* 2015; 91(1): 31-6.
700. Spinillo A, Gorini G, Piazzi G, Baltaro F, Monaco A, Zara F. The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. *Contraception* 1996; 54(3): 163-8.
701. Spinner CD, Boesecke C, Jordan C, et al. Prevalence of asymptomatic sexually transmitted infections in HIV-positive men who have sex with men in Germany: results of a multicentre cross-sectional study. *Infection* 2018; 46(3): 341-7.
702. Spornraft-Ragaller P, Dumke R. Prevalence and antibiotic resistance of rectal Mollicutes in HIV-infected men who have sex with men at the University Hospital of Dresden, Germany. *Infection* 2020; 48(2): 259-65.
703. Sprague DS, Bullough CHW, Rashid S, Roberts SAM. Screening for and treating Chlamydia trachomatis and Neisseria gonorrhoeae before contraceptive use and subsequent pelvic inflammatory infection. *British Journal of Family Planning* 1990; 16(2): 54-8.
704. Sprenger K, Evison JM, Zwahlen M, et al. Sexually transmitted infections in HIV-infected people in Switzerland: Cross-sectional study. *PeerJ* 2014; 2014(1) (no pagination).
705. Srugo I, Steinberg J, Madeb R, et al. Agents of non-gonococcal urethritis in males attending an Israeli clinic for sexually transmitted diseases. *Isr Med Assoc J* 2003; 5(1): 24-7.
706. Stacey CM, Munday PE, Taylor-Robinson D, et al. A longitudinal study of pelvic inflammatory disease. *Br J Obstet Gynaecol* 1992; 99(12): 994-9.
707. Staerfelt F, Gundersen TJ, Halsos AM, et al. A survey of genital infections in patients attending a clinic for sexually transmitted diseases. *Scand J Infect Dis Suppl* 1983; 40: 53-7.
708. Stanley B, Todd A. Testing for Neisseria gonorrhoeae by nucleic acid amplification testing of chlamydia samples using Roche Cobas Amplicor in a rural area in the north of England does not find more gonorrhoea in primary care. *Sex Transm Infect* 2005; 81(6): 518.
709. Starck V, Bygdeman M, Eriksson G, Heinertz NO, Moberg I. [Screening tests for gonorrhea in clinics for contraceptive advice]. *Nord Med* 1971; 86(48): 1430-2.
710. Stry A, Kopp W, Heller-Vitouch C. Coincidence of hepatitis B-virus markers and other sexually transmitted diseases in different STD-risk groups. *Zentralbl Bakteriol* 1992; 276(4): 548-55.
711. Stry A, Kopp W, Hofmann H, Heller-Vitouch C, Kunz C. Seroepidemiologic study of hepatitis C virus in sexually transmitted disease risk groups. *Sex Transm Dis* 1992; 19(5): 252-8.
712. Stry A, Kopp W, Söltz-Szöts J. Medical health care for Viennese prostitutes. *Sex Transm Dis* 1991; 18(3): 159-65.
713. Stry A, Söltz-Szöts J, Stry J, Gross W. [Chlamydia trachomatis in patients with genital contact infections in Austria--studies of 3,367 patients]. *Wien Klin Wochenschr* 1986; 98(20): 679-83.
714. Stengrimsson O, Þorarinsson H, Sigfusdóttir A, Kolbeinnsson A. [Comparison of the occurrence of infections caused by C. trachomatis and N. gonorrhea in Iceland]. *Nord Med* 1984; 99(8-9): 202-4.
715. Stewart CM, Schoeman SA, Booth RA, Smith SD, Wilcox MH, Wilson JD. Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. *Bmj* 2012; 345: e8107.
716. Stolte IG, de Wit JB, Kolader M, Fennema H, Coutinho RA, Dukers NH. Association between 'safer sex fatigue' and rectal gonorrhea is mediated by unsafe sex with casual partners among HIV-positive homosexual men. *Sex Transm Dis* 2006; 33(4): 201-8.
717. Stolte IG, Dukers NH, de Wit JB, Fennema JS, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. *Sex Transm Infect* 2001; 77(3): 184-6.
718. Storim J, Verheyen J, Wolff E, et al. Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections-a cross-sectional, single-center study. *Sex Transm Infect* 2019; 95(2): 95-8.
719. Stray-Pedersen B, Bjørnstad J, Dahl M, et al. Induced abortion: microbiological screening and medical complications. *Infection* 1991; 19(5): 305-8.
720. Streeck H, Janssen K, Crowell TA, et al. Prospective, multicenter study to assess point prevalence, incidence and recurrence of sexually transmitted infections in men who have sex with men in Germany: BRAHMS study. *Journal of the International AIDS Society Conference: 10th IAS Conference on HIV Science Mexico City Mexico* 2019; 22(Supplement 5).
721. Streeter T, Cousins D, Ghanem M, Riddell L. Sexual health outreach testing in drug and alcohol services to test for previously undiagnosed blood borne virus infections. *International Journal of STD and AIDS* 2013; 1): 32.
722. Sugunendran H, Birley HDL, Mallinson H, Abbott M, Tong CYW. Comparison of urine, first and second endourethral swabs for PCR based detection of genital Chlamydia trachomatis infection in male patients. *Sexually Transmitted Infections* 2001; 77(6): 423-6.
723. Sullivan AK, Elliot E, Singh S, et al. High rates of recreational drug use (RDU) and sexually transmitted infections (STIs) in HIV-positive men who have sex with men (MSM) attending clinics across London. *HIV Medicine* 2016; 17(Supplement 1): 32.
724. Sultan B, Lincoln S, Ghosh I, et al. High prevalence of sexually transmitted infections, homelessness and drug use among street- based sex workers in London: results from a pilot intervention of mobile outreach testing and treatment. *HIV Medicine* 2021; 22(S2): 24-119.
725. Sultan B, White JA, Fish R, et al. The "3 in 1" Study: Pooling Self-Taken Pharyngeal, Urethral, and Rectal Samples into a Single Sample for Analysis for Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in Men Who Have Sex with Men. *J Clin Microbiol* 2016; 54(3): 650-6.

726. Sultan BJ, Fish R, Carrick G, et al. P98 Is pooling of self-taken specimens an effective and acceptable method of testing for sexually transmitted infections in MSMs?: Abstract P98 Table 1. Sexually Transmitted Infections 2012; 88(Suppl 1): A42.3-A3.
727. Sural S, Wenzlova M. A French connection between microhematuria and urethritis. Nephrology Dialysis Transplantation 2012; 27(2): ii106.
728. Svensson L, Mårdh PA, Weström L. Infertility after acute salpingitis with special reference to Chlamydia trachomatis. Fertil Steril 1983; 40(3): 322-9.
729. Svensson L, Weström L, Mårdh PA. Chlamydia trachomatis in women attending a gynaecological outpatient clinic with lower genital tract infection. Br J Vener Dis 1981; 57(4): 259-62.
730. Svensson L, Westrom L, Ripa KT, Mardh PA. Differences in some clinical and laboratory parameters in acute salpingitis related to culture and serologic findings. Am J Obstet Gynecol 1980; 138(7 Pt 2): 1017-21.
731. Syred J, Holdsworth G, Howroyd C, Spelman K, Baraitser P. Choose to test: self-selected testing for sexually transmitted infections within an online service. Sex Transm Infect 2019; 95(3): 171-4.
732. Szymanowski K, Szumala-Kakol A, Pawlaczyk M, Laczowska-Pawlaczyk M, Jedrzejczak P. [Bacterial flora of genital organs in women treated for infertility]. Ginekol Pol 1997; 68(1): 41-5.
733. Taipale P, Tarjanne H, Ylostalo P. Transvaginal sonography in suspected pelvic inflammatory disease. Ultrasound Obstet Gynecol 1995; 6(6): 430-4.
734. Talbot MD, Kinghorn GR. Epidemiology and control of gonorrhoea in Sheffield. Genitourin Med 1985; 61(4): 230-3.
735. Taylor-Robinson D, Renton A, Jensen JS, et al. Association of Mycoplasma genitalium with acute non-gonococcal urethritis in Russian men: a comparison with gonococcal and chlamydial urethritis. Int J STD AIDS 2009; 20(4): 234-7.
736. Tchiokadze S, Galdava G. CLINICAL AND ANAMNESTIC CHARACTERISTICS OF DEVELOPMENT OF ANTISPERM IMMUNITY IN INFERTILE MEN. Georgian Med News 2015; (246): 18-22.
737. Tchoudomirova K, Stanilova M, Garov V. Clinical manifestations and diagnosis of bacterial vaginosis in a clinic of sexually transmitted diseases. Folia Med (Plovdiv) 1998; 40(1): 34-40.
738. Teisala K. Sexual behavior and risk for pelvic inflammatory disease. Arch Gynecol Obstet 1988; 243(4): 225-30.
739. Tekgul S, Aktepe O, Sahin A, Ergen A, Remzi D. Genital infections in men associated with Chlamydia trachomatis. Int Urol Nephrol 1992; 24(2): 167-70.
740. Theunissen JJ, Minderhoud-Bassie W, Wagenvoort JH, Stolz E, Michel MF, Huikeshoven FJ. Chlamydia trachomatis-specific antibodies in patients with pelvic inflammatory disease: comparison with isolation in tissue culture or detection with polymerase chain reaction. Genitourin Med 1994; 70(5): 304-7.
741. Thewissen EA, van der Meijden WI, Doppenberg HJ, et al. Screening for cervical Chlamydia trachomatis infections in two Dutch populations. Genitourin Med 1990; 66(5): 361-6.
742. Thin RN, Smith DM. Some characteristics of homosexual men. Br J Vener Dis 1976; 52(3): 161-4.
743. Thin RN, Whatley JD, Blackwell AL. STD and contraception in adolescents. Genitourin Med 1989; 65(3): 157-60.
744. Thorsteinsson K, Ladelund S, Storgaard M, et al. Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark - the SHADE cohort. BMC Infect Dis 2016; 16: 81.
745. Tielemans M, van Westreenen M, Klaassen C, Gotz HM. Confirmatory testing of Neisseria gonorrhoeae in a sexual health clinic: implications for epidemiology and treatment policy. Sex Transm Infect 2021.
746. Tittle C, Rayment M, Mandalia S, et al. An evaluation study of the Becton-Dickinson ProbeTec Qx (BDQx) Trichomonas vaginalis trichomoniasis molecular diagnostic test in two large, urban STD services. Sex Transm Infect 2018; 94(5): 334-6.
747. Tishchenko LD, Kirpatovskii ID, Sakhel MI. [Treatment of epididymitis in infertile men with urogenital Chlamydia infection]. Vestn Dermatol Venerol 1988; (2): 76-7.
748. Tittle V, Alston T, Kinsella R, Jones S, Day S, Asboe D. Sexual health London online testing: A review of service users and outcomes. Sexually Transmitted Infections 2019; 95(Supplement 1): A100.
749. Tjagur S, Mändar R, Punab M. Prevalence of Mycoplasma genitalium and other sexually transmitted infections causing urethritis among high-risk heterosexual male patients in Estonia. Infect Dis (Lond) 2018; 50(2): 133-9.
750. Tjiam KH, van Heijst BY, Polak-Vogelzang AA, et al. Sexually communicable micro-organisms in human semen samples to be used for artificial insemination by donor. Genitourin Med 1987; 63(2): 116-8.
751. Tjiam KH, Zeilmaker GH, Alberda AT, et al. Prevalence of antibodies to Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma hominis in infertile women. Genitourin Med 1985; 61(3): 175-8.
752. Tomkins A, Ahmad S, Cannon L, et al. Prevalence of recreational drug use reported by men who have sex with men attending sexual health clinics in Manchester, UK. Int J STD AIDS 2018; 29(4): 350-6.
753. Tomlinson DR, Hillman RJ, Harris JR, Taylor-Robinson D. Screening for sexually transmitted disease in London-based male prostitutes. Genitourin Med 1991; 67(2): 103-6.
754. Tomusiak A, Heczko PB, Janeczko J, Adamski P, Pilarczyk-Zurek M, Strus M. Bacterial infections of the lower genital tract in fertile and infertile women from the southeastern Poland. Ginekol Pol 2013; 84(5): 352-8.
755. Torgal-Garcia J, Thabaut A, Durosoir JL, Saliou P, Martin-Bouyer G. [Rarity of men as asymptomatic carriers of Neisseria gonorrhoeae]. Ann Dermatol Venereol 1980; 107(8-9): 829-30.
756. Tortorella C, Piazzolla G, Matteo M, et al. Interleukin-6, interleukin-1beta, and tumor necrosis factor alpha in menstrual effluents as biomarkers of chronic endometritis. Fertil Steril 2014; 101(1): 242-7.
757. Toskine I, Verraes-Derancourt S, Letawe C, et al. [Prevalence of asymptomatic sexually transmitted infections among high-risk patients attending a free anonymous HIV-screening center]. Ann Dermatol Venereol 2004; 131(3): 251-4.
758. Trevisan A, Mengoli C, Rossi L, Cattai M, Cavallaro A. [Epidemiology of reproductive tract infections in a symptomatic population of North-East of Italy]. Minerva Ginecol 2008; 60(2): 135-42.
759. Trotman D, Devlin J, Buss Z, et al. The sensitivity and associated features of culture positive rectal gonorrhoea in men who have sex with men. HIV Medicine 2021; 22(S2): 24-119.
760. Turner K, Clarke B, Priestley C, Scofield S, Chapman C. 'The grand slam': Surveying the local landscape of 'chemsex' drug use amongst MSMs in a community outreach sexual health clinic. Sexually Transmitted Infections 2015; 91: A85.
761. Tuveng JM, Skjeldstad FE, Iversen T. Postabortal insertion of IUD. Adv Contracept 1986; 2(4): 387-92.
762. Tuveng JM, Vold I, Jerve F. Hysterosalpingography: Value in estimating tubal function, and risk of infectious complications. Acta Europaea Fertilitatis 1985; 16(2): 125-8.
763. Tyulenev YA, Guschin AE, Kisina VI. Localization features of sexually transmitted infections in subjectively asymptomatic men who have sex with men. Klinicheskaya dermatologiya i venerologiya 2021; 20(1): 55-61.
764. Ujevic B, Habek J, Habek D. Prevalence of infection with neisseria gonorrhoeae or chlamydia trachomatis in acute mucopurulent cervicitis. Arhiv za Higijenu Rada i Toksikologiju 2009; 60(2): 197-203.
765. Ulla M, Campos A, Baranda J, et al. [Sexually transmitted diseases in a high risk subpopulation from the province of Soria]. Enferm Infecc Microbiol Clin 1993; 11(6): 299-303.

766. Unemo M, Salado-Rasmussen K, Hansen M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. *Clin Microbiol Infect* 2018; 24(5): 533-9.
767. Unemo M, Savicheva A, Budilovskaya O, Sokolovsky E, Larsson M, Domeika M. Laboratory diagnosis of *Neisseria gonorrhoeae* in St Petersburg, Russia: inventory, performance characteristics and recommended optimisations. *Sex Transm Infect* 2006; 82(1): 41-4.
768. Uria MJ, Gonzalez A, Saez E, Ballesta A. Prevalence of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections among women and men in Madrid, Spain. *Clinical Microbiology and Infection* 2012; 3): 509.
769. Uzlova TV, Teplova SN, Medvedev BI. [The role of different microorganisms in the genesis of tubal-peritoneal infertility and in immunity]. *Zh Mikrobiol Epidemiol Immunobiol* 2000; (2): 95-7.
770. Vahidnia A, Costa S, Veenings S, Tuin H, van Loon L, Blikenendaal H. Comparative evaluation of Roche Aurora FLOW, Becton and Dickinson Viper system, and Dynex DS2 for detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* in various clinical specimens. *Diagn Microbiol Infect Dis* 2014; 80(3): 191-2.
771. Vall-Mayans M, Villa M, Saravanya M, et al. Sexually transmitted *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and HIV-1 infections in two at-risk populations in Barcelona: female street prostitutes and STI clinic attendees. *Int J Infect Dis* 2007; 11(2): 115-22.
772. Valle SL. Sexually transmitted diseases and the use of condoms in a cohort of homosexual men followed since 1983 in Finland. *Scand J Infect Dis* 1988; 20(2): 153-61.
773. van Aar F, Schreuder I, van Weert Y, Spijker R, Götz H, de Coul EO. Current practices of partner notification among MSM with HIV, gonorrhoea and syphilis in the Netherlands: an urgent need for improvement. *BMC infectious diseases* 2012; 12(1): 1-11.
774. van Aar F, van Benthem BHB, van den Broek IVF, Gotz HM. STIs in sex partners notified for chlamydia exposure: implications for expedited partner therapy. *Sex Transm Infect* 2018; 94(8): 619-21.
775. Van Benthem BH, Prins M, Larsen C, Delmas MC, Brunet JB, van den Hoek A. Sexually transmitted infections in European HIV-infected women: incidence in relation to time from infection. *European Study on the Natural History of HIV Infection in Women*. *Aids* 2000; 14(5): 595-603.
776. van Bergen JE, Spaargaren J, Götz HM, et al. Population prevalence of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in the Netherlands. Should asymptomatic persons be tested during population-based Chlamydia screening also for gonorrhoea or only if chlamydial infection is found? *BMC Infect Dis* 2006; 6: 42.
777. Van Bergen JEAM. Increased incidence of gonorrhoea and *Chlamydia trachomatis* infection in a general practice in south-east Amsterdam, the Netherlands, 1996-2000. *Nederlands Tijdschrift voor Geneeskunde* 2001; 145(35): 1691-3.
778. van Bergen JEAM, Kerssens JJ, Schellevis FG, Sandfort TG, Coenen TJ, Bindels PJ. Prevalence of STI related consultations in general practice: Results from the second Dutch National Survey of General Practice. *British Journal of General Practice* 2006; 56(523): 104-9.
779. van de Laar MJ, Termorshuizen F, van den Hoek A. Partner referral by patients with gonorrhea and chlamydial infection. Case-finding observations. *Sex Transm Dis* 1997; 24(6): 334-42.
780. Van Den Hoek JA, Van Haastrecht HJ, Scheeringa-Troost B, Goudsmit J, Coutinho RA. HIV infection and STD in drug addicted prostitutes in Amsterdam: potential for heterosexual HIV transmission. *Genitourin Med* 1989; 65(3): 146-50.
781. Van Den Hoek JAR, Klompmaier J. Sexually transmitted diseases in victims of sexual assault. *Nederlands Tijdschrift voor Geneeskunde* 1986; 130(9): 405-7.
782. Van Der Bij AK, Dukers NHTM, Coutinho RA, Fennema HSA. Low HIV-testing rates and awareness of HIV infection among high-risk heterosexual STI clinic attendees in the Netherlands. *European Journal of Public Health* 2008; 18(4): 376-9.
783. van der Knaap N, Grady BPX, Schim van der Loeff MF, et al. Drug Users in Amsterdam: Are They Still at Risk for HIV? *PLoS ONE* 2013; 8(3) (no pagination).
784. van der Lugt B, Drogendijk A, Banffer JR. Prevalence of cervical gonorrhoea in women with unwanted pregnancies. *Br J Vener Dis* 1980; 56(3): 148-50.
785. Van Der Snoek E, De Wit J, Gotz H, et al. Demographics, Sexual Behaviour and STD/HIV Prevalence in Two Groups of Men Who Have Sex with Men, in Rotterdam, The Netherlands. *Acta Dermato-Venereologica* 2004; 84(2): 145-50.
786. Van Der Snoek EM, Chin ALRAM, De Ridder MAJ, Willems PWJM, Verkooyen RP, Van Der Meijden WI. The prevalence of venereal disease and HIV infection among persons attending the VD Outpatient Clinic of the Dijkzigt University Hospital in Rotterdam; A comparison of the years 1993 and 1998. [Dutch]. *Nederlands Tijdschrift voor Geneeskunde* 2000; 144(28): 1351-65.
787. van der Snoek EM, Gotz HM, Mulder PG, Verkooyen RP, van der Meijden WI. Prevalence of STD and HIV infections among attenders of the Erasmus MC STD clinic, Rotterdam, The Netherlands, during the years 1996 to 2000. *Int J STD AIDS* 2003; 14(2): 119-24.
788. van Doornum GJ, Schouls LM, Pijl A, Cairo I, Buimer M, Bruisten S. Comparison between the LCx Probe system and the COBAS AMPLICOR system for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections in patients attending a clinic for treatment of sexually transmitted diseases in Amsterdam, The Netherlands. *J Clin Microbiol* 2001; 39(3): 829-35.
789. Van Duynhoven YT, van de Laar MJ, Schop WA, Mouton JW, van der Meijden WI, Sprenger MJ. Different demographic and sexual correlates for chlamydial infection and gonorrhoea in Rotterdam. *Int J Epidemiol* 1997; 26(6): 1373-85.
790. van Liere G, Dukers-Muijers N, Kuizenga-Wessel S, Gotz HM, Hoebe C. What Is the Optimal Testing Strategy for Oropharyngeal *Neisseria gonorrhoeae* in Men Who Have Sex With Men? Comparing Selective Testing Versus Routine Universal Testing From Dutch Sexually Transmitted Infection Clinic Data (2008-2017). *Clin Infect Dis* 2020; 71(4): 944-51.
791. van Liere GA, Hoebe CJ, Dukers-Muijers NH. Evaluation of the anatomical site distribution of chlamydia and gonorrhoea in men who have sex with men and in high-risk women by routine testing: cross-sectional study revealing missed opportunities for treatment strategies. *Sex Transm Infect* 2014; 90(1): 58-60.
792. van Liere GA, Hoebe CJ, Wolffs PF, Dukers-Muijers NH. High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women. *BMC Infect Dis* 2014; 14: 274.
793. van Liere GA, van Rooijen MS, Hoebe CJ, Heijman T, de Vries HJ, Dukers-Muijers NH. Prevalence of and Factors Associated with Rectal-Only Chlamydia and Gonorrhoea in Women and in Men Who Have Sex with Men. *PLoS One* 2015; 10(10): e0140297.
794. Van Loo I, Mans C, Hoebe C, Van Westering-Kroon E. High prevalence of ureaplasma spp. In women visiting an STI clinic although no azithromycin resistance was discovered. *Sexually Transmitted Infections* 2019; 95(Supplement 1): A149.
795. Van Praet JT, Steyaert S, Vandecasteele S, et al. *Mycoplasma genitalium* acquisition and macrolide resistance after initiation of HIV pre-exposure prophylaxis in men who have sex with men. *Sex Transm Infect* 2020; 96(6): 396-8.
796. van Rooijen MS, Schim van der Loeff MF, van Kempen L, de Vries HJC. Sexually Transmitted Infection Positivity Rate and Treatment Uptake Among Female and Male Sexual Assault Victims Attending The Amsterdam STI Clinic Between 2005 and 2016. *Sex Transm Dis* 2018; 45(8): 534-41.
797. Van Rooijen MS, Van Der Loeff MFS, Morre SA, Van Dam AP, Speksnijder AGCL, De Vries HJC. Spontaneous pharyngeal *Chlamydia trachomatis* RNA clearance. A cross-sectional study followed by a cohort study of untreated STI clinic patients in Amsterdam, the Netherlands. *Sexually Transmitted Infections* 2015; 91(3): 157-64.
798. van Voorst Vader PC, Lier JG, Posma AL, Schroder FP, Schirm J, Kauer FM. [Chlamydia trachomatis infection in women and the use of oral contraceptives]. *Ned Tijdschr Geneesk* 1991; 135(8): 323-7.

799. Vanya M, Szili K, Magori K, Krisztina V. Skin diseases and sexually transmitted infection in a Hungarian prison. *Reviews in Medical Microbiology* 2017; 28(3): 95-6.
800. Varela JA, Otero L, García MJ, et al. Trends in the prevalence of pathogens causing urethritis in Asturias, Spain, 1989-2000. *Sex Transm Dis* 2003; 30(4): 280-3.
801. Varma R. Women requiring emergency contraception are a high risk group for sexually transmitted infections in future. *Sexually Transmitted Infections Conference: 4th Joint BASHH ASTDA Meeting Brighton United Kingdom Conference Publication: 2012; 88(SUPPL. 1).*
802. Vasylyev M, Sluzhynska M, Sluzhynska O, Grushynska O, Krystynyak O. Mobile gynecological clinic - Effective tool for HIV/STI screening diagnostics for commercial sex workers in Lviv Region (Ukraine). *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013; 89(SUPPL. 1).*
803. Vázquez F, Palacio V, Vázquez JA, Berrón S, González A, Llaneza JJ. Gonorrhea in women prostitutes: clinical data and auxotypes, serovars, plasmid contents of PPNG, and susceptibility profiles. *Sex Transm Dis* 1991; 18(1): 5-9.
804. Vera M, Rodriguez C, Perez JA, et al. Toxic habits and high-risk sexual behaviour in newly HIV-diagnosed coinfectd with other sexually transmitted diseases. *International Journal of STD and AIDS* 2015; 1): 37.
805. Verbrugge R, Van Beckhoven D, Sasse A. STI-Surveillance within AIDS reference centres in Belgium - High consistent sti incidence among HIV-positive men having sex with men, 2008-2009. *Sexually Transmitted Infections* 2011; 1): A137.
806. Vergunst C, Van Der Loeff MS, Van Rooijen M, De Vries H, Bruisten S, Van Dam A. Clinical improvement after standard treatment for urethritis: The role of mycoplasma genitalium. *Sexually Transmitted Infections* 2019; 95(Supplement 1): A272.
807. Verhaegh-Haasnoot A, Dukers-Muijers NHTM, Hoebe CJP. High burden of STI and HIV in male sex workers working as internet escorts for men in an observational study: A hidden key population compared with female sex workers and other men who have sex with men. *BMC Infectious Diseases* 2015; 15(1) (no pagination).
808. Vernazza PL, Rasi M, Ritzler M, et al. The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of women. *Swiss Med Wkly* 2020; 150: w20393.
809. Verneuil L, Vidal JS, Ze Bekolo R, et al. Prevalence and risk factors of the whole spectrum of sexually transmitted diseases in male incoming prisoners in France. *Eur J Clin Microbiol Infect Dis* 2009; 28(4): 409-13.
810. Verougstraete N, Verbeke V, De Cannière AS, Simons C, Padalko E, Coorevits L. To pool or not to pool? Screening of Chlamydia trachomatis and Neisseria gonorrhoeae in female sex workers: pooled versus single-site testing. *Sex Transm Infect* 2020; 96(6): 417-21.
811. Verschijden MMA, Woestenberg PJ, Gotz HM, Van Veen MG, Koedijk FDH, Van Benthem BHB. Sexually transmitted infections among female sex workers tested at STI clinics in the Netherlands, 2006-2013. *Emerging Themes in Epidemiology* 2015; 12(1) (no pagination).
812. Vica ML, Glevitzky I, Glevitzky M, Siserman CV, Matei HV, Teodoru CA. Antibacterial Activity of Propolis Extracts from the Central Region of Romania against Neisseria gonorrhoeae. *Antibiotics (Basel)* 2021; 10(6).
813. Vicari E, Di Mauro C, Caruso V, Mongioi A. [Antibiotic therapy in infertile subjects with chronic gonococcal infections: measurement of sperm output]. *Arch Ital Urol Nefrol Androl* 1991; 63(3): 315-21.
814. Vicari E, Mongioi A, Speciale A. Enhancing detection of gonococcus in ejaculates of adult males using sperm dilution. *Archives of Andrology* 1986; 16(1): 19-23.
815. Vlasopolder F, Mutsaers JA, Blog F, Notowicz A. Value of a DNA probe assay (Gen-Probe) compared with that of culture for diagnosis of gonococcal infection. *J Clin Microbiol* 1993; 31(1): 107-10.
816. Vriend HJ, Bogaards JA, van der Klis FRM, et al. Patterns of Human Papillomavirus DNA and Antibody Positivity in Young Males and Females, Suggesting a Site-Specific Natural Course of Infection. *PLoS ONE* 2013; 8(4) (no pagination).
817. Vu F, Cavassini M, D'Acremont V, et al. Epidemiology of sexually transmitted infections among female sex workers in Switzerland: a local, exploratory, cross-sectional study. *Swiss Med Wkly* 2020; 150: w20357.
818. Wallin J. Sexually transmitted diseases. The present situation in Sweden. *Br J Vener Dis* 1978; 54(1): 24-7.
819. Walsh A, Rourke FO, Crowley B. Molecular detection and confirmation of Neisseria gonorrhoeae in urogenital and extragenital specimens using the Abbott CT/NG RealTime assay and an in-house assay targeting the porA pseudogene. *Eur J Clin Microbiol Infect Dis* 2011; 30(4): 561-7.
820. Walsh APH, Omar AB, Marron KD, Walsh DJ, Salma U, Sills ES. Recipient screening in IVF: First data from women undergoing anonymous oocyte donation in Dublin. *Reproductive Health* 2011; 8(1) (no pagination).
821. Ward C, Hughes G, Mitchell H, Rogstad K. Associations between repeat attendances, sexually transmitted infections and child sexual exploitation in under 16 year olds attending genitourinary medicine clinics. *Sexually Transmitted Infections* 2015; 1): A4-A5.
822. Ward C, Lee V. Should we offer routine hepatitis C antibody testing in men who have sex with men? *Journal of the International AIDS Society* 2014; 3): 69-70.
823. Ward C, Thomas D, Anderson T, Evans R, McQuillan O. Manchester chemsex-injecting straight up the M6. *Sexually Transmitted Infections* 2016; 92(Supplement 1): A78.
824. Ward H, Day S, Mezzone J, et al. Prostitution and risk of HIV: Female prostitutes in London. *British Medical Journal* 1993; 307(6900): 356-8.
825. Weller IV, Hindley DJ, Adler MW, Meldrum JT. Gonorrhoea in homosexual men and media coverage of the acquired immune deficiency syndrome in London 1982-3. *Br Med J (Clin Res Ed)* 1984; 289(6451): 1041.
826. Were J, Mohammed H, Furegato M, Hughes G. Who is being diagnosed with bacterial sexually transmitted infections through partner notification? A comparison of persons diagnosed with chlamydia or gonorrhoea through partner notification and those diagnosed otherwise in genitourinary medicine clinics in England, 2013. *International Journal of STD and AIDS* 2015; 1): 69.
827. Were J, Mohammed H, Mitchell H, et al. Monitoring partner notification outcomes through national STI surveillance in England. *HIV Medicine* 2014; 3): 82.
828. Wesbonk J, Chmiel C, Rosemann T, Seidenberg A, Senn O. Prevalence and determinants of sexually transmitted infections in women at risk undergoing abortion in a Swiss primary care setting. *Praxis (Bern 1994)* 2014; 103(15): 875-82.
829. Whitfield C, Rodgers S. Audit of adherence to UK national guideline for management of epididymo-orchitis. *Sexually Transmitted Infections Conference: STI and AIDS World Congress 2013; 89(SUPPL. 1).*
830. Wijers J, Dukers-Muijers N, Hoebe C, Wolffs PFG, van Liere G. The characteristics of patients frequently tested and repeatedly infected with Chlamydia trachomatis in Southwest Limburg, the Netherlands. *BMC Public Health* 2020; 20(1): 1239.
831. Wilkinson AE. The use of vaginal and rectal cultures in the management of gonorrhea in the female. *Br J Vener Dis* 1949; 25(1): 9-12.
832. Williams H, Makia F, Bennett M, et al. Comorbidity and late presentation: Findings from an over-fifties cohort. *HIV Medicine* 2011; 1): 12.
833. Williams S, Scholfield C, Nadarzynski T, Symonds Y, Kidsley S. Acceptability, uptake and impact of online home-sampling for stis in Hampshire, UK: A service evaluation. *Sexually Transmitted Infections* 2017; 93(Supplement 1): A6.
834. Wilson E, Leyrat C, Baraitser P, Free C. Does internet-accessed STI (e-STI) testing increase testing uptake for chlamydia and other STIs among a young population who have never tested? Secondary analyses of data from a randomised controlled trial. *Sex Transm Infect* 2019; 95(8): 569-74.
835. Wilson J, Hulme C, Stewart C, Schoeman S, Wilcox M. Cost effectiveness of self-taken vaginal swabs using genprobe AC2 assay vs clinician taken urethral and endocervical swabs for detection of gonorrhoea. *Sexually Transmitted Infections* 2011; 1): A275.

836. Wilson JD, Wallace HE, Loftus-Keeling M, et al. Swab-yourself trial with economic monitoring and testing for infections collectively (SYSTEMATIC): Part 2. A diagnostic accuracy, and cost-effectiveness, study comparing rectal, pharyngeal and urogenital samples analysed individually, versus as a pooled specimen, for the diagnosis of gonorrhoea and chlamydia. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2020; 12.
837. Wilson TE, Uuskula A, Feldman J, Holman S, Dehovitz J. A case-control study of beliefs and behaviors associated with sexually transmitted disease occurrence in Estonia. *Sex Transm Dis* 2001; 28(11): 624-9.
838. Wind CM, de Vries HJ, Schim van der Loeff MF, Unemo M, van Dam AP. Successful Combination of Nucleic Acid Amplification Test Diagnostics and Targeted Deferred Neisseria gonorrhoeae Culture. *J Clin Microbiol* 2015; 53(6): 1884-90.
839. Wingrove I, McOwan A, Nwokolo N, Whitlock G. Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: a service evaluation. *Sex Transm Infect* 2014; 90(6): 474.
840. Woolley PD, Bowman CA, Kinghorn GR. Prostitution in Sheffield: differences between prostitutes. *Genitourin Med* 1988; 64(6): 391-3.
841. Young H, Harris AB, Robertson DH. Individual susceptibility to neisserial infection? *Br J Vener Dis* 1979; 55(3): 188-90.
842. Zarakolu P, Alp S, Yağci S. [Frequency of curable sexually transmitted infections among registered female sex-workers in Ankara City]. *Mikrobiyol Bul* 2010; 44(1): 117-21.
843. Zarakolu P, Çetik S, İnkaya A, Ünal S. [Comparison of immunochromatographic (IC) and real-time polymerase chain reaction (Rt-PCR) tests for screening Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma spp. and Mycoplasma spp. in HIV-infected men]. *Mikrobiyol Bul* 2019; 53(1): 37-42.
844. Zvulunov A, Medvedovsky E, Biton A, Horowitz S, Vardy D. Association of Ureaplasma urealyticum colonization in male urethra and Condyloma acuminatum. *Isr Med Assoc J* 2000; 2(8): 580-2.

Supplementary Table S3. Number of *Neisseria gonorrhoeae* prevalence measures by European subregion and country/territory.

European subregion	European country	Number of <i>Neisseria gonorrhoeae</i> prevalence measures
Eastern Europe	Bulgaria	10
	Czech Republic	29
	Hungary	7
	Poland	10
	Romania	5
	Russian Federation	45
	Slovakia	1
	Ukraine	6
	Overall	113
Northern Europe	Denmark	74
	Estonia	9
	Finland	16
	Greenland	13
	Iceland	6
	Ireland	19
	Latvia	1
	Lithuania	1
	Norway	38
	Sweden	67
	United Kingdom	441
	Overall	685
Southern Europe	Croatia	9
	Greece	7
	Italy	58
	Portugal	13
	Slovenia	10
	Spain	87
	Overall	184
Western Europe	Austria	15
	Belgium	27
	France	87
	Germany	69
	Netherlands	289
	Switzerland	34
	Overall	521
Intersection of Europe and Asia	Armenia	7
	Azerbaijan	2
	Cyprus	1
	Georgia	4
	Tajikistan	1
	Overall	15
Other	Israel	25
	Turkey	27
	Mixed regions	3
	Overall	55

Supplementary Table S4. Summary of precision assessment and risk of bias (ROB) assessment for studies reporting *Neisseria gonorrhoeae* prevalence in Europe.

Quality assessment	<i>Neisseria gonorrhoeae</i> prevalence measures	
	Number of studies	%
Precision of prevalence measures^a		
Low precision	341	21.7
High precision	1,232	78.3
Risk of bias quality domain^b		
Sampling method		
Low risk of bias	50	3.2
High risk of bias	1,523	96.8
Response rate		
Low risk of bias	93	5.9
High risk of bias	92	5.9
Unclear risk of bias	1,388	88.2
Summary of the risk of bias assessment		
Low risk of bias		
In at least one quality domain	137	8.7
In both quality domains	6	0.4
High risk of bias		
In at least one quality domain	1,540	97.9
In both quality domains	75	4.8
Unclear risk of bias		
In at least one quality domain	1,388	88.2
In both quality domains	0	0.0
Prevalence studies where risk of bias assessment was possible	1,573	100.0

^a Precision was assessed based on the overall sample size (not each stratum subsample size) of the study as reported in the record/publication.


^b Risk of bias was assessed based on the overall sample size (not each stratum subsample size) of the study as reported in the record/publication.

Supplementary Figure S1. Forest plots presenting outcomes of the pooled urogenital *Neisseria gonorrhoeae* prevalence among the different populations in Europe.


A. General populations

Author, Year	Gonorrhea positive	Sample size	Events per 100 observations	W(Random)	Prev(%)	95% CI
Claeys, 2001	9	320	+	0.4%	2.8	[1.3; 5.3]
Avonts, 1985	1	161	+	0.4%	0.6	[0.0; 3.4]
Avonts, 1989	1	248	+	0.4%	0.4	[0.0; 2.2]
Buekens, 1984	2	96	+	0.3%	2.1	[0.3; 7.3]
Buekens, 1984	1	207	+	0.4%	0.5	[0.0; 2.7]
Plecko, 2014	0	49	+	0.3%	0.0	[0.0; 7.3]
Kacena, 2001	0	134	+	0.4%	0.0	[0.0; 2.7]
Kacena, 2001	0	217	+	0.4%	0.0	[0.0; 1.7]
Andersen, 1974	18	847	+	0.4%	2.1	[1.3; 3.3]
Andersen, 1974	5	856	+	0.4%	0.6	[0.2; 1.4]
Bro, 1989	1	229	+	0.4%	0.4	[0.0; 2.4]
Gregersen, 1972	17	759	+	0.4%	2.2	[1.3; 3.6]
Henriques, 1994	2	297	+	0.4%	0.7	[0.1; 2.4]
Jensen, 1979	1	123	+	0.3%	0.8	[0.0; 4.4]
Knudsen, 1989	1	224	+	0.4%	0.4	[0.0; 2.5]
Nielsen, 1974	6	190	+	0.4%	3.2	[1.2; 6.7]
Nielsen, 1974	7	347	+	0.4%	2.0	[0.8; 4.1]
Nielsen, 1974	9	384	+	0.4%	2.3	[1.1; 4.4]
Nielsen, 1974	13	353	+	0.4%	3.7	[2.0; 6.2]
Nielsen, 1974	5	308	+	0.4%	1.6	[0.5; 3.7]
Nielsen, 1974	5	211	+	0.4%	2.4	[0.8; 5.4]
Nielsen, 1974	6	700	+	0.4%	0.9	[0.3; 1.9]
Nielsen, 1974	1	276	+	0.4%	0.4	[0.0; 2.0]
Nielsen, 1974	0	183	+	0.4%	0.0	[0.0; 2.0]
Nielsen, 1974	0	82	+	0.3%	0.0	[0.0; 4.4]
Nielsen, 1974	0	44	+	0.2%	0.0	[0.0; 8.0]
Ostergaard, 2000	0	487	+	0.4%	0.0	[0.0; 0.8]
Ostergaard, 2000	0	443	+	0.4%	0.0	[0.0; 0.8]
Prien-Larsen, 1989	2	355	+	0.4%	0.6	[0.1; 2.0]
Skovgaard, 2012	49	36727	+	0.5%	0.1	[0.1; 0.2]
Skovgaard, 2012	63	9055	+	0.5%	0.7	[0.5; 0.9]
Sorensen, 1992	3	431	+	0.4%	0.7	[0.1; 2.0]
Wilson, 2001	3	112	+	0.3%	2.7	[0.6; 7.6]
Bayette, 2013	9	63	+	0.3%	14.3	[6.7; 25.4]
Bayette, 2013	2	238	+	0.4%	0.8	[0.1; 3.0]
Bercot, 2015	10	93	+	0.3%	10.8	[5.3; 18.9]
Bourgeois-Nicolaos, 2015	4	82	+	0.3%	4.9	[1.3; 12.0]
Bourgeois-Nicolaos, 2015	13	285	+	0.4%	4.6	[2.5; 7.7]
Bourgeois-Nicolaos, 2015	1	222	+	0.4%	0.5	[0.0; 2.5]
Dao, 2020	0	209	+	0.4%	0.0	[0.0; 1.7]
Dautigny, 2013	21	683	+	0.4%	3.1	[1.9; 4.7]
Dautigny, 2013	12	2432	+	0.4%	0.5	[0.3; 0.9]
Diquelou, 1988	0	30	+	0.2%	0.0	[0.0; 11.6]
Ebel, 2015	15	2201	+	0.4%	0.7	[0.4; 1.1]
Ebel, 2015	35	785	+	0.4%	4.5	[3.1; 6.1]
Jaureguy, 2013	19	634	+	0.4%	3.0	[1.8; 4.6]
Benjamin, 1978	4	646	+	0.4%	0.6	[0.2; 1.6]
Pereyre, 2017	2	174	+	0.4%	1.1	[0.1; 4.1]
Pereyre, 2017	3	64	+	0.3%	4.7	[1.0; 13.1]
Pereyre, 2017	10	333	+	0.4%	3.0	[1.4; 5.5]
Pereyre, 2017	5	147	+	0.4%	3.4	[1.1; 7.8]
Pereyre, 2017	2	72	+	0.3%	2.8	[0.3; 9.7]
Pereyre, 2017	4	104	+	0.3%	3.8	[1.1; 9.6]
Pereyre, 2017	10	180	+	0.4%	5.6	[2.7; 10.0]
Pereyre, 2017	5	215	+	0.4%	2.3	[0.8; 5.3]
Pereyre, 2017	0	112	+	0.3%	0.0	[0.0; 3.2]
Pereyre, 2017	5	145	+	0.4%	3.4	[1.1; 7.9]
Pereyre, 2017	15	264	+	0.4%	5.7	[3.2; 9.2]
Pereyre, 2017	2	307	+	0.4%	0.7	[0.1; 2.3]
Pereyre, 2017	0	83	+	0.3%	0.0	[0.0; 4.3]
Pereyre, 2017	1	166	+	0.4%	0.6	[0.0; 3.3]
Pereyre, 2017	3	150	+	0.4%	2.0	[0.4; 5.7]
Pereyre, 2017	2	78	+	0.3%	2.6	[0.3; 9.0]
Peuchant, 2015a	5	265	+	0.4%	1.9	[0.6; 4.3]
Peuchant, 2015a	2	112	+	0.3%	1.8	[0.2; 6.3]
Peuchant, 2015b	0	1004	+	0.4%	0.0	[0.0; 0.4]
Peuchant, 2015b	0	1004	+	0.4%	0.0	[0.0; 0.4]
Shafer, 1993	14	148	+	0.4%	9.5	[5.3; 15.4]
Torgal-Garcia, 1980	0	259	+	0.4%	0.0	[0.0; 1.4]
Dewilde, 1986	2	263	+	0.4%	0.8	[0.1; 2.7]
Barthell, 2009	1	399	+	0.4%	0.3	[0.0; 1.4]
Bremer, 2013	5	809	+	0.4%	0.6	[0.2; 1.4]
Geuenich, 1993	7	4347	+	0.5%	0.2	[0.1; 0.3]
Graspeuntner, 2018	0	89	+	0.3%	0.0	[0.0; 4.1]
Mesko, 1972	7	795	+	0.4%	0.9	[0.4; 1.8]
Skaletz-Rorowski, 2021	1	250	+	0.4%	0.4	[0.0; 2.2]
Papanagiotou, 2012	0	5610	+	0.5%	0.0	[0.0; 0.1]
Papanagiotou, 2012	0	2793	+	0.4%	0.0	[0.0; 0.1]
Gesink, 2012	5	297	+	0.4%	1.7	[0.5; 3.9]
Homoe, 2018	95	690	+	0.4%	13.8	[11.3; 16.6]
Homoe, 2018	267	2421	+	0.4%	11.0	[9.8; 12.3]
Homoe, 2018	227	1430	+	0.4%	15.9	[14.0; 17.9]
Homoe, 2018	255	2993	+	0.4%	8.5	[7.5; 9.6]
Homoe, 2018	154	1231	+	0.4%	12.5	[10.7; 14.5]
Homoe, 2018	179	2500	+	0.4%	7.2	[6.2; 8.2]
Homoe, 2018	80	747	+	0.4%	10.7	[8.6; 13.2]
Homoe, 2018	79	1629	+	0.4%	4.8	[3.9; 6.0]
Homoe, 2018	47	499	+	0.4%	9.4	[7.0; 12.3]
Homoe, 2018	45	946	+	0.4%	4.8	[3.5; 6.3]
Homoe, 2018	21	355	+	0.4%	5.9	[3.7; 8.9]
Homoe, 2018	18	555	+	0.4%	3.2	[1.9; 5.1]
Homoe, 2018	26	326	+	0.4%	8.0	[5.3; 11.5]
Homoe, 2018	19	533	+	0.4%	3.6	[2.2; 5.5]
Homoe, 2018	14	240	+	0.4%	5.8	[3.2; 9.6]
Homoe, 2018	6	349	+	0.4%	1.7	[0.6; 3.7]
Homoe, 2018	11	151	+	0.4%	7.3	[3.7; 12.7]
Homoe, 2018	6	159	+	0.4%	3.8	[1.4; 8.0]
Homoe, 2018	9	122	+	0.3%	7.4	[3.4; 13.5]
Homoe, 2018	3	53	+	0.3%	5.7	[1.2; 15.7]


Dan, 2003	0	100	0.3%	0.0	[0.0; 3.6]
Camporiondo, 2016	0	309	0.4%	0.0	[0.0; 1.2]
Cevenini, 1982	0	30	0.2%	0.0	[0.0; 11.6]
Cevenini, 1982	0	106	0.3%	0.0	[0.0; 3.4]
Cevenini, 1982	0	70	0.3%	0.0	[0.0; 5.1]
Cevenini, 1982	0	50	0.3%	0.0	[0.0; 7.1]
Del Prete, 2017	2	1272	0.4%	0.2	[0.0; 0.6]
Del Prete, 2017	11	303	0.4%	3.6	[1.8; 6.4]
Frati, 2017	1	537	0.4%	0.2	[0.0; 1.0]
Marcone, 2012	0	1110	0.4%	0.0	[0.0; 0.3]
Matteelli, 2016	0	1606	0.4%	0.0	[0.0; 0.2]
Matteelli, 2016	0	1112	0.4%	0.0	[0.0; 0.3]
Pagani, 2012	3	233	0.4%	1.3	[0.3; 3.7]
Rimoldi, 2012	1	57	0.3%	1.8	[0.0; 9.4]
Sambri, 2017	0	78	0.3%	0.0	[0.0; 4.6]
Barthelli, 2009	11	4624	0.5%	0.2	[0.1; 0.4]
Bassiri, 1997	9	3340	0.4%	0.3	[0.1; 0.5]
Geelen, 2013	4	675	0.4%	0.6	[0.2; 1.5]
Gotz, 2006	1	73	0.3%	1.4	[0.0; 7.4]
Gotz, 2006	1	99	0.3%	1.0	[0.0; 5.5]
Heijne, 2019	0	550	0.4%	0.0	[0.0; 0.7]
Jenniskens, 2017	27	5628	0.5%	0.5	[0.3; 0.7]
Op de Coul, 2021	2	548	0.4%	0.4	[0.0; 1.3]
Op de Coul, 2021	1	425	0.4%	0.2	[0.0; 1.3]
Querido, 1980	3	1021	0.4%	0.3	[0.1; 0.9]
Thewessen, 1990	2	557	0.4%	0.4	[0.0; 1.3]
Tjiam, 1987	0	237	0.4%	0.0	[0.0; 1.5]
Van Bergen, 2006a	0	605	0.4%	0.0	[0.0; 0.6]
Van Der Lugt, 1980	4	340	0.4%	1.2	[0.3; 3.0]
Van Der Lugt, 1980	7	740	0.4%	0.9	[0.4; 1.9]
Van Der Lugt, 1980	2	608	0.4%	0.3	[0.0; 1.2]
Anestad, 1984	0	43	0.2%	0.0	[0.0; 8.2]
Anestad, 1984	0	68	0.3%	0.0	[0.0; 5.3]
Falk, 1993	1238	25938	0.5%	4.8	[4.5; 5.0]
Falk, 1993	1048	25901	0.5%	4.0	[3.8; 4.3]
Falk, 1993	988	23383	0.5%	4.2	[4.0; 4.5]
Falk, 1993	952	23415	0.5%	4.1	[3.8; 4.3]
Falk, 1993	727	22946	0.5%	3.2	[2.9; 3.4]
Falk, 1993	353	23104	0.5%	1.5	[1.4; 1.7]
Falk, 1993	204	23281	0.5%	0.9	[0.8; 1.0]
Falk, 1993	135	24445	0.5%	0.6	[0.5; 0.7]
Falk, 1993	68	26144	0.5%	0.3	[0.2; 0.3]
Falk, 1993	320	12565	0.5%	2.5	[2.3; 2.8]
Falk, 1993	454	15861	0.5%	2.9	[2.6; 3.1]
Falk, 1993	298	17677	0.5%	1.7	[1.5; 1.9]
Falk, 1993	228	17072	0.5%	1.3	[1.2; 1.5]
Falk, 1993	95	17039	0.5%	0.6	[0.5; 0.7]
Falk, 1993	54	19004	0.5%	0.3	[0.2; 0.4]
Falk, 1993	29	20125	0.5%	0.1	[0.1; 0.2]
Qvigstad, 1983	5	557	0.4%	0.9	[0.3; 2.1]
Skjeldestad, 1987	2	599	0.4%	0.3	[0.0; 1.2]
Skjeldestad, 1992	8	1702	0.4%	0.5	[0.2; 0.9]
Stray-Pedersen, 1991	10	1193	0.4%	0.8	[0.4; 1.5]
Tuveng, 1986	0	11	0.1%	0.0	[0.0; 28.5]
Tuveng, 1986	0	34	0.2%	0.0	[0.0; 10.3]
Tomusiak, 2013	0	60	0.3%	0.0	[0.0; 6.0]
Borges-Costa, 2012	10	204	0.4%	4.9	[2.4; 8.8]
Silva, 2021	3	224	0.4%	1.3	[0.3; 3.9]
Silva, 2021	2	130	0.4%	1.5	[0.2; 5.4]
Silva, 2021	1	182	0.4%	0.5	[0.0; 3.0]
Silva, 2021	1	51	0.3%	2.0	[0.0; 10.4]
Silva, 2021	1	37	0.2%	2.7	[0.1; 14.2]
Silva, 2021	1	56	0.3%	1.8	[0.0; 9.6]
Miron, 2013	1	45	0.2%	2.2	[0.1; 11.8]
Detels, 1988	4	2212	0.4%	0.2	[0.0; 0.5]
Frolova, 2013	3	403	0.4%	0.7	[0.2; 2.2]
Shipitsyna, 2013	6	1053	0.4%	0.6	[0.2; 1.2]
Shipitsyna, 2013	0	154	0.4%	0.0	[0.0; 2.4]
Shipitsyna, 2020	4	2598	0.4%	0.2	[0.0; 0.4]
klavs, 2019	0	430	0.4%	0.0	[0.0; 0.9]
klavs, 2019	0	593	0.4%	0.0	[0.0; 0.6]
Criado, 2019	2	71	0.3%	2.8	[0.3; 9.8]
Franceschi, 2007	0	157	0.4%	0.0	[0.0; 2.3]
Franceschi, 2007	0	327	0.4%	0.0	[0.0; 1.1]
Rodriguez, 2001	2	111	0.3%	1.8	[0.2; 6.4]
Anvidson, 1995	15	120	0.3%	12.5	[7.2; 19.8]
Anvidson, 1995	27	876	0.4%	3.1	[2.0; 4.5]
Anvidson, 1995	24	595	0.4%	4.0	[2.6; 5.9]
Bryman, 1988	0	130	0.4%	0.0	[0.0; 2.8]
Bryman, 1988	0	115	0.3%	0.0	[0.0; 3.2]
Frolund, 2011	0	30	0.2%	0.0	[0.0; 11.6]
Giertz, 1987	2	560	0.4%	0.4	[0.0; 1.3]
Hellberg, 1999	25	192	0.4%	13.0	[8.6; 18.6]
Hellberg, 1999	17	792	0.4%	2.1	[1.3; 3.4]
Nolskog, 2019	1	1001	0.4%	0.1	[0.0; 0.6]
Svensson, 1983	1	20	0.2%	5.0	[0.1; 24.9]
Svensson, 1983	0	10	0.1%	0.0	[0.0; 30.8]
Svensson, 1983	1	19	0.2%	5.3	[0.1; 26.0]
Wesbonk, 2014	2	192	0.4%	1.0	[0.1; 3.7]
Jamalova, 1999	1	400	0.4%	0.2	[0.0; 1.4]
Acik, 2004	1	60	0.3%	1.7	[0.0; 8.9]
Dolapci, 2005	2	58	0.3%	3.4	[0.4; 11.9]
Eksi, 2011	0	97	0.3%	0.0	[0.0; 3.7]
Eksi, 2011	0	97	0.3%	0.0	[0.0; 3.7]
Genc, 1993	0	190	0.4%	0.0	[0.0; 1.9]
Hassan, 2016	0	255	0.4%	0.0	[0.0; 1.4]
Hodoglugil, 1999	18	410	0.4%	4.4	[2.6; 6.8]
Hodoglugil, 2000	13	211	0.4%	6.2	[3.3; 10.3]
Hodoglugil, 2000	4	155	0.4%	2.6	[0.7; 6.5]
Kanbur, 2018	4	386	0.4%	1.0	[0.3; 2.6]
Ortayli, 2001	0	569	0.4%	0.0	[0.0; 0.6]
Tekgul, 1992	0	26	0.2%	0.0	[0.0; 13.2]
Adler, 1981	0	528	0.4%	0.0	[0.0; 0.7]
Adler, 1981	3	903	0.4%	0.3	[0.1; 1.0]
Adler, 1981	2	480	0.4%	0.4	[0.1; 1.5]
Adler, 1981	0	300	0.4%	0.0	[0.0; 1.2]
Bartholomew, 2021	0	267	0.4%	0.0	[0.0; 1.4]
Bartholomew, 2021	3	236	0.4%	1.3	[0.3; 3.7]
Blackwell, 1993	1	400	0.4%	0.2	[0.0; 1.4]
Dhairiyawan, 2012	0	430	0.4%	0.0	[0.0; 0.9]
Duthie, 1987	0	167	0.4%	0.0	[0.0; 2.2]
Fowler, 2013	59	18044	0.5%	0.3	[0.2; 0.4]
Fowler, 2013	174	41873	0.5%	0.4	[0.4; 0.5]
Gillespie, 2000	2	1630	0.4%	0.1	[0.0; 0.4]
Gillespie, 2000	2	1742	0.4%	0.1	[0.0; 0.4]
Gillespie, 2000	0	1622	0.4%	0.0	[0.0; 0.2]
Harindra, 2002	2	805	0.4%	0.2	[0.0; 0.9]
Harindra, 2002	3	255	0.4%	1.2	[0.2; 3.4]
Hay, 2016	30	1908	0.4%	1.6	[1.1; 2.2]
Hilton, 1974	0	63	0.3%	0.0	[0.0; 5.7]
Kerry-Barnard, 2020	3	108	0.3%	2.8	[0.6; 7.9]
Kerry-Barnard, 2020	0	94	0.3%	0.0	[0.0; 3.8]




B. Intermediate-risk populations




C. Infertility clinic attendees




D. Other populations




E. Female sex workers



F. Male sex workers and men who have sex with men



G. HIV-positive individuals and individuals in HIV-discordant couples




H. Sexually transmitted infection clinic attendees



Author, Year	Gonorrhea positive	Sample size	Events per 100 observations	W(Random)	Prev(%)	95% CI
Koch, 1997	153	10217		0.3%	1.5	[1.3; 1.8]
Koch, 1997	95	31763		0.3%	0.3	[0.2; 0.4]
Stary, 1986	309	1248		0.3%	24.8	[22.4; 27.3]
Stary, 1991	90	713		0.3%	12.6	[10.3; 15.3]
Stary, 1992a	56	120		0.3%	46.7	[37.5; 56.0]
Stary, 1992a	4	378		0.3%	1.1	[0.3; 2.7]
Stary, 1992b	44	200		0.3%	22.0	[16.5; 28.4]
Claeys, 2001	26	153		0.3%	17.0	[11.4; 23.9]
Ouzounova-Raykova, 2011	5	96		0.3%	5.2	[1.7; 11.7]
Ouzounova-Raykova, 2011	7	521		0.3%	1.3	[0.5; 2.7]
Ouzounova-Raykova, 2011	6	96		0.3%	6.2	[2.3; 13.1]
Ouzounova-Raykova, 2011	8	521		0.3%	1.5	[0.7; 3.0]
Tchoudomirova, 1998	8	156		0.3%	5.1	[2.2; 9.9]
Guralp, 2019	7	273		0.3%	2.6	[1.0; 5.2]
Kacena, 2001	2	91		0.3%	2.2	[0.3; 7.7]
Miki, 1998	64	304		0.3%	21.1	[16.8; 26.1]
Miki, 1998	134	1090		0.3%	12.3	[10.4; 14.4]
Christophersen, 1988	45	234		0.3%	19.2	[14.4; 24.9]
Christophersen, 1988	7	105		0.3%	6.7	[2.7; 13.3]
Jensen, 1979	49	153		0.3%	32.0	[24.7; 40.0]
Jensen, 1979	44	151		0.3%	29.1	[22.0; 37.1]
Skovgaard, 2012	94	4180		0.3%	2.2	[1.8; 2.7]
Krolov, 2014	1	70		0.2%	1.4	[0.0; 7.7]
Tjagur, 2018	31	825		0.3%	3.8	[2.6; 5.3]
Hiltunen-Back, 1998	490	14778		0.3%	3.3	[3.0; 3.6]
Hiltunen-Back, 1998	162	12887		0.3%	1.3	[1.1; 1.5]
Hiltunen-Back, 1998	92	10600		0.3%	0.9	[0.7; 1.1]
Bebear, 2011	7	658		0.3%	1.1	[0.4; 2.2]
Clarivet, 2014	3	743		0.3%	0.4	[0.1; 1.2]
Clarivet, 2014	2	638		0.3%	0.3	[0.0; 1.1]
Le Faou, 1991	218	1343		0.3%	16.2	[14.3; 18.3]
Le Faou, 1991	208	1393		0.3%	14.9	[13.1; 16.9]
Le Faou, 1991	161	1387		0.3%	11.6	[10.0; 13.4]
Le Faou, 1991	95	1315		0.3%	7.2	[5.9; 8.8]
Le Faou, 1991	37	1122		0.3%	3.3	[2.3; 4.5]
Le Faou, 1991	29	1171		0.3%	2.5	[1.7; 3.5]
Le Faou, 1991	17	857		0.3%	2.0	[1.2; 3.2]
Le Faou, 1991	14	642		0.3%	2.2	[1.2; 3.6]
Le Faou, 1991	97	1230		0.3%	7.9	[6.4; 9.5]
Le Faou, 1991	97	1238		0.3%	7.8	[6.4; 9.5]
Le Faou, 1991	39	1010		0.3%	3.9	[2.8; 5.2]
Le Faou, 1991	43	1112		0.3%	3.9	[2.8; 5.2]
Le Faou, 1991	18	1057		0.3%	1.7	[1.0; 2.7]
Le Faou, 1991	4	749		0.3%	0.5	[0.1; 1.4]
Le Faou, 1991	3	582		0.3%	0.5	[0.1; 1.5]
Le Faou, 1991	5	520		0.3%	1.0	[0.3; 2.2]
Le Roy, 2012	1	21		0.2%	4.8	[0.1; 23.8]
Le Roy, 2013	277	11010		0.3%	2.5	[2.2; 2.8]
Toskine, 2004	0	101		0.3%	0.0	[0.0; 3.6]
Bozdech, 1982	284	1096		0.3%	25.9	[23.3; 28.6]
Bozdech, 1982	206	643		0.3%	32.0	[28.4; 35.8]
Bozdech, 1982	70	235		0.3%	29.8	[24.0; 36.1]
Bozdech, 1982	15	122		0.3%	12.3	[7.0; 19.5]
Breustedt, 1989	54	321		0.3%	16.8	[12.9; 21.4]
Breustedt, 1989	14	230		0.3%	6.1	[3.4; 10.0]
Elsner, 1985	2	36		0.2%	5.6	[0.7; 18.7]
Elsner, 1987	0	420		0.3%	0.0	[0.0; 0.9]
Graspeuntner, 2018	4	54		0.2%	7.4	[2.1; 17.9]
Hofmann, 1985	123	526		0.3%	23.4	[19.8; 27.2]
Hofmann, 1985	44	464		0.3%	9.5	[7.0; 12.5]
Hofmann, 1985	123	526		0.3%	23.4	[19.8; 27.2]
Hofmann, 1985	63	464		0.3%	13.6	[10.6; 17.0]
Hofmann, 1985	31	261		0.3%	11.9	[8.2; 16.4]
Hofmann, 1985	16	220		0.3%	7.3	[4.2; 11.5]
Hofmann, 1985	33	261		0.3%	12.6	[8.9; 17.3]
Hofmann, 1985	17	220		0.3%	7.7	[4.6; 12.1]
Jansen, 2020	32	2303		0.3%	1.4	[1.0; 2.0]
Cordtz, 1988	483	1346		0.3%	35.9	[33.3; 38.5]
Cordtz, 1988	62	788		0.3%	7.9	[6.1; 10.0]
Cordtz, 1988	11	229		0.3%	4.8	[2.4; 8.4]
Mardh, 1980	84	132		0.3%	63.6	[54.8; 71.8]
Moller, 1992	52	465		0.3%	11.2	[8.5; 14.4]
Moller, 1992	25	338		0.3%	7.4	[4.8; 10.7]
Mihalik, 2013	1	51		0.2%	2.0	[0.0; 10.4]
Hilmarsdottir, 2021	0	491		0.3%	0.0	[0.0; 0.7]
Hilmarsdottir, 2021	0	487		0.3%	0.0	[0.0; 0.8]
Walsh, 2011b	2	164		0.3%	1.2	[0.1; 4.3]
Walsh, 2011b	1	58		0.2%	1.7	[0.0; 9.2]
Walsh, 2011b	2	164		0.3%	1.2	[0.1; 4.3]
Walsh, 2011b	1	58		0.2%	1.7	[0.0; 9.2]
Gottesman, 2017	2	141		0.3%	1.4	[0.2; 5.0]
Joffe, 2006	5	200		0.3%	2.5	[0.6; 5.7]
Joffe, 2006	0	176		0.3%	0.0	[0.0; 2.1]
Madjar, 1996	2	71		0.2%	2.8	[0.3; 9.8]
Madjar, 1996	0	32		0.2%	0.0	[0.0; 10.9]
Mor, 2012	78	4213		0.3%	1.9	[1.5; 2.3]
Rich, 2020	37	2259		0.3%	1.6	[1.2; 2.3]
Rich, 2020	2	130		0.3%	1.5	[0.2; 5.4]
Castriciano, 2011	14	134		0.3%	10.4	[5.8; 16.9]
Chiodo, 1991	4	385		0.3%	1.0	[0.3; 2.6]
Chiodo, 1991	6	385		0.3%	1.6	[0.6; 3.4]
D'Antuono, 2001	5	558		0.3%	0.9	[0.3; 2.1]
Ferrero, 2011	16	122		0.3%	13.1	[7.7; 20.4]
Foschi, 2017	4	100		0.3%	4.0	[1.1; 9.9]
Foschi, 2020	10	134		0.3%	7.5	[3.8; 13.3]
Marangoni, 2011	41	700		0.3%	5.9	[4.2; 7.9]
Marangoni, 2011	33	700		0.3%	4.7	[3.3; 6.6]
Pagani, 1996	6	25		0.2%	24.0	[9.4; 45.1]
Pagani, 1996	6	25		0.2%	24.0	[9.4; 45.1]
Achterbergh, 2020	103	3196		0.3%	3.2	[2.6; 3.9]
Achterbergh, 2020	39	1255		0.3%	3.1	[2.2; 4.2]
De Vrieze, 2014	0	139		0.3%	0.0	[0.0; 2.6]
De Vrieze, 2014	3	334		0.3%	0.9	[0.2; 2.6]
De Wit, 1993	174	3000		0.3%	5.8	[5.0; 6.7]
De Wit, 1993	95	2065		0.3%	4.6	[3.7; 5.6]
De Wit, 1993	73	1622		0.3%	4.5	[3.5; 5.6]
De Wit, 1993	101	1656		0.3%	6.1	[5.0; 7.4]
De Wit, 1993	157	1619		0.3%	9.7	[8.3; 11.2]
De Wit, 1993	163	1663		0.3%	9.8	[8.4; 11.3]

Den Heijer, 2017	68	10268	0.3%	0.7	[0.5; 0.8]
Den Heijer, 2017	123	5177	0.3%	2.4	[2.0; 2.8]
Druckler, 2018	145	4925	0.3%	2.9	[2.5; 3.5]
Druckler, 2021	0	218	0.3%	0.0	[0.0; 1.7]
Druckler, 2021	0	49	0.2%	0.0	[0.0; 7.3]
Dukers-Muijters, 2010	718	6706	0.3%	10.7	[10.0; 11.5]
Dukers-Muijters, 2010	177	861	0.3%	20.6	[17.9; 23.4]
Dukers-Muijters, 2010	20	358	0.3%	5.6	[3.4; 8.5]
Dukers-Muijters, 2010	153	1040	0.3%	14.7	[12.8; 17.0]
Fennema, 1997	162	680	0.3%	23.8	[20.7; 27.2]
Gotz, 2011	3	26	0.2%	30.8	[14.3; 51.8]
Heijman, 2007	630	14391	0.3%	4.4	[4.0; 4.7]
Heijman, 2007	52	8056	0.3%	0.6	[0.5; 0.8]
Heijman, 2009	69	340	0.3%	20.3	[16.1; 25.0]
Heijman, 2009	23	315	0.3%	7.3	[4.7; 10.8]
Heiligenberg, 2011b	11	961	0.3%	1.1	[0.6; 2.0]
Heiligenberg, 2011b	32	667	0.3%	4.8	[3.3; 6.7]
Heiligenberg, 2011b	9	1125	0.3%	0.8	[0.4; 1.5]
Hoebbe, 2006	5	413	0.3%	1.2	[0.4; 2.8]
Hoornenborg, 2019	3	354	0.3%	0.8	[0.2; 2.5]
Koedijk, 2012	2065	206525	0.3%	1.0	[1.0; 1.0]
Koedijk, 2012	2349	69077	0.3%	3.4	[3.3; 3.5]
Lelijveld, 1981	13	28	0.2%	46.4	[27.5; 66.1]
Lelijveld, 1981	36	101	0.3%	35.6	[26.4; 45.8]
Lelijveld, 1981	19	61	0.2%	31.1	[19.9; 44.3]
Lelijveld, 1981	7	29	0.2%	24.1	[10.3; 43.5]
Lelijveld, 1981	10	29	0.2%	34.5	[17.9; 54.3]
Matsen, 2018	126	2983	0.3%	4.2	[3.5; 5.0]
Peters, 2011	41	1451	0.3%	2.8	[2.0; 3.8]
Peters, 2011	48	4299	0.3%	1.1	[0.8; 1.5]
Prins, 1994	12	155	0.3%	7.7	[4.1; 13.1]
Prins, 1994	5	234	0.3%	2.1	[0.7; 4.9]
Slurink, 2020	53	2961	0.3%	1.8	[1.3; 2.3]
Slurink, 2020	103	4178	0.3%	2.5	[2.0; 3.0]
Slurink, 2020	66	2484	0.3%	2.7	[2.1; 3.4]
Slurink, 2020	39	825	0.3%	4.7	[3.4; 6.4]
Slurink, 2020	49	1795	0.3%	2.7	[2.0; 3.6]
Slurink, 2020	57	1237	0.3%	4.6	[3.5; 5.9]
Spauwen, 2015	3	289	0.3%	1.0	[0.2; 3.0]
Thewessen, 1990	12	482	0.3%	2.5	[1.3; 4.3]
Tielemans, 2021	94	3216	0.3%	2.9	[2.4; 3.6]
Tielemans, 2021	126	4175	0.3%	3.0	[2.5; 3.6]
Tielemans, 2021	105	2334	0.3%	4.5	[3.7; 5.4]
Tielemans, 2021	92	3089	0.3%	3.0	[2.4; 3.6]
Tielemans, 2021	52	1343	0.3%	3.9	[2.9; 5.0]
Tielemans, 2021	80	1828	0.3%	4.4	[3.5; 5.4]
Vahidnia, 2014	0	45	0.2%	0.0	[0.0; 7.9]
Vahidnia, 2014	1	255	0.3%	0.4	[0.0; 2.2]
Vahidnia, 2014	1	147	0.3%	0.7	[0.0; 3.7]
Vahidnia, 2014	0	83	0.2%	0.0	[0.0; 4.3]
Vahidnia, 2014	0	17	0.2%	0.0	[0.0; 19.5]
Vahidnia, 2014	3	100	0.3%	3.0	[0.6; 8.5]
Vahidnia, 2014	0	105	0.3%	0.0	[0.0; 3.5]
Vahidnia, 2014	2	84	0.2%	2.4	[0.3; 8.3]
Van den Hoek, 1989	53	281	0.3%	18.9	[14.5; 23.9]
Van der Snoek, 2004	3	286	0.3%	1.0	[0.2; 3.0]
Van der Snoek, 2004	17	318	0.3%	5.3	[3.1; 8.4]
Van Doornum, 2001	6	503	0.3%	1.2	[0.4; 2.6]
Van Doornum, 2001	21	498	0.3%	4.2	[2.6; 6.4]
Van Doornum, 2001	3	503	0.3%	0.6	[0.1; 1.7]
Van Doornum, 2001	18	498	0.3%	3.6	[2.2; 5.7]
Van Liere, 2014a	37	2436	0.3%	1.5	[1.1; 2.1]
Van Liere, 2014a	17	1321	0.3%	1.3	[0.8; 2.1]
Van Liere, 2014b	0	654	0.3%	0.0	[0.0; 0.6]
Van Liere, 2015	88	10972	0.3%	0.8	[0.6; 1.0]
Van Liere, 2015	176	9534	0.3%	1.8	[1.6; 2.1]
Van Liere, 2020	8438	221087	0.3%	3.8	[3.7; 3.9]
Van Liere, 2020	955	26290	0.3%	3.6	[3.4; 3.9]
Van Rooijen, 2015	357	12926	0.3%	2.8	[2.5; 3.1]
Van Rooijen, 2015	103	6690	0.3%	1.5	[1.3; 1.9]
Van Rooijen, 2018	1680	157763	0.3%	1.1	[1.0; 1.1]
Van Rooijen, 2018	5369	193137	0.3%	2.8	[2.7; 2.9]
Van Voorst Vader, 1991	41	217	0.3%	18.9	[13.9; 24.7]
Verhaegh-Haasnoot, 2015	23	801	0.3%	2.9	[1.8; 4.3]
Verscheijden, 2015	57	3762	0.3%	1.5	[1.1; 2.0]
Verscheijden, 2015	55	4173	0.3%	1.3	[1.0; 1.7]
Verscheijden, 2015	84	4933	0.3%	1.7	[1.4; 2.1]
Verscheijden, 2015	94	5286	0.3%	1.8	[1.4; 2.2]
Verscheijden, 2015	104	5805	0.3%	1.8	[1.5; 2.2]
Verscheijden, 2015	103	5749	0.3%	1.8	[1.5; 2.2]
Vlaspolder, 1993	25	491	0.3%	5.1	[3.3; 7.4]
Vlaspolder, 1993	89	623	0.3%	14.3	[11.6; 17.3]
Vlaspolder, 1993	22	491	0.3%	4.5	[2.8; 6.7]
Vlaspolder, 1993	84	623	0.3%	13.5	[10.9; 16.4]
Vriend, 2013	32	2226	0.3%	1.4	[1.0; 2.0]
Vriend, 2013	17	914	0.3%	1.9	[1.1; 3.0]
Vriend, 2013	7	171	0.3%	4.1	[1.7; 8.3]
Wind, 2015	37	1085	0.3%	3.4	[2.4; 4.7]
Wind, 2015	15	805	0.3%	1.9	[1.0; 3.1]
Wind, 2015	33	1085	0.3%	3.0	[2.1; 4.2]
Wind, 2015	13	805	0.3%	1.6	[0.9; 2.7]
Falk, 1993	1142	21824	0.3%	5.2	[4.9; 5.5]
Falk, 1993	1798	28893	0.3%	6.2	[5.9; 6.5]
Falk, 1993	1524	30942	0.3%	4.9	[4.7; 5.2]
Falk, 1993	1644	32097	0.3%	5.1	[4.9; 5.4]
Falk, 1993	1510	32857	0.3%	4.6	[4.4; 4.8]
Falk, 1993	1284	31706	0.3%	4.0	[3.8; 4.3]
Falk, 1993	1444	28561	0.3%	5.1	[4.8; 5.3]
Falk, 1993	1135	26095	0.3%	4.3	[4.1; 4.6]
Hjelmevoll, 2012	50	257	0.3%	19.5	[14.8; 24.8]
Moi, 2009	136	8468	0.3%	1.6	[1.3; 1.9]
Reinton, 2013	30	2000	0.3%	1.5	[1.0; 2.1]
Staerfelt, 1983	77	531	0.3%	14.5	[11.6; 17.8]
Staerfelt, 1983	40	216	0.3%	18.5	[13.6; 24.4]
Unemo, 2018	8	1826	0.3%	0.4	[0.2; 0.9]
Unemo, 2018	1	721	0.3%	0.1	[0.0; 0.8]
Grad, 2020	17	207	0.3%	8.2	[4.9; 12.8]
Grad, 2020	1	42	0.2%	2.4	[0.1; 12.6]
Vica, 2021	44	622	0.3%	7.1	[5.2; 9.4]
Renton, 2009	24	105	0.3%	22.9	[15.2; 32.1]
Renton, 2009	16	105	0.3%	15.2	[9.0; 23.6]
Renton, 2009	13	105	0.3%	12.4	[6.8; 20.2]
Renton, 2009	24	99	0.3%	24.2	[16.2; 33.9]
Renton, 2009	15	99	0.3%	15.2	[8.7; 23.8]
Renton, 2009	6	99	0.3%	6.1	[2.3; 12.7]
Taylor-Robinson, 2009	41	172	0.3%	23.8	[17.7; 30.9]


Unemo, 2006	91	19880	0.3%	0.5	[0.4; 0.6]
Unemo, 2006	205	200106	0.3%	0.1	[0.1; 0.1]
Unemo, 2006	73	5519	0.3%	1.3	[1.0; 1.7]
Unemo, 2006	260	30281	0.3%	0.9	[0.8; 1.0]
Jeverica, 2013	0	67	0.2%	0.0	[0.0; 5.4]
Aguirrebengoa, 2021	0	110	0.3%	0.0	[0.0; 3.3]
Ayerdi Aguirreb, 2020	11	149	0.3%	7.4	[3.7; 12.8]
Ayerdi Aguirreb, 2020	19	85	0.2%	22.4	[14.0; 32.7]
Ayerdi Aguirreb, 2020	14	140	0.3%	10.0	[5.6; 16.2]
Corbeto, 2011	1	423	0.3%	0.2	[0.0; 1.3]
De Salazar, 2019	2	107	0.3%	1.9	[0.2; 6.6]
De Salazar, 2019	11	214	0.3%	5.1	[2.6; 9.0]
Gonzalez, 1983	145	1380	0.3%	10.5	[8.9; 12.2]
Gonzalez, 1983	46	1380	0.3%	3.3	[2.5; 4.4]
Lopez-Corbeto, 2020	0	50	0.2%	0.0	[0.0; 7.1]
Lopez-Corbeto, 2020	6	982	0.3%	0.6	[0.2; 1.3]
Perea, 1981	61	534	0.3%	11.4	[8.9; 14.4]
Perea, 1981	31	345	0.3%	9.0	[6.2; 12.5]
Perez Bernal, 1987	72	1011	0.3%	7.1	[5.6; 8.9]
Vall-Mayans, 2007	9	201	0.3%	4.5	[2.1; 8.3]
Vall-Mayans, 2007	6	191	0.3%	3.1	[1.2; 6.7]
Vall-Mayans, 2007	9	132	0.3%	6.8	[3.2; 12.5]
Vazquez, 1991	89	757	0.3%	11.8	[9.5; 14.3]
Andersson, 2021b	1	101	0.3%	1.0	[0.0; 5.4]
Andersson, 2021b	1	193	0.3%	0.5	[0.0; 2.9]
Andersson, 2021b	4	109	0.3%	3.7	[1.0; 9.1]
Andersson, 2021b	0	356	0.3%	0.0	[0.0; 1.0]
Bjornelius, 2000	4	105	0.3%	3.8	[1.0; 9.5]
Falk, 2004	2	88	0.3%	2.3	[0.3; 8.0]
Hellgren, 1982	1686	8865	0.3%	19.0	[18.2; 19.9]
Hellgren, 1982	2629	8865	0.3%	29.7	[28.7; 30.6]
Lykke, 1980	99	211	0.3%	46.9	[40.0; 53.9]
Rumyantseva, 2015	2	554	0.3%	0.4	[0.0; 1.3]
Rumyantseva, 2015	0	209	0.3%	0.0	[0.0; 1.7]
Unemo, 2018	5	914	0.3%	0.5	[0.2; 1.3]
Unemo, 2018	5	535	0.3%	0.9	[0.3; 2.2]
Bovet, 1982	162	498	0.3%	32.5	[28.4; 36.8]
Dona, 2018	46	177	0.3%	26.0	[19.7; 33.1]
Dona, 2018	4	11	0.1%	36.4	[10.9; 69.2]
Sakem, 2011	11	1346	0.3%	0.8	[0.4; 1.5]
Sakem, 2011	26	436	0.3%	6.0	[3.9; 8.6]
Boiko, 2019	1	296	0.3%	0.3	[0.0; 1.9]
Boiko, 2019	1	296	0.3%	0.3	[0.0; 1.9]
Boiko, 2019	1	27	0.2%	3.7	[0.1; 19.0]
Boiko, 2019	6	159	0.3%	3.8	[1.4; 8.0]
Boiko, 2019	4	159	0.3%	2.5	[0.7; 6.3]
Boiko, 2019	3	16	0.2%	18.8	[4.0; 45.6]
Annan, 2009	142	3076	0.3%	4.6	[3.9; 5.4]
Arumainayagam, 1991	0	50	0.2%	0.0	[0.0; 7.1]
Arya, 1981	149	474	0.3%	31.4	[27.3; 35.8]
Bailey, 2004	2	708	0.3%	0.3	[0.0; 1.0]
Benn, 2007	16	165	0.3%	9.7	[5.6; 15.3]
Benn, 2007	22	303	0.3%	7.3	[4.6; 10.8]
Benn, 2007	5	131	0.3%	3.8	[1.3; 8.7]
Bhaduri, 2007	3	181	0.3%	1.7	[0.3; 4.8]
Bhaduri, 2007	3	181	0.3%	1.7	[0.3; 4.8]
Bhaduri, 2007	4	174	0.3%	2.3	[0.6; 5.8]
Bhaduri, 2007	0	174	0.3%	0.0	[0.0; 2.1]
Broad, 2021	4	307	0.3%	1.3	[0.4; 3.3]
Broad, 2021	10	173	0.3%	5.8	[2.8; 10.4]
Broad, 2021	11	79	0.2%	13.9	[7.2; 23.5]
Carne, 2013	3	140	0.3%	2.1	[0.4; 6.1]
Carne, 2013	3	458	0.3%	0.7	[0.1; 1.9]
Carne, 2013	1	200	0.3%	0.5	[0.0; 2.8]
Carne, 2013	0	151	0.3%	0.0	[0.0; 2.4]
Carne, 2013	2	231	0.3%	0.9	[0.1; 3.1]
Carne, 2013	2	431	0.3%	0.5	[0.1; 1.7]
Carne, 2013	0	126	0.3%	0.0	[0.0; 2.9]
Carne, 2013	0	75	0.2%	0.0	[0.0; 4.8]
Chalker, 2009	6	286	0.3%	2.1	[0.8; 4.5]
Chalker, 2009	0	25	0.2%	0.0	[0.0; 13.7]
Champion, 1999	1	19	0.2%	5.3	[0.1; 26.0]
Dave, 2012	1	197	0.3%	0.5	[0.0; 2.8]
Downing, 2010	18	3847	0.3%	0.5	[0.3; 0.7]
Downing, 2010	78	12181	0.3%	0.6	[0.5; 0.8]
Evans, 1998	7	748	0.3%	0.9	[0.4; 1.9]
Evans, 1998	24	156	0.3%	15.4	[10.1; 22.0]
Fraser, 2014	3	34	0.2%	8.8	[1.9; 23.7]
Garner, 2015	16	339	0.3%	4.7	[2.7; 7.6]
Garner, 2015	13	135	0.3%	9.6	[5.2; 15.9]
Garner, 2015	5	540	0.3%	0.9	[0.3; 2.1]
Garner, 2015	6	188	0.3%	3.2	[1.2; 6.8]
Garner, 2015	5	616	0.3%	0.8	[0.3; 1.9]
Garner, 2015	5	304	0.3%	1.6	[0.5; 3.8]
Gellian, 1986	940	18903	0.3%	5.0	[4.7; 5.3]
Gellian, 1986	768	17800	0.3%	4.3	[4.0; 4.6]
Gellian, 1986	723	18760	0.3%	3.9	[3.6; 4.1]
Gellian, 1986	483	17595	0.3%	2.7	[2.5; 3.0]
Harding-Esch, 2019	3	395	0.3%	0.8	[0.2; 2.2]
Harding-Esch, 2019	12	392	0.3%	3.1	[1.6; 5.3]
Higgins, 2016	37	390	0.3%	9.5	[6.8; 12.8]
Higgins, 2016	34	390	0.3%	8.7	[6.1; 12.0]
Higgins, 2016	35	390	0.3%	9.0	[6.3; 12.3]
Hilton, 1974	57	279	0.3%	20.4	[15.9; 25.6]
Hopkins, 2012	76	15253	0.3%	0.5	[0.4; 0.6]
Hunter, 1981	62	480	0.3%	12.9	[10.0; 16.3]
Hussey, 2003	2	12	0.1%	16.7	[2.1; 48.4]
Killick, 2012	15	4160	0.3%	0.4	[0.2; 0.6]
Killick, 2012	18	4160	0.3%	0.4	[0.3; 0.7]
King, 2020	3	50	0.2%	6.0	[1.3; 16.5]
Kinghorn, 1981	224	1080	0.3%	20.7	[18.4; 23.3]
Leung, 2006	2	378	0.3%	0.5	[0.1; 1.9]
Lewis, 2004	2	92	0.3%	2.2	[0.3; 7.6]
Mahto, 2011	1	358	0.3%	0.3	[0.0; 1.5]
Maini, 1992	262	5571	0.3%	4.7	[4.2; 5.3]
Maini, 1992	228	8992	0.3%	2.5	[2.2; 2.9]
Maini, 1992	806	15976	0.3%	5.0	[4.7; 5.4]
Manavi, 2004	26	411	0.3%	6.3	[4.2; 9.1]
Manavi, 2005	7	60	0.2%	11.7	[4.8; 22.6]
Morris, 2014	95	3804	0.3%	2.5	[2.0; 3.0]
Mulcahy, 1987	19	109	0.3%	17.4	[10.8; 25.9]
Mulcahy, 1987	16	115	0.3%	13.9	[8.2; 21.6]
Mulcahy, 1987	7	83	0.2%	8.4	[3.5; 16.6]
Nicholls, 2018	5	1584	0.3%	0.3	[0.1; 0.7]
Pittrof, 2007	1	295	0.3%	0.3	[0.0; 1.9]
Pond, 2017	0	124	0.3%	0.0	[0.0; 2.9]




I. Symptomatic women




J. Symptomatic men



K. Sexual contact of persons infected with *Neisseria gonorrhoeae*/*Chlamydia trachomatis*



L. Patients with confirmed/suspected sexually transmitted infections and related infections



Supplementary Table S5. Univariable and multivariable meta-regression analyses for *Neisseria gonorrhoeae* prevalence in urogenital specimens in Europe using the year of publication instead of the year of data collection as the time variable.

Urogenital specimens			Outcome measures	Sample size	Univariable analysis				Multivariable analyses			
			Total n	Total N	RR (95% CI)	p-value	LT test p-value	Adjusted R ²	Model 3 ^a		Model 4 ^b	
									ARR (95% CI)	p-value	ARR (95% CI)	p-value
Population characteristics	Population type	General populations	262	64,4913	1.00	-	<0.001	18.84	1.00	-	1.00	-
		Intermediate-risk populations	24	6,559	2.54 (1.28-5.04)	0.008			3.05 (1.61-5.76)	0.001	2.49 (1.33-4.66)	0.004
		FSWs	31	10,021	3.28 (1.96-5.47)	<0.001			4.10 (2.56-6.58)	<0.001	3.80 (2.39-6.04)	<0.001
		MSWs, MSM, and transgender people	16	6,436	0.95 (0.45-2.01)	0.887			1.29 (0.63-2.61)	0.483	1.35 (0.67-2.71)	0.401
		Infertility clinic attendees	51	7,150	2.58 (1.38-4.80)	0.003			1.84 (1.02-3.32)	0.042	1.49 (0.83-2.68)	0.178
		Symptomatic women	103	28,485	4.11 (2.97-5.69)	<0.001			3.25 (2.38-4.45)	<0.001	3.33 (2.45-4.53)	<0.001
		Symptomatic men	61	24,884	7.19 (4.99-10.30)	<0.001			5.50 (3.72-8.12)	<0.001	5.27 (3.60-7.73)	<0.001
		STI clinic attendees	374	1,962,406	2.91 (2.33-3.65)	<0.001			3.13 (2.50-3.91)	<0.001	3.03 (2.43-3.77)	<0.001
		HIV positive individuals and individuals in HIV discordant couples	19	5,069	0.85 (0.35-2.04)	0.714			1.03 (0.45-2.33)	0.949	0.94 (0.42-2.12)	0.888
		Sexual contacts of persons infected with NG/CT	10	6,375	7.83 (3.67-16.60)	<0.001			8.20 (4.14-16.20)	<0.001	7.15 (3.64-14.00)	<0.001
		Patients with confirmed or suspected STIs and related infections	36	30,716	4.53 (2.93-7.01)	<0.001			4.70 (3.14-7.03)	<0.001	4.68 (3.15-6.95)	<0.001
		Other populations ^c	25	23,715	2.83 (1.67-4.81)	<0.001			4.10 (2.53-6.65)	<0.001	3.67 (2.29-5.90)	<0.001
	Age group	<20 years	50	11,635	1.00	-	0.007	1.53	1.00	-	1.00	-
		20-29 years	34	16,002	0.74 (0.39-1.41)	0.359			0.85 (0.50-1.44)	0.539	0.90 (0.53-1.52)	0.696
		30-39 years	20	5,386	0.99 (0.43-2.26)	0.979			1.27 (0.65-2.47)	0.486	1.41 (0.73-2.73)	0.305
		≥40 years	18	4,012	0.82 (0.37-1.85)	0.639			1.67 (0.84-3.30)	0.142	2.00 (1.02-3.92)	0.045
		Mixed ages	890	2,719,694	0.53 (0.35-0.80)	0.003			0.36 (0.25-0.52)	<0.001	0.40 (0.28-0.58)	<0.001
	Sex	Women	558	1,154,985	1.00	-	<0.001	2.40	1.00	-	1.00	-
		Men	371	933,280	1.62 (1.34-1.98)	<0.001			1.41 (1.15-1.72)	0.001	1.46 (1.20-1.78)	<0.001
		Mixed sexes	83	668,464	1.21 (0.88-1.65)	0.239			1.33 (1.01-1.75)	0.042	1.26 (0.96-1.65)	0.095
	European Subregions	Eastern Europe	77	281,396	1.00	-	0.922	0.00	-	-	-	-
		Southern Europe	121	72,030	1.08 (0.70-1.67)	0.724			-	-	-	-
		Western Europe	330	1,242,348	0.96 (0.66-1.38)	0.816			-	-	-	-
		Northern Europe	424	1,136,092	1.04 (0.73-1.50)	0.815			-	-	-	-
		Israel, Turkey, and mixed regions	60	24,863	1.06 (0.62-1.81)	0.838			-	-	-	-
	Country's Income	LMIC	7	1,353	1.00	-	0.021	1.01	1.00	-	1.00	-
		UMIC	76	279,505	2.16 (0.68-6.89)	0.193			2.30 (0.84-6.30)	0.104	1.53 (0.57-4.09)	0.396
		HIC	927	2,467,907	1.93 (0.63-5.88)	0.246			1.53 (0.58-4.01)	0.388	1.09 (0.42-2.82)	0.862
		Mixed income	2	7,964	0.14 (0.02-1.17)	0.069			0.43 (0.07-2.55)	0.351	0.28 (0.05-1.62)	0.156
Study methodology characteristics	Assay type	NAAT/PCR	427	1,448,120	1.00	-	<0.001	6.31	1.00	-	1.00	-
		Culture	453	985,482	1.91 (1.57-2.32)	<0.001			1.02 (0.80-1.32)	0.849	0.87 (0.69-1.10)	0.232
		Gram Staining	32	247,107	2.52 (1.53-4.14)	<0.001			1.36 (0.87-2.14)	0.178	1.01 (0.64-1.59)	0.954
		Other/unclear	100	76,020	1.79 (1.30-2.46)	<0.001			0.98 (0.73-1.31)	0.873	0.88 (0.66-1.17)	0.381
	Sample size ^d	<200	189	14,814	1.00	-	<0.001	7.82	1.00	-	1.00	-
		≥200	823	2,741,915	0.38 (0.29-0.49)	<0.001			0.44 (0.35-0.56)	<0.001	0.44 (0.35-0.55)	<0.001

Temporal trend	Sampling method	Probability based	39	15,610	1.00	-	0.106	0.00	-	-	-	-
		Non-probability based	973	2,741,119	1.73 (0.89-3.34)	0.106			-	-	-	-
	Response rate	≥80%	62	44,933	1.00	-	<0.001	1.44	1.00	-	1.00	-
		<80%	68	30,509	1.05 (0.58-1.89)	0.874			0.82 (0.50-1.36)	0.450	0.76 (0.47-1.25)	0.286
		Unclear	882	2,681,287	1.99 (1.33-2.98)	0.001			1.34 (0.95-1.88)	0.092	1.30 (0.93-1.82)	0.129
	Year of publication category	<2005	455	949,433	1.00	-	<0.001	6.57	1.00	-	-	-
		2005-2014	258	874,728	0.49 (0.39-0.61)	<0.001			0.46 (0.36-0.59)	<0.001	-	-
		≥2015	299	932,568	0.54 (0.43-0.67)	<0.001			0.59 (0.45-0.78)	<0.001	-	-
	Year of publication		1,012	2,756,729	0.97 (0.97-0.98)	<0.001	<0.001	9.83	-	-	0.97 (0.96-0.98)	<0.001

^aAdjusted R² in the final multivariable model 3 = 37.24%.

^bAdjusted R² in the final multivariable model 4 = 39.19%.

^cOther populations include populations with an undetermined risk of acquiring *Neisseria gonorrhoeae* infection such as patients with cervical cancer, victims of sexual assault, specimens from virology/bacteriology laboratory and requesting home-based *N. gonorrhoeae* or *Chlamydia trachomatis* testing.

^dSample size denotes the sample size of each study population at the baseline found in the original publication.

Abbreviations: *ARR*: Adjusted risk ratio; *CI*: Confidence interval; *CT*: *Chlamydia trachomatis*; *FSWs*: Female sex workers; *HIC*: High-income country; *PCR*: Polymerase chain reaction; *MSM*: Men who have sex with men; *MSWs*: Male sex workers; *NAAT*: Nucleic acid amplification test; *NG*: *Neisseria gonorrhoeae*; *LMIC*: Low-middle income country; *LT* test: Likelihood ratio test; *RR*: Risk ratio; *STI*: Sexually transmitted infection; *UMIC*: Upper-middle income country.

Supplementary Table S6. Univariable and multivariable meta-regression analyses for *Neisseria gonorrhoeae* prevalence in anorectal specimens in Europe using the year of publication instead of the year of data collection as the time variable.

Anorectal specimens			Outcome measures	Sample size	Univariable analysis				Multivariable analyses			
			Total n	Total N	RR (95% CI)	p-value	LT test p-value	Adjusted R ²	Model 3 ^a		Model 4 ^b	
									ARR (95% CI)	p-value	ARR (95% CI)	p-value
Population characteristics	Population type	MSWs, MSM, and transgender ^c	15	9,893	1.00	-	<0.001	12.87	1.00	-	1.00	-
		General populations	3	1,258	0.41 (0.11-1.55)	0.187			1.33 (0.39-4.54)	0.644	1.23 (0.35-4.27)	0.743
		Intermediate-risk populations	2	141	4.01 (0.46-34.70)	0.207			9.84 (1.42-68.10)	0.021	9.08 (1.28-64.60)	0.028
		FSWs	5	2,440	0.50 (0.16-1.61)	0.244			1.11 (0.37-3.32)	0.850	1.01 (0.33-3.05)	0.988
		Symptomatic women	5	3,813	0.27 (0.09-0.81)	0.020			1.47 (0.44-4.88)	0.526	1.16 (0.35-3.84)	0.813
		Symptomatic men	13	8,398	1.30 (0.59-2.85)	0.512			1.11 (0.55-2.23)	0.775	1.10 (0.54-2.24)	0.786
		STI clinic attendees	137	739,542	0.86 (0.49-1.52)	0.597			1.30 (0.78-2.18)	0.315	1.21 (0.72-2.04)	0.469
		HIV positive individuals and individuals in HIV discordant couples	21	4,672	1.05 (0.51-2.19)	0.887			0.92 (0.48-1.77)	0.809	0.88 (0.46-1.70)	0.708
		Sexual contacts of persons infected with NG/CT	5	467	2.97 (0.98-9.00)	0.054			3.41 (1.25-9.33)	0.017	3.56 (1.29-9.85)	0.015
		Patients with confirmed or suspected STIs and related infections	16	2,605	3.13 (1.44-6.78)	0.004			3.29 (1.65-6.57)	0.001	3.18 (1.58-6.42)	0.001
		Other populations ^d	7	1,348	1.17 (0.42-3.25)	0.762			2.21 (0.87-5.64)	0.095	2.25 (0.87-5.79)	0.093
	Age group	≤30 years	8	1,165	1.00	-	0.559	0.00	-	-	-	-
		>30 years	6	498	1.41 (0.34-5.85)	0.631			-	-	-	-
		Mixed ages	215	772,914	0.80 (0.34-1.89)	0.615			-	-	-	-
	Sex	Women	52	176,849	1.00	-	<0.001	11.86	1.00	-	1.00	-
		Men	167	579,396	2.62 (1.83-3.75)	<0.001			2.99 (2.05-4.35)	<0.001	2.74 (1.88-3.99)	<0.001
		Mixed sexes	10	18,332	2.05 (0.99-4.24)	0.052			2.05 (1.07-3.93)	0.031	2.10 (1.09-4.06)	0.027
	European Subregions	Eastern Europe	6	2,132	1.00	-	0.004	5.83	1.00	-	1.00	-
		Southern Europe	24	11,557	3.39 (1.19-9.64)	0.023			0.71 (0.24-2.10)	0.538	0.61 (0.21-1.84)	0.383
		Western Europe	120	633,385	1.58 (0.61-4.14)	0.347			0.77 (0.29-2.06)	0.607	0.66 (0.24-1.78)	0.409
		Northern Europe	78	127,487	2.25 (0.85-5.97)	0.101			0.96 (0.35-2.63)	0.932	0.82 (0.30-2.29)	0.708
		Israel, Turkey, and mixed regions	1	16	12.30 (1.17-129.80)	0.037			2.08 (0.24-17.90)	0.504	1.86 (0.21-16.60)	0.575
	Country's Income	UMIC	4	1,342	1.00	-	0.784	0.00	-	-	-	-
		HIC	225	773,235	1.18 (0.37-3.76)	0.784			-	-	-	-
Study methodology characteristics	Assay type	NAAT/PCR	121	593,512	1.00	-	0.288	0.41	-	-	-	-
		Culture	65	129,889	0.74 (0.52-1.06)	0.098			-	-	-	-
		Gram Staining	4	9,857	0.80 (0.25-2.53)	0.707			-	-	-	-
		Other/unclear	39	41,319	1.10 (0.73-1.65)	0.661			-	-	-	-
	Sample size ^e	<200	38	2,715	1.00	-	<0.001	11.42	1.00	-	1.00	-
		≥200	191	771,862	0.38 (0.26-0.56)	<0.001			0.48 (0.33-0.69)	<0.001	0.46 (0.31-0.67)	<0.001
	Sampling method	Probability based	4	1,154	1.00	-	0.927	0.00	-	-	-	-
		Non-probability based	225	773,423	0.95 (0.32-2.85)	0.927			-	-	-	-
		≥80%	7	22,936	1.00	-	0.509	0.00	-	-	-	-

	Response rate	<80%	16	5,859	0.95 (0.32-2.78)	0.925		-	-	-	-	
		Unclear	206	745,782	1.32 (0.54-3.21)	0.536		-	-	-	-	
Temporal trend	Year of publication category	<2005	50	130,383	1.00	-	<0.001	7.60	1.00	-	-	-
		2005-2014	61	133,879	1.45 (0.95-2.21)	0.088			1.54 (1.06-2.23)	0.024	-	-
		≥2015	118	310,315	2.11 (1.47-3.03)	<0.001			2.28 (1.61-3.24)	<0.001	-	-
	Year of publication		229	774,577	1.02 (1.01-1.03)	0.001	0.001	5.40	-	-	1.02 (1.01-1.04)	<0.001

^aAdjusted R² in the final multivariable model 3 = 37.63%.

^bAdjusted R² in the final multivariable model 4 = 35.04%.

^cMSM, MSW, and transgender people group was used as a reference because of epidemiological relevance and because the general populations group had small number of measures.

^dOther populations include populations with an undetermined risk of acquiring *Neisseria gonorrhoeae* infection such as patients with cervical cancer, victims of sexual assault, specimens from virology/bacteriology laboratory and requesting home-based *N. gonorrhoeae* or *Chlamydia trachomatis* testing.

^eSample size denotes the sample size of each study population at the baseline found in the original publication.

Abbreviations: *ARR*: Adjusted risk ratio; *CI*: Confidence interval; *CT*: *Chlamydia trachomatis*; *FSWs*: Female sex workers; *HIC*: High-income country; *PCR*: Polymerase chain reaction; *MSM*: Men who have sex with men; *MSWs*: Male sex workers; *NAAT*: Nucleic acid amplification test; *NG*: *Neisseria gonorrhoeae*; *LT* test: Likelihood ratio test; *RR*: Risk ratio; *STI*: Sexually transmitted infection; *UMIC*: Upper-middle income country.

Supplementary Table S7. Univariable and multivariable meta-regression analyses for *Neisseria gonorrhoeae* prevalence in oropharyngeal specimens in Europe using the year of publication instead of the year of data collection as the time variable.

Oropharyngeal specimens			Outcome measures	Sample size	Univariable analysis				Multivariable analyses			
			Total n	Total N	RR (95% CI)	p-value	LT test p-value	Adjusted R ²	Model 3 ^a		Model 4 ^b	
									ARR (95% CI)	p-value	ARR (95% CI)	p-value
Population characteristics	Population type ^c	MSWs, MSM, and transgender ^d	19	11,395	1.00	-	0.266	1.56	1.00	-	1.00	-
		General populations	3	475	1.08 (0.14-8.34)	0.936			1.62 (0.25-10.60)	0.614	1.56 (0.24-10.20)	0.642
		FSWs	7	2,949	0.84 (0.31-2.28)	0.738			1.64 (0.64-4.22)	0.298	1.58 (0.62-4.05)	0.340
		STI clinic attendees	107	394,371	1.08 (0.63-1.82)	0.772			1.58 (0.98-2.55)	0.060	1.55 (0.96-2.49)	0.071
		HIV positive individuals and individuals in HIV discordant couples	14	3,510	0.87 (0.39-1.95)	0.752			0.85 (0.42-1.76)	0.668	0.78 (0.39-1.58)	0.493
		Sexual contacts of persons infected with NG/CT	3	433	4.37 (1.26-15.10)	0.020			5.10 (1.73-14.90)	0.003	5.05 (1.72-14.80)	0.003
		Patients with confirmed or suspected STIs and related infections	6	469	1.73 (0.57-5.28)	0.329			2.83 (1.05-7.65)	0.041	2.82 (1.04-7.60)	0.041
		Other populations ^e	8	1,460	1.76 (0.70-4.45)	0.224			2.58 (1.10-6.06)	0.029	2.62 (1.12-6.12)	0.026
	Age group	≤30 years	6	664	1.00	-	0.253	0.45	-	-	-	-
		>30 years	4	462	0.83 (0.16-4.37)	0.832			-	-	-	-
		Mixed ages	157	413,936	0.50 (0.20-1.22)	0.129			-	-	-	-
	Sex	Women	43	151,890	1.00	-	0.020	5.66	1.00	-	1.00	-
		Men	116	241,147	1.70 (1.15-2.50)	0.007			2.71 (1.82-4.03)	<0.001	2.63 (1.76-3.92)	<0.001
		Mixed sexes	8	22,025	1.12 (0.51-2.45)	0.767			1.50 (0.71-3.19)	0.288	1.52 (0.72-3.22)	0.275
	European Subregions	Eastern Europe	3	1,198	1.00	-	0.979	0.00	-	-	-	-
		Southern Europe	19	8,217	1.36 (0.35-5.30)	0.648			-	-	-	-
		Western Europe	85	379,721	1.31 (0.36-4.72)	0.668			-	-	-	-
		Northern Europe	57	23,580	1.43 (0.39-5.21)	0.579			-	-	-	-
		Israel, Turkey, and mixed regions	3	2,346	1.25 (0.22-7.05)	0.793			-	-	-	-
	Country's Income	UMIC	3	1,198	1.00	-	0.629	0.00	-	-	-	-
		HIC	164	413,864	1.35 (0.38-4.76)	0.629			-	-	-	-
Study methodology characteristics	Assay type	NAAT/PCR	102	359,846	1.00	-	0.029	4.14	1.00	-	1.00	-
		Culture	40	29,580	0.56 (0.37-0.85)	0.008			0.60 (0.35-1.05)	0.073	0.58 (0.34-1.01)	0.054
		Gram Staining	3	2,544	0.44 (0.13-1.46)	0.181			0.42 (0.14-1.23)	0.113	0.44 (0.15-1.29)	0.132
		Other/unclear	22	23,092	1.05 (0.65-1.71)	0.822			0.69 (0.43-1.10)	0.116	0.71 (0.45-1.13)	0.145
	Sample size ^f	<200	18	1,557	1.00	-	0.011	5.10	1.00	-	1.00	-
		≥200	149	413,505	0.48 (0.27-0.84)	0.011			0.42 (0.25-0.71)	0.001	0.41 (0.24-0.69)	0.001
	Sampling method	Probability based	4	1,118	1.00	-	0.505	0.00	-	-	-	-
		Non-probability based	163	413,944	1.43 (0.49-4.20)	0.505			-	-	-	-
	Response rate	≥80%	9	3,826	1.00	-	0.156	1.10	-	-	-	-
		<80%	11	3,909	0.36 (0.12-1.01)	0.054			-	-	-	-
		Unclear	147	407,327	0.59 (0.27-1.29)	0.192			-	-	-	-

Temporal trend	Year of publication	<2005	27	9,573	1.00	-	<0.001	6.20	1.00	-	-	-
		2005-2014	48	150,948	1.57 (0.92-2.67)	0.094			1.34 (0.75-2.41)	0.323	-	-
	category	≥2015	92	254,541	2.25 (1.39-3.62)	<0.001			1.76 (0.92-3.36)	0.087	-	-
	Year of publication		167	415,062	1.03 (1.01-1.04)	0.001	0.001	8.00	-	-	1.02 (1.00-1.04)	0.107

^aAdjusted R² in the final multivariable model 3 = 30.02%.

^bAdjusted R² in the final multivariable model 4 = 30.23%.

^cPopulation classification was included in the multivariable analyses for epidemiological relevance.

^dMSM, MSW, and transgender people group was used as a reference because of epidemiological relevance and because the general populations group had small number of measures.


^eOther populations include populations with an undetermined risk of acquiring *Neisseria gonorrhoeae* infection such as patients with cervical cancer, victims of sexual assault, specimens from virology/bacteriology laboratory and requesting home-based *N. gonorrhoeae* or *Chlamydia trachomatis* testing.

^fSample size denotes the sample size of each study population at the baseline found in the original publication.

Abbreviations: *ARR*: Adjusted risk ratio; *CI*: Confidence interval; *CT*: *Chlamydia trachomatis*; *FSWs*: Female sex workers; *HIC*: High-income country; *PCR*: Polymerase chain reaction; *MSM*: Men who have sex with men; *MSWs*: Male sex workers; *NAAT*: Nucleic acid amplification test; *NG*: *Neisseria gonorrhoeae*; *LT* test: Likelihood ratio test; *RR*: Risk ratio; *STI*: Sexually transmitted infection; *UMIC*: Upper-middle income country.


Supplementary Figure S2. Forest plots displaying the results of cumulative meta-analyses, utilizing the year of publication as the ordering variable, to confirm the trend in *Neisseria gonorrhoeae* prevalence identified by the meta-regression analyses.

A. Urogenital^a



Adding Falk, 1993 (k=75)	0.02	[0.02; 0.02]	.00017	0.0417	93%
Adding Falk, 1993 (k=76)	0.02	[0.02; 0.02]	.00018	0.0425	93%
Adding Falk, 1993 (k=77)	0.02	[0.02; 0.03]	.00021	0.0453	93%
Adding Falk, 1993 (k=78)	0.02	[0.02; 0.02]	.00021	0.0460	93%
Adding Falk, 1993 (k=79)	0.03	[0.03; 0.03]	.00023	0.0482	94%
Adding Falk, 1993 (k=80)	0.02	[0.02; 0.03]	.00023	0.0478	94%
Adding Falk, 1993 (k=81)	0.03	[0.03; 0.03]	.00024	0.0494	95%
Adding Falk, 1993 (k=82)	0.03	[0.03; 0.03]	.00025	0.0499	94%
Adding Falk, 1993 (k=83)	0.02	[0.02; 0.02]	.00024	0.0495	95%
Adding Falk, 1993 (k=84)	0.02	[0.02; 0.02]	.00024	0.0490	96%
Adding Falk, 1993 (k=85)	0.02	[0.02; 0.02]	.00024	0.0485	96%
Adding Falk, 1993 (k=86)	0.02	[0.02; 0.02]	.00023	0.0483	97%
Adding Shafer, 1993 (k=87)	0.02	[0.02; 0.02]	.00026	0.0511	97%
Adding Falk, 1993 (k=88)	0.02	[0.02; 0.02]	.00026	0.0508	97%
Adding Falk, 1993 (k=89)	0.02	[0.02; 0.02]	.00026	0.0509	98%
Adding Geuenich, 1993 (k=90)	0.02	[0.01; 0.02]	.00026	0.0512	98%
Adding Blackwell, 1993 (k=91)	0.02	[0.01; 0.02]	.00026	0.0511	98%
Adding Falk, 1993 (k=92)	0.01	[0.01; 0.01]	.00026	0.0511	98%
Adding Falk, 1993 (k=93)	0.01	[0.01; 0.01]	.00026	0.0514	98%
Adding Genc, 1993 (k=94)	0.01	[0.01; 0.01]	.00027	0.0515	98%
Adding Henriques, 1994 (k=95)	0.01	[0.01; 0.01]	.00026	0.0511	98%
Adding Arvidson, 1995 (k=96)	0.01	[0.01; 0.01]	.00030	0.0547	98%
Adding Arvidson, 1995 (k=97)	0.01	[0.01; 0.01]	.00030	0.0550	98%
Adding Arvidson, 1995 (k=98)	0.01	[0.01; 0.01]	.00031	0.0558	98%
Adding Bassiri, 1997 (k=99)	0.01	[0.01; 0.01]	.00031	0.0557	98%
Adding Penney, 1998 (k=100)	0.01	[0.01; 0.01]	.00031	0.0555	98%
Adding Penney, 1998 (k=101)	0.01	[0.01; 0.01]	.00031	0.0556	98%
Adding Hellberg, 1999 (k=102)	0.01	[0.01; 0.01]	.00037	0.0605	98%
Adding Hellberg, 1999 (k=103)	0.01	[0.01; 0.01]	.00036	0.0603	98%
Adding Jamalova, 1999 (k=104)	0.01	[0.01; 0.01]	.00036	0.0601	98%
Adding Hodoglulil, 1999 (k=105)	0.01	[0.01; 0.01]	.00037	0.0608	98%
Adding Gillespie, 2000 (k=106)	0.01	[0.01; 0.01]	.00037	0.0609	98%
Adding Gillespie, 2000 (k=107)	0.01	[0.01; 0.01]	.00037	0.0610	98%
Adding Hodoglulil, 2000 (k=108)	0.01	[0.01; 0.01]	.00039	0.0622	98%
Adding Hodoglulil, 2000 (k=109)	0.01	[0.01; 0.01]	.00039	0.0621	98%
Adding Gillespie, 2000 (k=110)	0.01	[0.01; 0.01]	.00039	0.0627	98%
Adding Ostergaard, 2000 (k=111)	0.01	[0.01; 0.01]	.00040	0.0629	98%
Adding Ostergaard, 2000 (k=112)	0.01	[0.01; 0.01]	.00040	0.0631	98%
Adding Kacena, 2001 (k=113)	0.01	[0.01; 0.01]	.00040	0.0630	98%
Adding Kacena, 2001 (k=114)	0.01	[0.01; 0.01]	.00040	0.0630	98%
Adding Wilson, 2001 (k=115)	0.01	[0.01; 0.01]	.00040	0.0629	98%
Adding Rodriguez, 2001 (k=116)	0.01	[0.01; 0.01]	.00039	0.0627	98%
Adding Ortayli, 2001 (k=117)	0.01	[0.01; 0.01]	.00040	0.0630	98%
Adding Claeys, 2001 (k=118)	0.01	[0.01; 0.01]	.00040	0.0630	98%
Adding Harindra, 2002 (k=119)	0.01	[0.01; 0.01]	.00039	0.0628	98%
Adding Harindra, 2002 (k=120)	0.01	[0.01; 0.01]	.00039	0.0625	98%
Adding Dan, 2003 (k=121)	0.01	[0.01; 0.01]	.00039	0.0623	98%
Adding Low, 2003 (k=122)	0.01	[0.01; 0.01]	.00039	0.0622	98%
Adding Low, 2003 (k=123)	0.01	[0.01; 0.01]	.00038	0.0620	98%
Adding Acik, 2004 (k=124)	0.01	[0.01; 0.01]	.00038	0.0619	98%
Adding Dolapci, 2005 (k=125)	0.01	[0.01; 0.01]	.00038	0.0620	98%
Adding Van Bergen, 2006a (k=126)	0.01	[0.01; 0.01]	.00039	0.0622	98%
Adding Gotz, 2006 (k=127)	0.01	[0.01; 0.01]	.00038	0.0620	98%
Adding Gotz, 2006 (k=128)	0.01	[0.01; 0.01]	.00038	0.0618	98%
Adding Franceschi, 2007 (k=129)	0.01	[0.01; 0.01]	.00038	0.0617	98%
Adding Franceschi, 2007 (k=130)	0.01	[0.01; 0.01]	.00038	0.0618	98%
Adding Kourbatova, 2008 (k=131)	0.01	[0.01; 0.01]	.00039	0.0621	98%
Adding Kourbatova, 2008 (k=132)	0.01	[0.01; 0.01]	.00038	0.0619	98%
Adding Kourbatova, 2008 (k=133)	0.01	[0.01; 0.01]	.00038	0.0619	98%
Adding Schabereiter-Gurtner, 2008 (k=134)	0.01	[0.01; 0.01]	.00038	0.0615	98%
Adding Barthell, 2009 (k=135)	0.01	[0.01; 0.01]	.00038	0.0613	98%
Adding Barthell, 2009 (k=136)	0.01	[0.01; 0.01]	.00037	0.0612	98%
Adding Oakeshott, 2010 (k=137)	0.01	[0.01; 0.01]	.00037	0.0610	98%
Adding Detels, 2011 (k=138)	0.01	[0.01; 0.01]	.00037	0.0609	98%
Adding Frolund, 2011 (k=139)	0.01	[0.01; 0.01]	.00037	0.0608	98%
Adding Mahto, 2011 (k=140)	0.01	[0.01; 0.01]	.00037	0.0609	98%
Adding Eksi, 2011 (k=141)	0.01	[0.01; 0.01]	.00037	0.0607	98%
Adding Eksi, 2011 (k=142)	0.01	[0.01; 0.01]	.00037	0.0606	98%

Adding Marcone, 2012 (k=143)	0.01	[0.01; 0.01]	0.0037	0.0608	98%
Adding Borges-Costa, 2012 (k=144)	0.01	[0.01; 0.01]	0.0038	0.0615	98%
Adding Skovgaard, 2012 (k=145)	0.01	[0.01; 0.01]	0.0038	0.0615	98%
Adding Skovgaard, 2012 (k=146)	0.01	[0.01; 0.01]	0.0037	0.0611	98%
Adding Gesink, 2012 (k=147)	0.01	[0.01; 0.01]	0.0037	0.0610	98%
Adding Surel, 2012 (k=148)	0.01	[0.01; 0.01]	0.0037	0.0607	98%
Adding Surel, 2012 (k=149)	0.01	[0.01; 0.01]	0.0037	0.0607	98%
Adding Pagani, 2012 (k=150)	0.01	[0.01; 0.01]	0.0037	0.0605	98%
Adding Papanagiotou, 2012 (k=151)	0.01	[0.01; 0.01]	0.0037	0.0608	98%
Adding Papanagiotou, 2012 (k=152)	0.01	[0.01; 0.01]	0.0037	0.0611	98%
Adding Dhairyawan, 2012 (k=153)	0.01	[0.01; 0.01]	0.0037	0.0612	98%
Adding Rimoldi, 2012 (k=154)	0.01	[0.01; 0.01]	0.0037	0.0611	98%
Adding Dautigny, 2013 (k=155)	0.01	[0.01; 0.01]	0.0038	0.0613	98%
Adding Dautigny, 2013 (k=156)	0.01	[0.01; 0.01]	0.0037	0.0610	98%
Adding Tomusiak, 2013 (k=157)	0.01	[0.01; 0.01]	0.0037	0.0609	98%
Adding Frolova, 2013 (k=158)	0.01	[0.01; 0.01]	0.0037	0.0606	98%
Adding Fowler, 2013 (k=159)	0.01	[0.01; 0.01]	0.0037	0.0605	98%
Adding Fowler, 2013 (k=160)	0.01	[0.01; 0.01]	0.0036	0.0602	98%
Adding Bayette, 2013 (k=161)	0.01	[0.01; 0.01]	0.0038	0.0619	98%
Adding Bayette, 2013 (k=162)	0.01	[0.01; 0.01]	0.0038	0.0616	98%
Adding Geelen, 2013 (k=163)	0.01	[0.01; 0.01]	0.0038	0.0614	98%
Adding Miron, 2013 (k=164)	0.01	[0.01; 0.01]	0.0038	0.0613	98%
Adding Shipitsyna, 2013 (k=165)	0.01	[0.01; 0.01]	0.0037	0.0611	98%
Adding Shipitsyna, 2013 (k=166)	0.01	[0.01; 0.01]	0.0037	0.0610	98%
Adding Sonnenberg, 2013 (k=167)	0.01	[0.01; 0.01]	0.0037	0.0609	98%
Adding Sonnenberg, 2013 (k=168)	0.01	[0.01; 0.01]	0.0037	0.0608	98%
Adding Sonnenberg, 2013 (k=169)	0.01	[0.01; 0.01]	0.0037	0.0607	98%
Adding Sonnenberg, 2013 (k=170)	0.01	[0.01; 0.01]	0.0037	0.0609	98%
Adding Sonnenberg, 2013 (k=171)	0.01	[0.01; 0.01]	0.0037	0.0609	98%
Adding Sonnenberg, 2013 (k=172)	0.01	[0.01; 0.01]	0.0037	0.0608	98%
Adding Sonnenberg, 2013 (k=173)	0.01	[0.01; 0.01]	0.0037	0.0607	98%
Adding Sonnenberg, 2013 (k=174)	0.01	[0.01; 0.01]	0.0037	0.0606	98%
Adding Sonnenberg, 2013 (k=175)	0.01	[0.01; 0.01]	0.0037	0.0606	98%
Adding Sonnenberg, 2013 (k=176)	0.01	[0.01; 0.01]	0.0037	0.0606	98%
Adding Jaureguy, 2013 (k=177)	0.01	[0.01; 0.01]	0.0037	0.0608	98%
Adding Bremer, 2013 (k=178)	0.01	[0.01; 0.01]	0.0037	0.0606	98%
Adding Wesbonk, 2014 (k=179)	0.01	[0.01; 0.01]	0.0036	0.0604	98%
Adding Plecko, 2014 (k=180)	0.01	[0.01; 0.01]	0.0036	0.0603	98%
Adding Peuchant, 2015b (k=181)	0.01	[0.01; 0.01]	0.0036	0.0604	98%
Adding Peuchant, 2015b (k=182)	0.01	[0.01; 0.01]	0.0037	0.0605	98%
Adding Bercot, 2015 (k=183)	0.01	[0.01; 0.01]	0.0038	0.0619	98%
Adding Bourgeois-Nicolaos, 2015 (k=184)	0.01	[0.01; 0.01]	0.0039	0.0623	98%
Adding Bourgeois-Nicolaos, 2015 (k=185)	0.01	[0.01; 0.01]	0.0039	0.0628	98%
Adding Bourgeois-Nicolaos, 2015 (k=186)	0.01	[0.01; 0.01]	0.0039	0.0626	98%
Adding Peuchant, 2015a (k=187)	0.01	[0.01; 0.01]	0.0039	0.0625	98%
Adding Peuchant, 2015a (k=188)	0.01	[0.01; 0.01]	0.0039	0.0624	98%
Adding Ebel, 2015 (k=189)	0.01	[0.01; 0.01]	0.0039	0.0621	98%
Adding Ebel, 2015 (k=190)	0.01	[0.01; 0.01]	0.0039	0.0628	98%
Adding Hay, 2016 (k=191)	0.01	[0.01; 0.01]	0.0039	0.0626	98%
Adding Matteelli, 2016 (k=192)	0.01	[0.01; 0.01]	0.0039	0.0627	98%
Adding Matteelli, 2016 (k=193)	0.01	[0.01; 0.01]	0.0039	0.0628	98%
Adding Camporondo, 2016 (k=194)	0.01	[0.01; 0.01]	0.0039	0.0628	98%
Adding Hassan, 2016 (k=195)	0.01	[0.01; 0.01]	0.0039	0.0628	98%
Adding Frati, 2017 (k=196)	0.01	[0.01; 0.01]	0.0039	0.0626	98%
Adding Sambri, 2017 (k=197)	0.01	[0.01; 0.01]	0.0039	0.0625	98%
Adding Jenniskens, 2017 (k=198)	0.01	[0.01; 0.01]	0.0039	0.0623	98%
Adding Pereyre, 2017 (k=199)	0.01	[0.01; 0.01]	0.0039	0.0621	98%
Adding Pereyre, 2017 (k=200)	0.01	[0.01; 0.01]	0.0039	0.0623	98%
Adding Pereyre, 2017 (k=201)	0.01	[0.01; 0.01]	0.0039	0.0624	98%
Adding Pereyre, 2017 (k=202)	0.01	[0.01; 0.01]	0.0039	0.0626	98%
Adding Pereyre, 2017 (k=203)	0.01	[0.01; 0.01]	0.0039	0.0626	98%
Adding Pereyre, 2017 (k=204)	0.01	[0.01; 0.01]	0.0039	0.0628	98%
Adding Pereyre, 2017 (k=205)	0.01	[0.01; 0.01]	0.0040	0.0634	98%
Adding Pereyre, 2017 (k=206)	0.01	[0.01; 0.01]	0.0040	0.0634	98%
Adding Pereyre, 2017 (k=207)	0.01	[0.01; 0.01]	0.0040	0.0633	98%
Adding Pereyre, 2017 (k=208)	0.01	[0.01; 0.01]	0.0040	0.0634	98%
Adding Pereyre, 2017 (k=209)	0.01	[0.01; 0.01]	0.0041	0.0641	98%
Adding Pereyre, 2017 (k=210)	0.01	[0.01; 0.01]	0.0041	0.0639	98%
Adding Pereyre, 2017 (k=211)	0.01	[0.01; 0.01]	0.0041	0.0638	98%
Adding Pereyre, 2017 (k=212)	0.01	[0.01; 0.01]	0.0040	0.0636	98%
Adding Pereyre, 2017 (k=213)	0.01	[0.01; 0.01]	0.0040	0.0635	98%
Adding Pereyre, 2017 (k=214)	0.01	[0.01; 0.01]	0.0040	0.0635	98%
Adding Del Prete, 2017 (k=215)	0.01	[0.01; 0.01]	0.0040	0.0634	98%
Adding Del Prete, 2017 (k=216)	0.01	[0.01; 0.01]	0.0041	0.0637	98%




^aFor the cumulative meta-analysis of urogenital measures, only measures from general populations were included due to technical limitations. Attempting to include the very large urogenital dataset for all population types encountered code-related challenges in conducting this analysis.

B. Anorectal

Study	Proportion	95%-CI	P-value	Tau2	Tau	I2
Adding Palous, 1971 (k=1)	0.00	[0.00; 0.01]
Adding Palous, 1971 (k=2)	0.01	[0.00; 0.02]	.	0.0017	0.0407	72%
Adding Gregersen, 1972 (k=3)	0.01	[0.00; 0.01]	.	0.0007	0.0269	58%
Adding Robinson, 1974 (k=4)	0.02	[0.01; 0.03]	.	0.0190	0.1378	97%
Adding Shahidullah, 1976 (k=5)	0.02	[0.02; 0.03]	.	0.0295	0.1717	97%
Adding Shahidullah, 1976 (k=6)	0.03	[0.02; 0.04]	.	0.0361	0.1900	97%
Adding Shahidullah, 1976 (k=7)	0.03	[0.02; 0.03]	.	0.0377	0.1943	97%
Adding Shahidullah, 1976 (k=8)	0.02	[0.02; 0.03]	.	0.0358	0.1892	97%
Adding Hellgren, 1982 (k=9)	0.05	[0.05; 0.06]	.	0.0306	0.1750	97%
Adding Hellgren, 1982 (k=10)	0.09	[0.08; 0.09]	.	0.0280	0.1674	99%
Adding Bovet, 1982 (k=11)	0.09	[0.08; 0.09]	.	0.0251	0.1584	99%
Adding Gonzalez, 1983 (k=12)	0.08	[0.07; 0.08]	.	0.0296	0.1720	99%
Adding Gonzalez, 1983 (k=13)	0.07	[0.07; 0.07]	.	0.0304	0.1744	99%
Adding Gellan, 1986 (k=14)	0.03	[0.03; 0.03]	.	0.0296	0.1720	100%
Adding Gellan, 1986 (k=15)	0.02	[0.02; 0.02]	.	0.0283	0.1683	100%
Adding Gellan, 1986 (k=16)	0.02	[0.02; 0.02]	.	0.0275	0.1658	100%
Adding Gellan, 1986 (k=17)	0.01	[0.01; 0.01]	.	0.0269	0.1640	100%
Adding Christophersen, 1988 (k=18)	0.01	[0.01; 0.01]	.	0.0257	0.1604	100%
Adding Christophersen, 1988 (k=19)	0.01	[0.01; 0.01]	.	0.0248	0.1576	100%
Adding Stary, 1991 (k=20)	0.01	[0.01; 0.01]	.	0.0239	0.1547	100%
Adding Ross, 1991a (k=21)	0.01	[0.01; 0.01]	.	0.0225	0.1500	100%
Adding Ross, 1991a (k=22)	0.01	[0.01; 0.01]	.	0.0212	0.1456	99%
Adding Ross, 1991a (k=23)	0.01	[0.01; 0.01]	.	0.0202	0.1421	99%
Adding Ross, 1991a (k=24)	0.01	[0.01; 0.01]	.	0.0192	0.1387	99%
Adding Ross, 1991a (k=25)	0.01	[0.01; 0.01]	.	0.0187	0.1367	99%
Adding Ross, 1991a (k=26)	0.01	[0.01; 0.01]	.	0.0180	0.1343	99%
Adding Tomlinson, 1991 (k=27)	0.01	[0.01; 0.01]	.	0.0179	0.1340	99%
Adding De Wit, 1993 (k=28)	0.01	[0.01; 0.01]	.	0.0171	0.1308	99%
Adding De Wit, 1993 (k=29)	0.01	[0.01; 0.02]	.	0.0164	0.1280	99%
Adding De Wit, 1993 (k=30)	0.01	[0.01; 0.02]	.	0.0157	0.1254	99%
Adding De Wit, 1993 (k=31)	0.01	[0.01; 0.02]	.	0.0151	0.1228	99%
Adding De Wit, 1993 (k=32)	0.02	[0.01; 0.02]	.	0.0145	0.1205	99%
Adding De Wit, 1993 (k=33)	0.02	[0.02; 0.02]	.	0.0143	0.1198	99%
Adding Vlaspolder, 1993 (k=34)	0.02	[0.01; 0.02]	.	0.0140	0.1182	99%
Adding Vlaspolder, 1993 (k=35)	0.02	[0.01; 0.02]	.	0.0136	0.1167	99%
Adding Lister, 1993 (k=36)	0.02	[0.01; 0.02]	.	0.0134	0.1157	99%
Adding Van Der Snoek, 2000 (k=37)	0.02	[0.01; 0.02]	.	0.0131	0.1145	99%
Adding Van Der Snoek, 2000 (k=38)	0.01	[0.01; 0.02]	.	0.0133	0.1155	99%
Adding Van Der Snoek, 2000 (k=39)	0.01	[0.01; 0.02]	.	0.0133	0.1154	99%
Adding Van Der Snoek, 2000 (k=40)	0.01	[0.01; 0.02]	.	0.0132	0.1149	99%
Adding Stolte, 2001 (k=41)	0.01	[0.01; 0.02]	.	0.0128	0.1131	99%
Adding Stolte, 2001 (k=42)	0.02	[0.01; 0.02]	.	0.0124	0.1113	99%
Adding Stolte, 2001 (k=43)	0.02	[0.01; 0.02]	.	0.0120	0.1098	99%
Adding Stolte, 2001 (k=44)	0.02	[0.02; 0.02]	.	0.0117	0.1084	99%
Adding Stolte, 2001 (k=45)	0.02	[0.02; 0.02]	.	0.0114	0.1068	99%
Adding Stolte, 2001 (k=46)	0.02	[0.02; 0.02]	.	0.0112	0.1060	99%
Adding Van der Snoek, 2004 (k=47)	0.02	[0.02; 0.02]	.	0.0110	0.1047	99%
Adding Van der Snoek, 2004 (k=48)	0.02	[0.02; 0.02]	.	0.0107	0.1033	99%
Adding Manavi, 2004 (k=49)	0.02	[0.02; 0.02]	.	0.0105	0.1025	99%
Adding Manavi, 2004 (k=50)	0.02	[0.02; 0.02]	.	0.0102	0.1012	99%
Adding Manavi, 2005 (k=51)	0.02	[0.02; 0.02]	.	0.0106	0.1029	99%
Adding Papadogeorgaki, 2006 (k=52)	0.02	[0.02; 0.02]	.	0.0109	0.1043	99%
Adding Stolte, 2006 (k=53)	0.02	[0.02; 0.02]	.	0.0117	0.1081	99%
Adding Stolte, 2006 (k=54)	0.02	[0.02; 0.02]	.	0.0115	0.1070	99%
Adding Stolte, 2006 (k=55)	0.02	[0.02; 0.02]	.	0.0113	0.1064	99%
Adding Unemo, 2006 (k=56)	0.02	[0.02; 0.02]	.	0.0112	0.1060	99%
Adding Heijman, 2007 (k=57)	0.02	[0.02; 0.02]	.	0.0110	0.1049	99%
Adding Benn, 2007 (k=58)	0.02	[0.02; 0.02]	.	0.0112	0.1060	99%
Adding Benn, 2007 (k=59)	0.02	[0.02; 0.02]	.	0.0111	0.1055	99%
Adding Benn, 2007 (k=60)	0.02	[0.02; 0.02]	.	0.0109	0.1046	99%
Adding Ivens, 2007 (k=61)	0.02	[0.02; 0.02]	.	0.0107	0.1035	99%
Adding Soni, 2008 (k=62)	0.02	[0.02; 0.02]	.	0.0105	0.1026	99%
Adding Soni, 2008 (k=63)	0.02	[0.02; 0.02]	.	0.0106	0.1028	99%
Adding Bozicevic, 2009 (k=64)	0.02	[0.02; 0.02]	.	0.0109	0.1045	99%
Adding Shipitsyna, 2009 (k=65)	0.02	[0.02; 0.02]	.	0.0111	0.1055	99%
Adding Annan, 2009 (k=66)	0.02	[0.02; 0.02]	.	0.0109	0.1045	99%
Adding Kamarashev, 2010 (k=67)	0.02	[0.02; 0.02]	.	0.0110	0.1050	99%
Adding Sethupathi, 2010 (k=68)	0.02	[0.02; 0.02]	.	0.0117	0.1083	99%
Adding Soni, 2010 (k=69)	0.02	[0.02; 0.02]	.	0.0115	0.1073	99%
Adding Walsh, 2011b (k=70)	0.02	[0.02; 0.02]	.	0.0113	0.1065	99%
Adding Walsh, 2011b (k=71)	0.02	[0.02; 0.02]	.	0.0111	0.1056	99%
Adding Heiligenberg, 2011b (k=72)	0.02	[0.02; 0.02]	.	0.0109	0.1046	99%
Adding Heiligenberg, 2011b (k=73)	0.02	[0.02; 0.02]	.	0.0111	0.1055	99%
Adding Peters, 2011 (k=74)	0.02	[0.02; 0.02]	.	0.0110	0.1049	99%
Adding Peters, 2011 (k=75)	0.02	[0.02; 0.02]	.	0.0108	0.1041	99%
Adding Heras, 2011 (k=76)	0.02	[0.02; 0.02]	.	0.0109	0.1044	99%
Adding McCarty, 2011 (k=77)	0.02	[0.02; 0.02]	.	0.0107	0.1035	99%
Adding Soni, 2011 (k=78)	0.02	[0.02; 0.02]	.	0.0105	0.1026	99%
Adding Skovgaard, 2012 (k=79)	0.02	[0.02; 0.02]	.	0.0106	0.1028	99%
Adding Skovgaard, 2012 (k=80)	0.02	[0.02; 0.02]	.	0.0104	0.1019	99%
Adding Heiligenberg, 2012 (k=81)	0.02	[0.02; 0.02]	.	0.0102	0.1011	98%
Adding Heiligenberg, 2012 (k=82)	0.02	[0.02; 0.02]	.	0.0101	0.1003	98%
Adding Koedijk, 2012 (k=83)	0.02	[0.02; 0.02]	.	0.0100	0.1001	99%


Adding Koedijk, 2012 (k=84)	0.02	[0.02; 0.02]	0.0099	0.0994	99%
Adding Geelen, 2013 (k=85)	0.02	[0.02; 0.02]	0.0098	0.0988	99%
Adding Vriend, 2013 (k=86)	0.02	[0.02; 0.02]	0.0096	0.0982	99%
Adding Vriend, 2013 (k=87)	0.02	[0.02; 0.02]	0.0096	0.0981	99%
Adding Reinton, 2013 (k=88)	0.02	[0.02; 0.02]	0.0095	0.0974	99%
Adding Jeverica, 2013 (k=89)	0.02	[0.02; 0.02]	0.0095	0.0974	99%
Adding Roberts, 2013 (k=90)	0.02	[0.02; 0.02]	0.0094	0.0967	99%
Adding Dudareva-Vizule, 2014 (k=91)	0.02	[0.02; 0.02]	0.0092	0.0960	99%
Adding Keaveney, 2014 (k=92)	0.02	[0.02; 0.02]	0.0092	0.0959	99%
Adding Keaveney, 2014 (k=93)	0.02	[0.02; 0.02]	0.0091	0.0955	99%
Adding De Vrieze, 2014 (k=94)	0.02	[0.02; 0.02]	0.0090	0.0951	99%
Adding De Vrieze, 2014 (k=95)	0.02	[0.02; 0.02]	0.0089	0.0944	99%
Adding Vahidnia, 2014 (k=96)	0.02	[0.02; 0.02]	0.0089	0.0942	99%
Adding Vahidnia, 2014 (k=97)	0.02	[0.02; 0.02]	0.0088	0.0940	99%
Adding Vahidnia, 2014 (k=98)	0.02	[0.02; 0.02]	0.0088	0.0938	99%
Adding Van Liere, 2014a (k=99)	0.02	[0.02; 0.02]	0.0087	0.0931	99%
Adding Van Liere, 2014a (k=100)	0.02	[0.02; 0.02]	0.0087	0.0932	99%
Adding Van Liere, 2014b (k=101)	0.02	[0.02; 0.02]	0.0090	0.0947	99%
Adding Hagemann, 2014 (k=102)	0.02	[0.02; 0.02]	0.0090	0.0947	99%
Adding Perez-Hernandez, 2014 (k=103)	0.02	[0.02; 0.02]	0.0089	0.0941	99%
Adding Rodríguez-Domínguez, 2014 (k=104)	0.02	[0.02; 0.02]	0.0092	0.0957	99%
Adding Sprenger, 2014 (k=105)	0.02	[0.02; 0.02]	0.0091	0.0952	99%
Adding Sprenger, 2014 (k=106)	0.02	[0.02; 0.02]	0.0091	0.0954	99%
Adding Sprenger, 2014 (k=107)	0.02	[0.02; 0.02]	0.0091	0.0953	99%
Adding Cresswell, 2014 (k=108)	0.02	[0.02; 0.02]	0.0090	0.0951	99%
Adding Dolling, 2014 (k=109)	0.02	[0.02; 0.02]	0.0089	0.0945	99%
Adding Fraser, 2014 (k=110)	0.02	[0.02; 0.02]	0.0089	0.0942	98%
Adding Ward, 2014 (k=111)	0.02	[0.02; 0.02]	0.0090	0.0947	98%
Adding Plaas, 2015 (k=112)	0.02	[0.02; 0.02]	0.0089	0.0942	98%
Adding Marcus, 2015 (k=113)	0.02	[0.02; 0.02]	0.0088	0.0936	98%
Adding Spauwen, 2015 (k=114)	0.02	[0.02; 0.02]	0.0088	0.0939	98%
Adding Van Liere, 2015 (k=115)	0.02	[0.02; 0.02]	0.0088	0.0939	98%
Adding Van Liere, 2015 (k=116)	0.02	[0.02; 0.02]	0.0087	0.0934	98%
Adding Van Rooijen, 2015 (k=117)	0.02	[0.02; 0.02]	0.0086	0.0928	98%
Adding Van Rooijen, 2015 (k=118)	0.02	[0.02; 0.02]	0.0088	0.0936	98%
Adding Van Rooijen, 2015 (k=119)	0.02	[0.02; 0.02]	0.0088	0.0938	98%
Adding Van Rooijen, 2015 (k=120)	0.02	[0.02; 0.02]	0.0087	0.0933	98%
Adding Verscheijden, 2015 (k=121)	0.02	[0.02; 0.02]	0.0086	0.0929	98%
Adding Verscheijden, 2015 (k=122)	0.02	[0.02; 0.02]	0.0086	0.0927	98%
Adding Verscheijden, 2015 (k=123)	0.02	[0.02; 0.02]	0.0086	0.0926	98%
Adding Verscheijden, 2015 (k=124)	0.02	[0.02; 0.02]	0.0085	0.0924	98%
Adding Verscheijden, 2015 (k=125)	0.02	[0.02; 0.02]	0.0085	0.0922	98%
Adding Verscheijden, 2015 (k=126)	0.02	[0.02; 0.02]	0.0085	0.0922	98%
Adding Wind, 2015 (k=127)	0.02	[0.02; 0.02]	0.0086	0.0926	98%
Adding Wind, 2015 (k=128)	0.02	[0.02; 0.02]	0.0085	0.0924	98%
Adding Garner, 2015 (k=129)	0.02	[0.02; 0.02]	0.0086	0.0926	98%
Adding Garner, 2015 (k=130)	0.02	[0.02; 0.02]	0.0085	0.0921	98%
Adding Garner, 2015 (k=131)	0.02	[0.02; 0.02]	0.0084	0.0919	98%
Adding Garner, 2015 (k=132)	0.02	[0.02; 0.02]	0.0084	0.0918	98%
Adding Thorsteinsson, 2016 (k=133)	0.02	[0.02; 0.02]	0.0086	0.0926	98%
Adding Jaureguy, 2016 (k=134)	0.02	[0.02; 0.02]	0.0086	0.0928	98%
Adding Fuchs, 2016 (k=135)	0.02	[0.02; 0.02]	0.0087	0.0930	98%
Adding Cabello Ubeda, 2016 (k=136)	0.02	[0.02; 0.02]	0.0087	0.0932	98%
Adding Moreno-Ribera, 2016 (k=137)	0.02	[0.02; 0.02]	0.0087	0.0931	98%
Adding Gardner, 2016 (k=138)	0.02	[0.02; 0.02]	0.0087	0.0935	98%
Adding Gardner, 2016 (k=139)	0.02	[0.02; 0.02]	0.0090	0.0951	98%
Adding Gardner, 2016 (k=140)	0.02	[0.02; 0.02]	0.0097	0.0983	98%
Adding Sultan, 2016 (k=141)	0.02	[0.02; 0.02]	0.0100	0.1000	98%
Adding Apers, 2017 (k=142)	0.02	[0.02; 0.02]	0.0109	0.1042	98%
Adding Edouard, 2017a (k=143)	0.02	[0.02; 0.02]	0.0108	0.1038	98%
Adding Edouard, 2017b (k=144)	0.02	[0.02; 0.02]	0.0108	0.1039	98%
Adding Fata, 2017 (k=145)	0.02	[0.02; 0.02]	0.0107	0.1035	98%
Adding Achterbergh, 2017 (k=146)	0.02	[0.02; 0.02]	0.0106	0.1030	98%
Adding Den Heijer, 2017 (k=147)	0.02	[0.02; 0.02]	0.0106	0.1028	98%
Adding Den Heijer, 2017 (k=148)	0.02	[0.02; 0.02]	0.0105	0.1023	98%
Adding Cox, 2017 (k=149)	0.02	[0.02; 0.02]	0.0104	0.1019	98%
Adding Davies, 2017 (k=150)	0.02	[0.02; 0.02]	0.0107	0.1032	98%
Adding Lawrence, 2017 (k=151)	0.02	[0.02; 0.02]	0.0108	0.1041	98%
Adding Marchant, 2017 (k=152)	0.02	[0.02; 0.02]	0.0110	0.1050	98%
Adding Sacks, 2017 (k=153)	0.02	[0.02; 0.02]	0.0118	0.1088	98%
Adding Lourtet Hascoet, 2018 (k=154)	0.02	[0.02; 0.02]	0.0126	0.1122	98%
Adding Lourtet Hascoet, 2018 (k=155)	0.02	[0.02; 0.02]	0.0131	0.1145	98%
Adding Spinner, 2018 (k=156)	0.02	[0.02; 0.02]	0.0130	0.1141	98%
Adding Levy, 2018 (k=157)	0.02	[0.02; 0.02]	0.0133	0.1151	98%
Adding Druckler, 2018 (k=158)	0.02	[0.02; 0.02]	0.0132	0.1148	98%
Adding Matser, 2018 (k=159)	0.02	[0.02; 0.02]	0.0131	0.1143	98%



C. Oropharyngeal

Study	Proportion	95%-CI	P-value	Tau2	Tau	I2
Adding Robinson, 1974 (k=1)	0.02	[0.01; 0.03]				
Adding Shahidullah, 1976 (k=2)	0.03	[0.02; 0.05]		0.0272	0.1649	95%
Adding Shahidullah, 1976 (k=3)	0.03	[0.02; 0.05]		0.0131	0.1146	91%
Adding Reimann, 1980 (k=4)	0.03	[0.02; 0.04]		0.0124	0.1112	88%
Adding Reimann, 1980 (k=5)	0.02	[0.02; 0.03]		0.0097	0.0987	85%
Adding Bovet, 1982 (k=6)	0.02	[0.01; 0.03]		0.0079	0.0889	82%
Adding Gonzalez, 1983 (k=7)	0.01	[0.00; 0.01]		0.0112	0.1059	93%
Adding Gonzalez, 1983 (k=8)	0.00	[0.00; 0.01]		0.0108	0.1042	93%
Adding Christophersen, 1988 (k=9)	0.00	[0.00; 0.01]		0.0094	0.0968	92%
Adding Christophersen, 1988 (k=10)	0.00	[0.00; 0.01]		0.0083	0.0909	91%
Adding Christophersen, 1988 (k=11)	0.00	[0.00; 0.01]		0.0080	0.0896	90%
Adding Stry, 1991 (k=12)	0.00	[0.00; 0.01]		0.0071	0.0844	89%
Adding Ross, 1991a (k=13)	0.01	[0.00; 0.01]		0.0064	0.0800	90%
Adding Ross, 1991a (k=14)	0.01	[0.01; 0.01]		0.0060	0.0772	90%
Adding Ross, 1991a (k=15)	0.01	[0.01; 0.01]		0.0056	0.0749	90%
Adding Ross, 1991a (k=16)	0.01	[0.01; 0.01]		0.0053	0.0727	90%
Adding Ross, 1991a (k=17)	0.01	[0.01; 0.01]		0.0048	0.0696	89%
Adding Ross, 1991a (k=18)	0.01	[0.01; 0.01]		0.0048	0.0690	89%
Adding Tomlinson, 1991 (k=19)	0.01	[0.01; 0.01]		0.0046	0.0679	89%
Adding Vlassembler, 1993 (k=20)	0.01	[0.01; 0.01]		0.0044	0.0667	88%
Adding Vlassembler, 1993 (k=21)	0.01	[0.01; 0.01]		0.0047	0.0686	88%
Adding Vlassembler, 1993 (k=22)	0.01	[0.01; 0.01]		0.0045	0.0673	88%
Adding Vlassembler, 1993 (k=23)	0.01	[0.01; 0.01]		0.0046	0.0677	87%
Adding Van der Snoek, 2004 (k=24)	0.01	[0.01; 0.01]		0.0046	0.0675	87%
Adding Van der Snoek, 2004 (k=25)	0.01	[0.01; 0.01]		0.0044	0.0663	86%
Adding Manavi, 2004 (k=26)	0.01	[0.00; 0.01]		0.0043	0.0659	86%
Adding Manavi, 2004 (k=27)	0.01	[0.01; 0.01]		0.0041	0.0641	86%
Adding Manavi, 2005 (k=28)	0.01	[0.01; 0.01]		0.0047	0.0685	86%
Adding Papadogeorgaki, 2006 (k=29)	0.01	[0.01; 0.01]		0.0051	0.0711	86%
Adding Heijman, 2007 (k=30)	0.00	[0.00; 0.01]		0.0049	0.0702	87%
Adding Benn, 2007 (k=31)	0.00	[0.00; 0.01]		0.0059	0.0769	88%
Adding Benn, 2007 (k=32)	0.00	[0.00; 0.01]		0.0061	0.0779	89%
Adding Benn, 2007 (k=33)	0.01	[0.00; 0.01]		0.0064	0.0799	89%
Adding Linhart, 2008 (k=34)	0.01	[0.00; 0.01]		0.0070	0.0835	91%
Adding Soni, 2008 (k=35)	0.01	[0.00; 0.01]		0.0068	0.0826	90%
Adding Soni, 2008 (k=36)	0.01	[0.00; 0.01]		0.0066	0.0812	90%
Adding Shipitsyna, 2009 (k=37)	0.01	[0.00; 0.01]		0.0067	0.0821	90%
Adding Annan, 2009 (k=38)	0.01	[0.01; 0.01]		0.0065	0.0808	90%
Adding Walsh, 2011b (k=39)	0.01	[0.01; 0.01]		0.0068	0.0825	90%
Adding Walsh, 2011b (k=40)	0.01	[0.01; 0.01]		0.0066	0.0812	90%
Adding Heiligenberg, 2011b (k=41)	0.01	[0.01; 0.01]		0.0064	0.0801	91%
Adding Heiligenberg, 2011b (k=42)	0.01	[0.01; 0.01]		0.0066	0.0810	91%
Adding Peters, 2011 (k=43)	0.01	[0.01; 0.01]		0.0064	0.0800	91%
Adding Peters, 2011 (k=44)	0.01	[0.01; 0.01]		0.0064	0.0797	91%
Adding Soni, 2011 (k=45)	0.01	[0.01; 0.01]		0.0062	0.0787	91%
Adding Bozicevic, 2012 (k=46)	0.01	[0.01; 0.01]		0.0060	0.0776	91%
Adding Skovgaard, 2012 (k=47)	0.01	[0.01; 0.01]		0.0059	0.0765	91%
Adding Skovgaard, 2012 (k=48)	0.01	[0.01; 0.01]		0.0058	0.0763	92%
Adding Heiligenberg, 2012 (k=49)	0.01	[0.01; 0.01]		0.0057	0.0753	92%
Adding Heiligenberg, 2012 (k=50)	0.01	[0.01; 0.01]		0.0055	0.0744	92%
Adding Koedijk, 2012 (k=51)	0.01	[0.01; 0.01]		0.0054	0.0738	92%
Adding Koedijk, 2012 (k=52)	0.02	[0.02; 0.02]		0.0053	0.0730	97%
Adding Reinton, 2013 (k=53)	0.02	[0.02; 0.02]		0.0052	0.0722	97%
Adding Jeverica, 2013 (k=54)	0.02	[0.02; 0.02]		0.0051	0.0713	97%
Adding Jeverica, 2013 (k=55)	0.02	[0.02; 0.02]		0.0050	0.0707	97%
Adding Jimenez, 2013 (k=56)	0.02	[0.02; 0.02]		0.0054	0.0731	97%
Adding Roberts, 2013 (k=57)	0.02	[0.02; 0.02]		0.0053	0.0730	97%
Adding Dudareva-Vizule, 2014 (k=58)	0.02	[0.02; 0.02]		0.0053	0.0730	97%
Adding Keaveney, 2014 (k=59)	0.02	[0.02; 0.02]		0.0054	0.0734	97%
Adding Keaveney, 2014 (k=60)	0.02	[0.02; 0.02]		0.0054	0.0735	97%
Adding De Vrieze, 2014 (k=61)	0.02	[0.02; 0.02]		0.0053	0.0728	97%
Adding De Vrieze, 2014 (k=62)	0.02	[0.02; 0.02]		0.0053	0.0729	97%
Adding Vahidnia, 2014 (k=63)	0.02	[0.02; 0.02]		0.0053	0.0727	97%
Adding Vahidnia, 2014 (k=64)	0.02	[0.02; 0.02]		0.0053	0.0725	97%
Adding Vahidnia, 2014 (k=65)	0.02	[0.02; 0.02]		0.0052	0.0723	96%
Adding Van Liere, 2014a (k=66)	0.02	[0.02; 0.02]		0.0051	0.0715	96%
Adding Van Liere, 2014a (k=67)	0.02	[0.02; 0.02]		0.0050	0.0707	96%
Adding Hagemann, 2014 (k=68)	0.02	[0.02; 0.02]		0.0050	0.0707	96%
Adding Perez-Hernandez, 2014 (k=69)	0.02	[0.02; 0.02]		0.0049	0.0701	96%
Adding Sprenger, 2014 (k=70)	0.02	[0.02; 0.02]		0.0049	0.0697	96%
Adding Sprenger, 2014 (k=71)	0.02	[0.02; 0.02]		0.0048	0.0693	96%
Adding Sprenger, 2014 (k=72)	0.02	[0.02; 0.02]		0.0048	0.0692	96%
Adding Dakshina, 2014 (k=73)	0.02	[0.02; 0.02]		0.0053	0.0731	96%
Adding Dakshina, 2014 (k=74)	0.02	[0.02; 0.02]		0.0058	0.0764	97%
Adding Fraser, 2014 (k=75)	0.02	[0.02; 0.02]		0.0058	0.0761	97%
Adding Plaas, 2015 (k=76)	0.02	[0.02; 0.02]		0.0063	0.0795	97%
Adding Marcus, 2015 (k=77)	0.02	[0.02; 0.02]		0.0063	0.0791	97%

Adding Spauwen, 2015 (k=78)	0.02	[0.02; 0.02]	0.0062	0.0786	97%
Adding Van Liere, 2015 (k=79)	0.02	[0.02; 0.02]	0.0222	0.1491	98%
Adding Van Rooijen, 2015 (k=80)	0.02	[0.02; 0.02]	0.0220	0.1482	98%
Adding Van Rooijen, 2015 (k=81)	0.02	[0.02; 0.02]	0.0219	0.1479	98%
Adding Van Rooijen, 2015 (k=82)	0.02	[0.02; 0.02]	0.0217	0.1472	98%
Adding Van Rooijen, 2015 (k=83)	0.02	[0.02; 0.02]	0.0215	0.1465	98%
Adding Verscheijden, 2015 (k=84)	0.02	[0.02; 0.02]	0.0213	0.1458	98%
Adding Verscheijden, 2015 (k=85)	0.02	[0.02; 0.02]	0.0210	0.1451	98%
Adding Verscheijden, 2015 (k=86)	0.02	[0.02; 0.02]	0.0208	0.1443	98%
Adding Verscheijden, 2015 (k=87)	0.02	[0.02; 0.02]	0.0206	0.1434	98%
Adding Verscheijden, 2015 (k=88)	0.02	[0.02; 0.02]	0.0203	0.1426	98%
Adding Verscheijden, 2015 (k=89)	0.02	[0.02; 0.02]	0.0201	0.1418	98%
Adding Lenart, 2015 (k=90)	0.02	[0.02; 0.02]	0.0200	0.1413	98%
Adding Lenart, 2015 (k=91)	0.02	[0.02; 0.02]	0.0198	0.1406	98%
Adding Lenart, 2015 (k=92)	0.02	[0.02; 0.02]	0.0196	0.1398	98%
Adding Garner, 2015 (k=93)	0.02	[0.02; 0.02]	0.0193	0.1391	98%
Adding Garner, 2015 (k=94)	0.02	[0.02; 0.02]	0.0192	0.1387	98%
Adding Garner, 2015 (k=95)	0.02	[0.02; 0.02]	0.0192	0.1385	98%
Adding Garner, 2015 (k=96)	0.02	[0.02; 0.02]	0.0191	0.1381	98%
Adding Garner, 2015 (k=97)	0.02	[0.02; 0.02]	0.0190	0.1378	98%
Adding Garner, 2015 (k=98)	0.02	[0.02; 0.02]	0.0189	0.1374	98%
Adding Thorsteinsson, 2016 (k=99)	0.02	[0.02; 0.02]	0.0189	0.1377	98%
Adding Jaureguy, 2016 (k=100)	0.02	[0.02; 0.02]	0.0188	0.1370	98%
Adding Sultan, 2016 (k=101)	0.02	[0.02; 0.02]	0.0190	0.1379	98%
Adding Edouard, 2017b (k=102)	0.02	[0.02; 0.02]	0.0189	0.1373	98%
Adding Fata, 2017 (k=103)	0.02	[0.02; 0.02]	0.0187	0.1366	98%
Adding Den Heijer, 2017 (k=104)	0.02	[0.02; 0.02]	0.0185	0.1359	98%
Adding Den Heijer, 2017 (k=105)	0.02	[0.02; 0.02]	0.0183	0.1353	98%
Adding Spinner, 2018 (k=106)	0.02	[0.02; 0.02]	0.0181	0.1346	98%
Adding Druckler, 2018 (k=107)	0.02	[0.02; 0.02]	0.0180	0.1341	98%
Adding Matser, 2018 (k=108)	0.02	[0.02; 0.02]	0.0178	0.1335	98%
Adding Van Rooijen, 2018 (k=109)	0.02	[0.02; 0.02]	0.0178	0.1332	98%
Adding Van Rooijen, 2018 (k=110)	0.02	[0.02; 0.02]	0.0176	0.1327	98%
Adding Van Rooijen, 2018 (k=111)	0.02	[0.02; 0.02]	0.0175	0.1323	98%
Adding Van Rooijen, 2018 (k=112)	0.02	[0.02; 0.03]	0.0173	0.1317	99%
Adding Dona, 2018 (k=113)	0.02	[0.02; 0.03]	0.0190	0.1379	99%
Adding Jeffery, 2018 (k=114)	0.02	[0.02; 0.03]	0.0190	0.1378	99%
Adding Rahib, 2019 (k=115)	0.02	[0.02; 0.03]	0.0189	0.1374	99%
Adding Hoornenborg, 2019 (k=116)	0.02	[0.02; 0.03]	0.0187	0.1368	99%
Adding Ribeiro, 2019 (k=117)	0.02	[0.02; 0.03]	0.0185	0.1362	99%
Adding De Salazar, 2019 (k=118)	0.02	[0.02; 0.03]	0.0184	0.1356	99%
Adding Cherkaoui, 2019 (k=119)	0.02	[0.02; 0.03]	0.0193	0.1390	99%
Adding De Baetselier, 2020 (k=120)	0.02	[0.02; 0.03]	0.0192	0.1386	99%
Adding Verougstraete, 2020 (k=121)	0.02	[0.02; 0.03]	0.0190	0.1380	99%
Adding Jansen, 2020 (k=122)	0.02	[0.02; 0.03]	0.0189	0.1373	99%
Adding Rich, 2020 (k=123)	0.02	[0.02; 0.03]	0.0187	0.1368	99%
Adding Rich, 2020 (k=124)	0.02	[0.02; 0.03]	0.0186	0.1362	99%
Adding Foschi, 2020 (k=125)	0.02	[0.02; 0.03]	0.0184	0.1358	99%
Adding Marangoni, 2020 (k=126)	0.02	[0.02; 0.03]	0.0198	0.1407	99%
Adding Achterbergh, 2020 (k=127)	0.03	[0.02; 0.03]	0.0196	0.1402	99%
Adding Achterbergh, 2020 (k=128)	0.03	[0.02; 0.03]	0.0195	0.1395	99%
Adding Druckler, 2020 (k=129)	0.03	[0.02; 0.03]	0.0193	0.1391	99%
Adding Druckler, 2020 (k=130)	0.03	[0.02; 0.03]	0.0193	0.1388	99%
Adding Druckler, 2020 (k=131)	0.03	[0.02; 0.03]	0.0192	0.1384	99%
Adding Druckler, 2020 (k=132)	0.03	[0.02; 0.03]	0.0190	0.1379	99%
Adding Nijhuis, 2020 (k=133)	0.03	[0.02; 0.03]	0.0189	0.1375	99%
Adding Nijhuis, 2020 (k=134)	0.02	[0.02; 0.03]	0.0188	0.1373	99%
Adding Slurink, 2020 (k=135)	0.03	[0.02; 0.03]	0.0187	0.1367	98%
Adding Slurink, 2020 (k=136)	0.03	[0.02; 0.03]	0.0185	0.1361	98%
Adding Slurink, 2020 (k=137)	0.03	[0.02; 0.03]	0.0184	0.1355	98%
Adding Slurink, 2020 (k=138)	0.03	[0.02; 0.03]	0.0182	0.1350	98%
Adding Slurink, 2020 (k=139)	0.03	[0.03; 0.03]	0.0181	0.1345	98%
Adding Slurink, 2020 (k=140)	0.03	[0.03; 0.03]	0.0181	0.1344	98%



References

1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj*. 2021;372.
2. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *Journal of Clinical Epidemiology*. 2012;65(9):934-9.
3. World Bank. World bank country and lending groups 2020. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> (accessed January 21, 2023).